cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"Based on the provided mRNA TPM data of the tumor immune microenvironment and clinical details (male, white, bladder tissue, Bladder Urothelial Carcinoma diagnosis, and a tumor mutational burden of 18 mutations/Mb), can you assess the predicted responsiveness of this patient to Atezolizumab? Please provide a detailed conclusion on whether the patient is more likely to be a responder or non-responder and explain the reasoning behind your assessment.","Based on the provided mRNA TPM data of the tumor immune microenvironment and clinical details (male, white, bladder tissue, Bladder Urothelial Carcinoma diagnosis, and a tumor mutational burden of 18 mutations/Mb), can you assess the predicted responsiveness of this patient to Atezolizumab? Please provide a detailed conclusion on whether the patient is more likely to be a responder or non-responder and explain the reasoning behind your assessment. Assess the tumor microenvironment's transcriptomic profile using COMPASS to predict treatment response. Specifically, evaluate markers associated with immune deficiency (such as natural killer cells, exhausted T cells, and B cells) and markers linked to immune enhancement (including macrophages, the interferon-gamma pathway, and indicators of genome integrity). Integrate these markers with the COMPASS prediction to provide a detailed, evidence-based analysis of the patient’s likely treatment response, highlighting key transcriptomic features and their implications for immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"I have processed mRNA TPM data to evaluate the tumor immune microenvironment of a bladder urothelial carcinoma (BLCA) patient with the following characteristics: male, white, bladder tissue involved, and a tumor mutational burden of 1.0 mutations per MB. Could you assess whether this patient is predicted to be a responder or non-responder to atezolizumab, and provide the rationale for the prediction?","I have processed mRNA TPM data to evaluate the tumor immune microenvironment of a bladder urothelial carcinoma (BLCA) patient with the following characteristics: male, white, bladder tissue involved, and a tumor mutational burden of 1.0 mutations per MB. Could you assess whether this patient is predicted to be a responder or non-responder to atezolizumab, and provide the rationale for the prediction? Please evaluate the transcriptomic profile of the tumor microenvironment using COMPASS to predict the patient's likely treatment response. In your assessment, focus on markers associated with immune deficiency (for example, natural killer cells, exhausted T cells, and B cells) as well as markers indicative of immune enhancement (such as macrophages, components of the interferon-gamma pathway, and markers of genome integrity). Then, integrate these findings with the COMPASS prediction to develop a detailed, evidence-based analysis that highlights the key transcriptomic features and explains their relevance to the patient's immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"A patient with Bladder Urothelial Carcinoma presents with the following characteristics: female, White, bladder tissue, and a high tumor mutational burden of 44.0 mutations per MB. Based on the processed mRNA TPM data of the tumor immune microenvironment, can we determine if this patient is likely to be a responder or non-responder to atezolizumab? Please include the supporting rationale for your conclusion.","A patient with Bladder Urothelial Carcinoma presents with the following characteristics: female, White, bladder tissue, and a high tumor mutational burden of 44.0 mutations per MB. Based on the processed mRNA TPM data of the tumor immune microenvironment, can we determine if this patient is likely to be a responder or non-responder to atezolizumab? Please include the supporting rationale for your conclusion. Evaluate the transcriptomic profile of the tumor microenvironment using the COMPASS tool to predict the patient’s treatment response. Concentrate on immune deficiency markers (for instance, indicators of natural killer cell activity, exhausted T cells, and B cell levels) as well as markers of immune enhancement (including macrophage presence, elements of the interferon-gamma pathway, and markers related to genomic integrity). Then, correlate these observations with the COMPASS prediction to produce a detailed, evidence-based analysis that identifies the critical transcriptomic features and clarifies their implications for the patient’s immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"Can you assess whether a female patient with bladder urothelial carcinoma, whose mRNA TPM data of the tumor immune microenvironment was obtained from a lymph node, is likely to respond to Atezolizumab therapy? The patient's tumor mutational burden is 2.0 mutations per MB. Please provide your rationale based on these parameters.","Can you assess whether a female patient with bladder urothelial carcinoma, whose mRNA TPM data of the tumor immune microenvironment was obtained from a lymph node, is likely to respond to Atezolizumab therapy? The patient's tumor mutational burden is 2.0 mutations per MB. Please provide your rationale based on these parameters. Use the COMPASS tool to analyze the tumor microenvironment's transcriptomic profile and predict the patient's treatment response. Focus on identifying markers related to immune deficiencies—such as those indicating natural killer cell activity, T-cell exhaustion, and B-cell levels—as well as markers suggestive of immune enhancement, including macrophage presence, components of the interferon-gamma pathway, and indicators of genomic integrity. Then, integrate these findings with the COMPASS prediction to deliver an evidence-based analysis that highlights key transcriptomic features and explains their implications for the patient's immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"For a white male patient with bladder urothelial carcinoma (BLCA) whose tumor microenvironment has been profiled by mRNA TPM data and who presents with a tumor mutational burden of 8.0 FMOne mutation per MB, how would you assess the likelihood of responsiveness to Atezolizumab? Please provide your rationale for classifying this patient as a responder or non-responder.","For a white male patient with bladder urothelial carcinoma (BLCA) whose tumor microenvironment has been profiled by mRNA TPM data and who presents with a tumor mutational burden of 8.0 FMOne mutation per MB, how would you assess the likelihood of responsiveness to Atezolizumab? Please provide your rationale for classifying this patient as a responder or non-responder. Utilize the COMPASS tool to evaluate the transcriptomic profile of the tumor microenvironment, specifically identifying markers associated with immune deficiencies—such as those reflecting natural killer cell activity, T-cell exhaustion, and B-cell counts—as well as markers indicative of immune enhancement, including macrophage levels, interferon-gamma pathway components, and genomic integrity. Then, combine these insights with the COMPASS prediction to provide an evidence-based analysis that delineates the key transcriptomic features and their implications for the patient’s immune response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"Based on processed mRNA TPM data for the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you please determine whether this patient is likely to respond to Atezolizumab? The patient details are as follows: female, white, bladder tissue origin, and a tumor mutational burden of 6.0 mutations/MB. Please provide your conclusion along with the supporting rationale.","Based on processed mRNA TPM data for the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you please determine whether this patient is likely to respond to Atezolizumab? The patient details are as follows: female, white, bladder tissue origin, and a tumor mutational burden of 6.0 mutations/MB. Please provide your conclusion along with the supporting rationale. Please use the COMPASS tool to analyze the tumor microenvironment’s transcriptomic profile. In doing so, identify markers that indicate immune deficiencies (such as decreased natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts) and markers that suggest enhanced immune function (including increased macrophage presence, active interferon-gamma signaling, and maintained genomic integrity). Then, integrate these findings with the COMPASS prediction to provide an evidence-based summary of the key transcriptomic features and their potential impact on the patient’s immune response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, with kidney tissue involvement, and has a tumor mutational burden of 11.0 per MB. Could you please assess the predicted responsiveness of this patient to Atezolizumab, and provide your reasoning along with a conclusion on whether they are classified as a responder or non-responder?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, with kidney tissue involvement, and has a tumor mutational burden of 11.0 per MB. Could you please assess the predicted responsiveness of this patient to Atezolizumab, and provide your reasoning along with a conclusion on whether they are classified as a responder or non-responder? Please run the COMPASS tool to examine the transcriptomic profile of the tumor microenvironment. While doing so, look for specific markers that point to immune deficiencies—such as reduced natural killer cell activity, signs of T-cell exhaustion, and low B-cell counts—and also for markers that indicate a robust immune response—like an increased presence of macrophages, active interferon-gamma signaling, and preserved genomic integrity. Finally, combine these results with the COMPASS prediction to compile an evidence-based summary outlining the main transcriptomic features and their potential influence on the patient's immune response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"Based on processed mRNA TPM data that characterizes the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you assess the predicted responsiveness to Atezolizumab? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 18.0 mutations per megabase. Please provide a conclusion on whether this patient should be classified as a responder or non-responder, along with the supporting rationale.","Based on processed mRNA TPM data that characterizes the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you assess the predicted responsiveness to Atezolizumab? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 18.0 mutations per megabase. Please provide a conclusion on whether this patient should be classified as a responder or non-responder, along with the supporting rationale. Please use the COMPASS tool to analyze the tumor microenvironment’s transcriptomic profile. In your evaluation, specifically assess markers of immune deficiency—including decreased natural killer cell activity, signs of T-cell exhaustion, and diminished B-cell counts—as well as markers indicative of a strong immune response, such as an increased presence of macrophages, active interferon-gamma signaling, and maintained genomic integrity. Integrate these findings with the COMPASS prediction to create a concise, evidence-based summary that outlines the main transcriptomic features and their potential impact on the patient's immune response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"We have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a female Caucasian patient with bladder urothelial carcinoma (BLCA) to predict her responsiveness to Atezolizumab. Given that the tumor mutational burden data is unavailable (nan), does the current transcriptomic profile support a classification of responder or non-responder to Atezolizumab, and what is the rationale for this assessment?","We have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a female Caucasian patient with bladder urothelial carcinoma (BLCA) to predict her responsiveness to Atezolizumab. Given that the tumor mutational burden data is unavailable (nan), does the current transcriptomic profile support a classification of responder or non-responder to Atezolizumab, and what is the rationale for this assessment? Please use the COMPASS tool to evaluate the transcriptomic profile of the tumor microenvironment. In your analysis, pay particular attention to indicators of immune deficiency—such as reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts—as well as markers of an active immune response, including an increased presence of macrophages, active interferon-gamma signaling, and preserved genomic integrity. Based on these findings, along with the COMPASS prediction, prepare a succinct, evidence-based summary that highlights the key transcriptomic features and their potential impact on the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA), we have evaluated mRNA TPM data reflecting the tumor immune microenvironment. The patient is a male of White race; however, data for tissue type and tumor mutational burden are not available. Based on these details, could you assess whether this patient is more likely to respond to Atezolizumab and explain your reasoning?","For a patient with Bladder Urothelial Carcinoma (BLCA), we have evaluated mRNA TPM data reflecting the tumor immune microenvironment. The patient is a male of White race; however, data for tissue type and tumor mutational burden are not available. Based on these details, could you assess whether this patient is more likely to respond to Atezolizumab and explain your reasoning? Use the COMPASS tool to assess the tumor microenvironment's transcriptomic profile. Focus on identifying signs of immune deficiency, such as diminished natural killer cell function, T-cell exhaustion, and reduced B-cell counts, as well as features indicative of an active immune response like an increased number of macrophages, active interferon-gamma signaling, and intact genomic integrity. Then, based on these findings and the COMPASS prediction, provide a concise, evidence-based summary that outlines the key transcriptomic characteristics and their potential implications for the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"Based on the mRNA TPM data reflecting this patient's tumor immune microenvironment in Bladder Urothelial Carcinoma, how would you evaluate the potential response to Atezolizumab? The patient is a white male with a tumor mutational burden of 2.0 mutations per MB (as per FMOne), and the tissue origin is kidney. Please provide a clinical interpretation regarding whether this patient is likely to be a responder or non-responder, including your supporting rationale.","Based on the mRNA TPM data reflecting this patient's tumor immune microenvironment in Bladder Urothelial Carcinoma, how would you evaluate the potential response to Atezolizumab? The patient is a white male with a tumor mutational burden of 2.0 mutations per MB (as per FMOne), and the tissue origin is kidney. Please provide a clinical interpretation regarding whether this patient is likely to be a responder or non-responder, including your supporting rationale. Apply the COMPASS tool to analyze the transcriptomic profile of the tumor microenvironment. Specifically, evaluate for signs of immune suppression—such as reduced natural killer cell activity, T-cell exhaustion, and low B-cell numbers—as well as indicators of an active immune response, including increased macrophage infiltration, active interferon-gamma signaling, and preserved genomic integrity. Based on these observations and the COMPASS prediction, prepare a concise, evidence-based summary of the key transcriptomic features and discuss their potential implications for the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"I have processed mRNA TPM data capturing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient’s clinical attributes are as follows: male, White, bladder tissue, with a tumor mutational burden of 8.0 mutations per megabase. Based on these details, could you please assess whether this patient is predicted to be responsive to Atezolizumab and explain the reasoning behind the prediction?","I have processed mRNA TPM data capturing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient’s clinical attributes are as follows: male, White, bladder tissue, with a tumor mutational burden of 8.0 mutations per megabase. Based on these details, could you please assess whether this patient is predicted to be responsive to Atezolizumab and explain the reasoning behind the prediction? Use the COMPASS tool to evaluate the transcriptomic profile of the tumor microenvironment. Focus on identifying markers of immune suppression—such as decreased natural killer cell activity, T-cell exhaustion, and diminished B-cell counts—as well as signs of an active immune response, like enhanced macrophage infiltration, robust interferon-gamma signaling, and intact genomic stability. Based on these findings and the COMPASS analysis, compile a concise, evidence-based summary that highlights the key transcriptomic characteristics and explains their potential impact on the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"Given mRNA TPM data that characterize the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), and considering the following details: Female, WHITE, tissue sample from lymph node, and an undefined tumor mutational burden (FMOne mutation burden per MB: nan), could you provide an assessment regarding the patient's predicted responsiveness to Atezolizumab, along with the rationale behind the classification as a responder or non-responder?","Given mRNA TPM data that characterize the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), and considering the following details: Female, WHITE, tissue sample from lymph node, and an undefined tumor mutational burden (FMOne mutation burden per MB: nan), could you provide an assessment regarding the patient's predicted responsiveness to Atezolizumab, along with the rationale behind the classification as a responder or non-responder? Utilize the COMPASS tool to analyze the tumor microenvironment’s transcriptional landscape. Concentrate on detecting markers of immune suppression—such as reduced natural killer cell activity, T-cell exhaustion, or lower B-cell frequencies—and indicators of an active immune response, like increased macrophage presence, strong interferon-gamma signaling, and maintained genomic stability. Following your analysis, prepare a concise, evidence-based summary that outlines these key transcriptomic features and discusses their potential implications for the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"For a male Caucasian patient with bladder urothelial carcinoma (sample from the ureter) and a tumor mutational burden of 9.0 mutations per MB, based on the processed mRNA TPM data of his tumor immune microenvironment, what is the predicted response to Atezolizumab, and what is the scientific rationale supporting this prediction?","For a male Caucasian patient with bladder urothelial carcinoma (sample from the ureter) and a tumor mutational burden of 9.0 mutations per MB, based on the processed mRNA TPM data of his tumor immune microenvironment, what is the predicted response to Atezolizumab, and what is the scientific rationale supporting this prediction? Use the COMPASS tool to evaluate the transcriptional profile of the tumor microenvironment. Focus on identifying signs of immune suppression—such as decreased natural killer cell activity, T-cell exhaustion, or reduced B-cell presence—and markers of an active immune response, like increased macrophage infiltration, robust interferon-gamma signaling, and maintained genomic integrity. After your evaluation, create a concise, evidence-based summary that outlines these key transcriptomic features and explains their potential impact on the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"Based on mRNA TPM data reflecting the tumor immune microenvironment of a white female patient with Bladder Urothelial Carcinoma (BLCA) and an FMOne mutation burden of 4.0 per MB, could you evaluate whether she is likely to respond to Atezolizumab? Please include your reasoning along with the classification.","Based on mRNA TPM data reflecting the tumor immune microenvironment of a white female patient with Bladder Urothelial Carcinoma (BLCA) and an FMOne mutation burden of 4.0 per MB, could you evaluate whether she is likely to respond to Atezolizumab? Please include your reasoning along with the classification. Please use the COMPASS tool to analyze the tumor microenvironment's transcriptional profile. In your assessment, prioritize identifying indicators of immune suppression—such as reduced natural killer cell activity, signs of T-cell exhaustion, or a lower number of B cells—as well as features suggesting an active immune response, which include elevated macrophage infiltration, strong interferon-gamma signaling, and preserved genomic integrity. Following the analysis, prepare a brief, evidence-based summary that outlines these key transcriptomic characteristics and discusses their potential implications for the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"Based on the patient's mRNA TPM data characterizing the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you determine whether the patient—male, White, with a ureter tissue sample, diagnosed with BLCA, and a tumor mutational burden of 32.0 mutations per megabase—is likely to respond to Atezolizumab therapy? Please provide a conclusion along with the supporting rationale.","Based on the patient's mRNA TPM data characterizing the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you determine whether the patient—male, White, with a ureter tissue sample, diagnosed with BLCA, and a tumor mutational burden of 32.0 mutations per megabase—is likely to respond to Atezolizumab therapy? Please provide a conclusion along with the supporting rationale. Please employ the COMPASS tool to evaluate the transcriptional profile of the tumor microenvironment. Your analysis should focus on identifying markers of immune suppression—such as diminished natural killer cell activity, evidence of T-cell exhaustion, or reduced B-cell counts—as well as indicators of an active immune response, including increased macrophage infiltration, robust interferon-gamma signaling, and intact genomic integrity. After completing the analysis, please compile a concise, evidence-based summary outlining these transcriptomic features and discussing their potential impact on the patient’s therapeutic outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"Based on the processed mRNA TPM data reflecting the tumor immune microenvironment and the following clinical details—a 21 mutations/MB tumor mutational burden in a male, white patient with bladder urothelial carcinoma—could you assess the patient’s likelihood of responding to Atezolizumab and provide the supporting rationale?","Based on the processed mRNA TPM data reflecting the tumor immune microenvironment and the following clinical details—a 21 mutations/MB tumor mutational burden in a male, white patient with bladder urothelial carcinoma—could you assess the patient’s likelihood of responding to Atezolizumab and provide the supporting rationale? Utilize the COMPASS tool to assess the tumor microenvironment’s transcriptional profile. Specifically, analyze markers of immune suppression—such as reduced NK cell activity, signs of T-cell exhaustion, or decreased B-cell counts—as well as indicators of an active immune response, including elevated macrophage infiltration, strong interferon-gamma signaling, and preserved genomic integrity. Following your analysis, prepare a concise, evidence-based summary that outlines these transcriptomic features and discusses their potential implications for the patient’s therapeutic outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"I have processed mRNA TPM data that characterizes the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with kidney tissue involvement, and the tumor mutational burden is 10.0 mutations per megabase. Based on these details, could you please assess the predicted response to Atezolizumab, determining whether this patient is likely to be a responder or non-responder, and provide the clinical reasoning behind your assessment?","I have processed mRNA TPM data that characterizes the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with kidney tissue involvement, and the tumor mutational burden is 10.0 mutations per megabase. Based on these details, could you please assess the predicted response to Atezolizumab, determining whether this patient is likely to be a responder or non-responder, and provide the clinical reasoning behind your assessment? Please use the COMPASS tool to evaluate the transcriptional profile of the tumor microenvironment. Focus on detecting markers of immune suppression—such as diminished NK cell function, signs of T-cell exhaustion, or lower B-cell counts—as well as markers of an active immune response like increased macrophage presence, robust interferon-gamma signaling, and intact genomic integrity. After completing your analysis, please compile a brief, evidence-based summary that highlights these transcriptomic characteristics and discusses their potential impact on the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"I have processed mRNA TPM data from the tumor immune microenvironment in a male, white patient with bladder urothelial carcinoma, who has a high tumor mutational burden of 38 mutations per megabase. Based on these findings, can you assess the predicted responsiveness to Atezolizumab and provide the rationale for classifying this patient as a responder or non-responder?","I have processed mRNA TPM data from the tumor immune microenvironment in a male, white patient with bladder urothelial carcinoma, who has a high tumor mutational burden of 38 mutations per megabase. Based on these findings, can you assess the predicted responsiveness to Atezolizumab and provide the rationale for classifying this patient as a responder or non-responder? Please use the COMPASS tool to analyze the transcriptional profile of the tumor microenvironment. In your evaluation, look for indicators of immune suppression—such as reduced NK cell function, signs of T-cell exhaustion, or lower B-cell counts—and for indicators of an active immune response, such as increased macrophage presence, strong interferon-gamma signaling, and maintained genomic integrity. Once your analysis is complete, prepare a concise, evidence-based summary outlining these transcriptomic features and discussing how they might affect the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"Based on mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) — a 7.0 FMOne mutation burden per MB in a white female patient — could you provide an assessment of her likely responsiveness to Atezolizumab, including the rationale behind that interpretation?","Based on mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) — a 7.0 FMOne mutation burden per MB in a white female patient — could you provide an assessment of her likely responsiveness to Atezolizumab, including the rationale behind that interpretation? Please apply the COMPASS tool to evaluate the transcriptional profile of the tumor microenvironment. Specifically, examine the data for signs of immune suppression—such as diminished NK cell activity, T-cell exhaustion, or reduced B-cell counts—as well as for evidence of an active immune response, including increased macrophage infiltration, enhanced interferon-gamma signaling, and preserved genomic integrity. After conducting your analysis, compile a concise, evidence-based summary that details these transcriptomic characteristics and discusses their potential impact on the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,Can you evaluate this male patient with bladder urothelial carcinoma (BLCA)—whose processed mRNA TPM data of the tumor immune microenvironment and a tumor mutational burden of 5 mutations/MB have been provided—to determine whether he is likely to respond to Atezolizumab? Please include your supporting rationale for classifying him as a responder or non-responder.,"Can you evaluate this male patient with bladder urothelial carcinoma (BLCA)—whose processed mRNA TPM data of the tumor immune microenvironment and a tumor mutational burden of 5 mutations/MB have been provided—to determine whether he is likely to respond to Atezolizumab? Please include your supporting rationale for classifying him as a responder or non-responder. Using the COMPASS tool, please evaluate the tumor microenvironment's transcriptomic profile. Look for indicators of immune suppression—such as reduced natural killer (NK) cell activity, evidence of T-cell exhaustion, or lower levels of B cells—as well as markers of an active immune response, including increased macrophage presence, elevated interferon-gamma signaling, and maintained genomic stability. Once your analysis is complete, prepare a concise, evidence-based summary that outlines these transcriptomic features and discusses their potential implications for the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"Could you help determine whether, based on the mRNA TPM data of the tumor immune microenvironment for a male, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 15.0 mutations per megabase, this patient is likely to respond to Atezolizumab? Please include the reasoning behind your conclusion.","Could you help determine whether, based on the mRNA TPM data of the tumor immune microenvironment for a male, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 15.0 mutations per megabase, this patient is likely to respond to Atezolizumab? Please include the reasoning behind your conclusion. Please use the COMPASS tool to analyze the transcriptomic profile of the tumor microenvironment. Specifically, assess for signs of immune suppression—such as decreased natural killer (NK) cell activity, T-cell exhaustion, or lower B-cell levels—as well as indicators of an active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and well-preserved genomic stability. Once your analysis is complete, prepare a concise, evidence-based summary that details these transcriptomic characteristics and discusses how they might impact the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"Given the mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) and the following clinical details—male, white, tissue sample from kidney, and a tumor mutational burden reported as “nan”—can you determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the rationale behind it.","Given the mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) and the following clinical details—male, white, tissue sample from kidney, and a tumor mutational burden reported as “nan”—can you determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the rationale behind it. Please employ the COMPASS tool to evaluate the tumor microenvironment's transcriptomic profile. In your analysis, look for indicators of immune suppression—such as diminished natural killer cell activity, evidence of T-cell exhaustion, or reduced B-cell levels—and also assess markers of an active immune response, including increased macrophage infiltration, enhanced interferon-gamma signaling, and maintained genomic stability. Once you have completed your assessment, compile a concise, evidence-based summary that outlines these transcriptomic features and discusses their potential impact on the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-181b63-ar-181b638.pkl. "
BLCA,,,,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) characterized by mRNA TPM data from the tumor immune microenvironment, can you assess the predicted response to Atezolizumab? The patient is a white male, the tissue sample is derived from lung tissue, and his tumor mutational burden is undetermined (nan per MB). Based on these factors, should he be classified as a responder or non-responder, and what is the reasoning behind that classification?","For a patient with Bladder Urothelial Carcinoma (BLCA) characterized by mRNA TPM data from the tumor immune microenvironment, can you assess the predicted response to Atezolizumab? The patient is a white male, the tissue sample is derived from lung tissue, and his tumor mutational burden is undetermined (nan per MB). Based on these factors, should he be classified as a responder or non-responder, and what is the reasoning behind that classification? Please use the COMPASS tool to analyze the tumor microenvironment's transcriptomic profile. In your evaluation, examine for signs of immune suppression, including decreased natural killer cell activity, T-cell exhaustion, and lower B-cell counts, as well as for indicators of an active immune response, such as elevated macrophage infiltration, increased interferon-gamma signaling, and preserved genomic stability. Once your analysis is complete, please prepare a concise, evidence-based summary outlining these transcriptomic features and discussing their potential implications for the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"I have processed mRNA TPM data characterizing the tumor immune microenvironment of a male, white patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 18.0 mutations per megabase. Based on these molecular and clinical attributes, could you assess whether this patient is likely to respond to Atezolizumab and provide the supporting rationale for your conclusion?","I have processed mRNA TPM data characterizing the tumor immune microenvironment of a male, white patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 18.0 mutations per megabase. Based on these molecular and clinical attributes, could you assess whether this patient is likely to respond to Atezolizumab and provide the supporting rationale for your conclusion? Please employ the COMPASS tool to evaluate the transcriptomic profile of the tumor microenvironment. In your analysis, assess for evidence of immune suppression—such as reduced natural killer cell activity, T-cell exhaustion, and lower B-cell counts—as well as markers of an active immune response, including increased macrophage infiltration, heightened interferon-gamma signaling, and intact genomic stability. Once your evaluation is complete, prepare a concise, evidence-based summary that outlines these transcriptomic features and discusses their potential implications for the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"For a male patient of Black or African American descent with bladder urothelial carcinoma originating in the ureter and a tumor mutational burden of 7.0 mutations per megabase, can we conclude whether he is predicted to be a responder or non-responder to Atezolizumab? Please include the supporting reasoning based on his mRNA TPM data analysis.","For a male patient of Black or African American descent with bladder urothelial carcinoma originating in the ureter and a tumor mutational burden of 7.0 mutations per megabase, can we conclude whether he is predicted to be a responder or non-responder to Atezolizumab? Please include the supporting reasoning based on his mRNA TPM data analysis. Use the COMPASS tool to analyze the tumor microenvironment's transcriptomic profile. Specifically, examine the data for signs of immune suppression—such as diminished natural killer cell activity, T-cell exhaustion, and reduced B-cell counts—while also looking for evidence of an active immune response, including increased macrophage infiltration, enhanced interferon-gamma signaling, and maintained genomic stability. After completing your analysis, please compile a concise, evidence-based summary that highlights these features and discusses how they might impact the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"I am evaluating a male, white patient with Bladder Urothelial Carcinoma, whose tumor tissue has been analyzed using mRNA TPM data to characterize the immune microenvironment. With a tumor mutational burden of 19.0 mutations per MB, could you assess the likelihood of response to Atezolizumab and provide the supporting clinical rationale for classifying him as a responder or non-responder?","I am evaluating a male, white patient with Bladder Urothelial Carcinoma, whose tumor tissue has been analyzed using mRNA TPM data to characterize the immune microenvironment. With a tumor mutational burden of 19.0 mutations per MB, could you assess the likelihood of response to Atezolizumab and provide the supporting clinical rationale for classifying him as a responder or non-responder? Use the COMPASS tool to evaluate the transcriptomic profile of the tumor microenvironment. Focus on detecting signs of immune suppression—such as reduced natural killer cell function, T-cell exhaustion, and lower B-cell counts—as well as evidence of an active immune response, like increased macrophage infiltration, elevated interferon-gamma signaling, and preserved genomic stability. Once the analysis is complete, prepare a concise, evidence-based summary that details these findings and discusses their potential implications for the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"Based on processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), can you evaluate the predicted responsiveness to Atezolizumab? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Please provide your conclusion on whether the patient is likely to respond to treatment, along with the supporting rationale.","Based on processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), can you evaluate the predicted responsiveness to Atezolizumab? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Please provide your conclusion on whether the patient is likely to respond to treatment, along with the supporting rationale. Please use the COMPASS tool to assess the transcriptomic profile of the tumor microenvironment. In your evaluation, look specifically for indicators of immune suppression—such as reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts—as well as markers of an active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and maintained genomic stability. Once your analysis is complete, compile a concise, evidence-based report outlining these findings and discussing their potential impact on the patient’s treatment responsiveness.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"I have mRNA TPM data detailing the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  male, white individual with bladder tissue involvement and a tumor mutational burden of 5.0 mutations/Mb. Based on these clinical and molecular characteristics, can we determine if the patient is likely to respond to Atezolizumab, and what is the rationale for classifying them as a responder or non-responder?","I have mRNA TPM data detailing the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  male, white individual with bladder tissue involvement and a tumor mutational burden of 5.0 mutations/Mb. Based on these clinical and molecular characteristics, can we determine if the patient is likely to respond to Atezolizumab, and what is the rationale for classifying them as a responder or non-responder? Please apply the COMPASS tool to analyze the tumor microenvironment's transcriptomic profile. Specifically, evaluate for signs of immune suppression—such as decreased natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell levels—as well as indicators of an active immune response like increased macrophage infiltration, higher interferon-gamma signaling, and preserved genomic stability. Once your analysis is complete, compile a clear, evidence-based report that summarizes these findings and discusses their potential implications for the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"I have compiled mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) that reflects the tumor immune microenvironment. The patient is a  male, White, with bladder tissue involvement and a tumor mutational burden of 8.0 mutations per MB. Based on this data, could you evaluate the likelihood of a positive response to Atezolizumab and provide the rationale for your assessment?","I have compiled mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) that reflects the tumor immune microenvironment. The patient is a  male, White, with bladder tissue involvement and a tumor mutational burden of 8.0 mutations per MB. Based on this data, could you evaluate the likelihood of a positive response to Atezolizumab and provide the rationale for your assessment? Please utilize the COMPASS tool to assess the tumor microenvironment’s transcriptomic profile. In your evaluation, look for markers that indicate immune suppression, such as reduced natural killer cell function, signs of T-cell exhaustion, and lower levels of B-cells. Also, examine evidence of an active immune response—specifically, increased macrophage infiltration, heightened interferon-gamma signaling, and preserved genomic stability. After your analysis, prepare a clear, evidence-based report that summarizes your findings and discusses their potential implications for the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient's details are as follows: female, White, tissue from the ureter, and a tumor mutational burden of 13.0 FMOne mutations per MB. Based on these data, could you provide an assessment of her predicted response to Atezolizumab, including your rationale for classifying her as a responder or non-responder?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient's details are as follows: female, White, tissue from the ureter, and a tumor mutational burden of 13.0 FMOne mutations per MB. Based on these data, could you provide an assessment of her predicted response to Atezolizumab, including your rationale for classifying her as a responder or non-responder? Please use the COMPASS tool to evaluate the transcriptomic profile of the tumor microenvironment. Focus your assessment on markers indicating immune suppression, such as reduced natural killer cell function, signs of T-cell exhaustion, and decreased B-cell levels. Additionally, evaluate for evidence of an active immune response by checking for increased macrophage infiltration, elevated interferon-gamma signaling, and maintained genomic stability. Once you have completed your analysis, compile a clear, evidence-based report summarizing your findings and discussing their potential implications for the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"I have mRNA TPM data characterizing the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient's details are as follows: male, white, with kidney tissue involvement and a tumor mutational burden of 16.0 mutations per MB. Based on these data, can you provide a clinical assessment on whether the patient is likely to respond to Atezolizumab, including your supporting rationale?","I have mRNA TPM data characterizing the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient's details are as follows: male, white, with kidney tissue involvement and a tumor mutational burden of 16.0 mutations per MB. Based on these data, can you provide a clinical assessment on whether the patient is likely to respond to Atezolizumab, including your supporting rationale? Please use the COMPASS tool to analyze the transcriptomic profile of the tumor microenvironment. In your assessment, pay particular attention to markers of immune suppression, including reduced natural killer cell activity, evidence of T-cell exhaustion, and decreased B-cell counts. Also, evaluate indicators of an active immune response such as increased macrophage infiltration, elevated interferon-gamma signaling, and preserved genomic stability. After completing your analysis, prepare a detailed, evidence-based report that summarizes your findings and discusses their potential implications for the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"I have analyzed mRNA TPM data characterizing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, with kidney tissue involved, and exhibits a tumor mutational burden of 2.0 mutations per megabase. Based on these clinical and molecular findings, could you determine whether the patient is likely to respond to Atezolizumab, and please explain your reasoning?","I have analyzed mRNA TPM data characterizing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, with kidney tissue involved, and exhibits a tumor mutational burden of 2.0 mutations per megabase. Based on these clinical and molecular findings, could you determine whether the patient is likely to respond to Atezolizumab, and please explain your reasoning? Use the COMPASS tool to examine the transcriptomic profile of the tumor microenvironment. Focus on identifying signs of immune suppression such as diminished natural killer cell activity, T-cell exhaustion, and lower B-cell counts, while also looking for evidence of an active immune response like increased macrophage infiltration, higher interferon-gamma signaling, and maintained genomic stability. Once your analysis is complete, compile your findings into a comprehensive, evidence-based report that explains the potential impact on the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA) and need to evaluate her potential response to Atezolizumab therapy. The patient is a white female with bladder involvement, and her tumor mutational burden (FMOne mutation burden per MB) is not available (nan). Based on these details, could you provide an assessment of whether she is likely to be a responder or non-responder to Atezolizumab, along with the supporting rationale?","I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA) and need to evaluate her potential response to Atezolizumab therapy. The patient is a white female with bladder involvement, and her tumor mutational burden (FMOne mutation burden per MB) is not available (nan). Based on these details, could you provide an assessment of whether she is likely to be a responder or non-responder to Atezolizumab, along with the supporting rationale? Evaluate the tumor transcriptomic profile using the COMPASS tool, emphasizing both immunosuppressive indicators and active immune responses within the tumor microenvironment. Specifically, look for reduced natural killer cell activity, signs of T-cell exhaustion, and decreased B-cell counts as evidence of immune suppression. In parallel, assess for increased macrophage infiltration, elevated interferon-gamma signaling, and preserved genomic stability as markers of an active immune response. After completing your analysis, please compile a detailed, evidence-based report that discusses how these findings might influence the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"I have mRNA TPM data characterizing the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white male with bladder tissue involvement and a tumor mutational burden of 7.0 (FMOne mutations per MB). Based on this clinical and molecular profile, could you determine whether the patient is likely to respond to Atezolizumab, and please provide your supporting rationale?","I have mRNA TPM data characterizing the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white male with bladder tissue involvement and a tumor mutational burden of 7.0 (FMOne mutations per MB). Based on this clinical and molecular profile, could you determine whether the patient is likely to respond to Atezolizumab, and please provide your supporting rationale? Please use the COMPASS tool to analyze the tumor's transcriptomic profile, focusing on evidence of both immunosuppression and immune activation within the tumor microenvironment. Specifically, assess for reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell levels as indicators of immunosuppressive behavior. Concurrently, evaluate markers of an active immune response, such as increased macrophage infiltration, heightened interferon-gamma signaling, and maintained genomic stability. Once your analysis is complete, compile a detailed, evidence-based report discussing how these findings may impact the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient is a white male with a bladder tumor and a tumor mutational burden of 20 mutations per megabase. Could you please assess whether this patient is likely to respond to Atezolizumab and provide the clinical rationale for your assessment?,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient is a white male with a bladder tumor and a tumor mutational burden of 20 mutations per megabase. Could you please assess whether this patient is likely to respond to Atezolizumab and provide the clinical rationale for your assessment? Please use the COMPASS tool to evaluate the tumor transcriptomic profile, specifically examining evidence of both immunosuppressive and immunoactive features. For immunosuppression, assess for indicators such as decreased natural killer cell activity, T-cell exhaustion, and lower B-cell levels. At the same time, look for markers of an active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and well-preserved genomic stability. Once the analysis is completed, prepare a comprehensive, evidence-based report that discusses how these findings might influence the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a female Caucasian patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tumor mutational burden of 5.0 mutations per megabase. Based on these clinical characteristics, could you please determine whether this patient is likely to respond to Atezolizumab, and provide the underlying rationale for your conclusion?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a female Caucasian patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tumor mutational burden of 5.0 mutations per megabase. Based on these clinical characteristics, could you please determine whether this patient is likely to respond to Atezolizumab, and provide the underlying rationale for your conclusion? Use the COMPASS tool to analyze the tumor's transcriptomic profile by specifically assessing markers associated with immunosuppression—such as reduced natural killer cell activity, T-cell exhaustion, and lower B-cell levels—as well as indicators of an active immune response, including increased macrophage infiltration, higher interferon-gamma signaling, and preserved genomic stability. After completing this evaluation, please compile a detailed, evidence-based report that discusses the potential impact of these findings on the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"I have processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma, and I am seeking to evaluate the predicted responsiveness to Atezolizumab. The patient’s profile includes: male sex, white race, bladder tissue origin, and a tumor mutational burden of 38.0 (FMOne mutations per MB). Based on these data, how would you determine if the patient is likely to be classified as a responder or non-responder to Atezolizumab, and what is the rationale behind this conclusion?","I have processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma, and I am seeking to evaluate the predicted responsiveness to Atezolizumab. The patient’s profile includes: male sex, white race, bladder tissue origin, and a tumor mutational burden of 38.0 (FMOne mutations per MB). Based on these data, how would you determine if the patient is likely to be classified as a responder or non-responder to Atezolizumab, and what is the rationale behind this conclusion? Please use the COMPASS tool to evaluate the tumor’s transcriptomic profile. Focus on identifying markers of immunosuppression, such as decreased natural killer cell activity, T-cell exhaustion, and reduced B-cell abundance, as well as signs of an active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and maintained genomic stability. Once this assessment is complete, prepare a comprehensive, evidence-based report that addresses how these findings might influence the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"For a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) whose tissue sample (from the kidney) yielded mRNA TPM data reflecting the tumor immune microenvironment and a Tumor Mutational Burden of 6.0 FMOne mutations per MB, can you assess the likelihood of response to Atezolizumab? Please include your rationale in categorizing the patient as a likely responder or non-responder.","For a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) whose tissue sample (from the kidney) yielded mRNA TPM data reflecting the tumor immune microenvironment and a Tumor Mutational Burden of 6.0 FMOne mutations per MB, can you assess the likelihood of response to Atezolizumab? Please include your rationale in categorizing the patient as a likely responder or non-responder. Utilize the COMPASS tool to analyze the tumor’s transcriptomic profile. During your analysis, assess for markers of immunosuppression—including reduced activity of natural killer cells, signs of T-cell exhaustion, and lower B-cell levels—as well as indicators of an active immune response, such as increased macrophage infiltration, heightened interferon-gamma signaling, and genomic stability. Once your evaluation is complete, compile a detailed, evidence-based report discussing how these findings may impact the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"Based on processed mRNA TPM data describing the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA)—a white male with bladder tissue involvement and a tumor mutational burden of 8 mutations per MB—could you provide a clinical interpretation regarding his predicted responsiveness to Atezolizumab? Please indicate whether he is likely to be a responder or non-responder, and include the supporting rationale for your conclusion.","Based on processed mRNA TPM data describing the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA)—a white male with bladder tissue involvement and a tumor mutational burden of 8 mutations per MB—could you provide a clinical interpretation regarding his predicted responsiveness to Atezolizumab? Please indicate whether he is likely to be a responder or non-responder, and include the supporting rationale for your conclusion. Please use the COMPASS tool to review the tumor's transcriptomic profile. In your evaluation, look for immunosuppressive markers—such as decreased natural killer cell function, signs of T-cell exhaustion, and reduced B-cell levels—as well as signs of an active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and genomic stability. After completing the analysis, please prepare a detailed, evidence-based report describing how these findings might affect the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"Based on the following patient details and mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma, could you evaluate the likelihood of a favorable response to Atezolizumab? The patient is a 65-year-old white male with bladder carcinoma, and his tumor exhibits a mutational burden of 13 mutations per MB. Please provide your assessment of responder status and the reasoning behind your conclusion.","Based on the following patient details and mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma, could you evaluate the likelihood of a favorable response to Atezolizumab? The patient is a 65-year-old white male with bladder carcinoma, and his tumor exhibits a mutational burden of 13 mutations per MB. Please provide your assessment of responder status and the reasoning behind your conclusion. Please employ the COMPASS tool to analyze the tumor’s transcriptomic profile. Specifically, assess for immunosuppressive indicators—such as reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts—as well as for markers of an active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and maintained genomic stability. Once your evaluation is complete, prepare a comprehensive, evidence-based report explaining how these findings might impact the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"We have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  (male, White) individual with kidney tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Based on these characteristics, could you provide your assessment of whether the patient is likely to respond to Atezolizumab, including the reasoning behind your conclusion?","We have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  (male, White) individual with kidney tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Based on these characteristics, could you provide your assessment of whether the patient is likely to respond to Atezolizumab, including the reasoning behind your conclusion? Use the COMPASS tool to examine the tumor’s transcriptomic profile. Evaluate the data for immunosuppressive features—for example, decreased natural killer cell function, signs of T-cell exhaustion, and reduced B-cell numbers—as well as for indications of an active immune response, such as increased macrophage infiltration, higher interferon-gamma signaling, and preserved genomic stability. After your analysis, compile a detailed, evidence-based report discussing how these findings could affect the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"Given a patient's mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and the following clinical details—female, white, bladder tissue, BLCA diagnosis, and a tumor mutational burden of 5 mutations/MB—what is the predicted response to Atezolizumab, and what is the rationale behind this prediction?","Given a patient's mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and the following clinical details—female, white, bladder tissue, BLCA diagnosis, and a tumor mutational burden of 5 mutations/MB—what is the predicted response to Atezolizumab, and what is the rationale behind this prediction? Please use the COMPASS platform to analyze the tumor's transcriptomic profile. In your evaluation, look for immunosuppressive indicators—such as reduced natural killer cell function, evidence of T-cell exhaustion, and diminished B-cell counts—as well as signs of an active immune response like increased macrophage infiltration, heightened interferon-gamma signaling, and maintained genomic stability. After your analysis, prepare a comprehensive, evidence-based report detailing how these findings may impact the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"Based on the available mRNA TPM data reflecting the tumor immune microenvironment in a Bladder Urothelial Carcinoma (BLCA) patient, could you evaluate whether this patient is likely to respond to Atezolizumab? The specific patient details are: Female, White, tissue sampled from the kidney, diagnosis of BLCA, and a tumor mutational burden of 5.0 mutations per MB. Please provide your assessment along with the supporting rationale.","Based on the available mRNA TPM data reflecting the tumor immune microenvironment in a Bladder Urothelial Carcinoma (BLCA) patient, could you evaluate whether this patient is likely to respond to Atezolizumab? The specific patient details are: Female, White, tissue sampled from the kidney, diagnosis of BLCA, and a tumor mutational burden of 5.0 mutations per MB. Please provide your assessment along with the supporting rationale. Please use the COMPASS platform to examine the tumor’s transcriptomic profile. Specifically, assess whether there are features of immunosuppression—such as reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts—as well as markers of an active immune response like increased macrophage infiltration, elevated interferon-gamma signaling, and stable genomic features. Once you have completed the analysis, please prepare a detailed, evidence-based report discussing how these findings might affect the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"Based on the patient's mRNA TPM data representing the tumor immune microenvironment in bladder urothelial carcinoma, can we determine if this white male—whose tissue sample is noted as ""other"" and with an undefined tumor mutational burden—is likely to respond to Atezolizumab? Please provide your conclusion on responder status along with a detailed rationale for your assessment.","Based on the patient's mRNA TPM data representing the tumor immune microenvironment in bladder urothelial carcinoma, can we determine if this white male—whose tissue sample is noted as ""other"" and with an undefined tumor mutational burden—is likely to respond to Atezolizumab? Please provide your conclusion on responder status along with a detailed rationale for your assessment. Please use the COMPASS platform to analyze the transcriptomic profile of the tumor. In your analysis, check for immunosuppressive characteristics—such as diminished natural killer cell activity, indicators of T-cell exhaustion, and lower B-cell counts—as well as signs of an active immune response, including increased macrophage infiltration, higher levels of interferon-gamma signaling, and preserved genomic stability. Once your review is complete, provide a thorough, evidence-based report discussing how these findings may influence the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"Based on the patient's mRNA TPM data from a lymph node sample of a Bladder Urothelial Carcinoma (BLCA) tumor, along with the following clinical characteristics—Female, White, and an FMOne mutation burden of 12.0 per MB—can we determine her likelihood of responding to Atezolizumab? Please provide a conclusion on whether she is classified as a responder or non-responder, supported by the relevant reasoning.","Based on the patient's mRNA TPM data from a lymph node sample of a Bladder Urothelial Carcinoma (BLCA) tumor, along with the following clinical characteristics—Female, White, and an FMOne mutation burden of 12.0 per MB—can we determine her likelihood of responding to Atezolizumab? Please provide a conclusion on whether she is classified as a responder or non-responder, supported by the relevant reasoning. Access the COMPASS platform to evaluate the tumor's transcriptomic profile. Please assess for immunosuppressive features—specifically reduced natural killer cell activity, evidence of T-cell exhaustion, and decreased B-cell counts—as well as indicators of an active immune response, such as increased macrophage infiltration, elevated interferon-gamma signaling, and maintained genomic stability. After your analysis, compile a comprehensive, evidence-based report that discusses how these findings might affect the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"Based on mRNA TPM data from the tumor immune microenvironment of a male, Asian patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 1.0 mutations per megabase, could you evaluate his likelihood of responding to Atezolizumab and provide the rationale for classifying him as a responder or non-responder?","Based on mRNA TPM data from the tumor immune microenvironment of a male, Asian patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 1.0 mutations per megabase, could you evaluate his likelihood of responding to Atezolizumab and provide the rationale for classifying him as a responder or non-responder? Please log into the COMPASS platform and review the tumor's transcriptomic profile. When performing your analysis, focus on detecting any immunosuppressive characteristics such as reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts. Additionally, look for evidence of an active immune response, including increased macrophage infiltration, higher interferon-gamma signaling, and maintained genomic stability. Once your evaluation is complete, prepare a detailed, evidence-based report discussing how these findings may impact the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"Based on mRNA TPM data profiling the tumor immune microenvironment in a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 6.0 mutations per MB, could you determine whether this patient is likely to respond to Atezolizumab treatment, and please provide the supporting rationale for your conclusion?","Based on mRNA TPM data profiling the tumor immune microenvironment in a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 6.0 mutations per MB, could you determine whether this patient is likely to respond to Atezolizumab treatment, and please provide the supporting rationale for your conclusion? Please log into the COMPASS platform and review the tumor’s transcriptomic profile. In your analysis, specifically assess for markers of immunosuppression—including decreased natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts—and simultaneously look for indicators of an active immune response, such as increased macrophage infiltration, heightened interferon-gamma signaling, and stable genomic features. Once your evaluation is complete, compile a comprehensive, evidence-based report outlining how these findings may affect the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"A patient diagnosed with bladder urothelial carcinoma has been evaluated using mRNA TPM data to characterize the tumor immune microenvironment. The patient is female, with an unknown racial background, and presents with a bladder tumor displaying a tumor mutational burden of 8.0 mutations per megabase. Based on these details, can you determine whether the patient is more likely to respond to Atezolizumab, and please explain the rationale behind your conclusion?","A patient diagnosed with bladder urothelial carcinoma has been evaluated using mRNA TPM data to characterize the tumor immune microenvironment. The patient is female, with an unknown racial background, and presents with a bladder tumor displaying a tumor mutational burden of 8.0 mutations per megabase. Based on these details, can you determine whether the patient is more likely to respond to Atezolizumab, and please explain the rationale behind your conclusion? Please sign in to the COMPASS platform and examine the tumor's transcriptomic profile. As you review the data, pay particular attention to signs of immunosuppression—such as reduced natural killer cell activity, indications of T-cell exhaustion, and lower B-cell counts—as well as signals of an active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and consistent genomic stability. Upon completing your evaluation, please prepare a detailed, evidence-supported report discussing the potential implications of these findings on the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a 6.0 FMOne mutation burden per MB, white, male, and the sample tissue is from the kidney. Based on these details, can you assess whether the patient is likely to respond to treatment with atezolizumab, and please provide your supporting rationale?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a 6.0 FMOne mutation burden per MB, white, male, and the sample tissue is from the kidney. Based on these details, can you assess whether the patient is likely to respond to treatment with atezolizumab, and please provide your supporting rationale? Please log into the COMPASS platform and review the tumor's transcriptomic profile. In your analysis, focus on evidence of immunosuppression such as decreased natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts. Additionally, evaluate markers of an active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and stable genomic characteristics. Once your review is complete, compile a detailed report supported by the data that discusses how these findings might impact the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"Based on the available mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) and considering the following clinical attributes: male gender, White race, bladder tissue origin, and a tumor mutational burden of 22.0 mutations per megabase, could you please assess the predicted response to Atezolizumab? Kindly indicate whether the patient is likely to be classified as a responder or non-responder and provide the supporting rationale for your conclusion.","Based on the available mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) and considering the following clinical attributes: male gender, White race, bladder tissue origin, and a tumor mutational burden of 22.0 mutations per megabase, could you please assess the predicted response to Atezolizumab? Kindly indicate whether the patient is likely to be classified as a responder or non-responder and provide the supporting rationale for your conclusion. Please access the COMPASS platform and examine the tumor's transcriptomic data. In your evaluation, look for signs of immunosuppression—such as decreased natural killer cell activity, T-cell exhaustion, and lower B-cell counts—as well as indicators of active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and stable genomic features. When you have completed your analysis, compile a thorough, data-supported report discussing how these findings could influence the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"For a male white patient diagnosed with bladder urothelial carcinoma (BLCA) and exhibiting a tumor mutational burden of 1.0 mutations per megabase, what is the predicted likelihood of response to atezolizumab based on mRNA TPM data from the tumor immune microenvironment? Please provide your conclusion on whether the patient would be classified as a responder or non-responder, along with the supporting rationale.","For a male white patient diagnosed with bladder urothelial carcinoma (BLCA) and exhibiting a tumor mutational burden of 1.0 mutations per megabase, what is the predicted likelihood of response to atezolizumab based on mRNA TPM data from the tumor immune microenvironment? Please provide your conclusion on whether the patient would be classified as a responder or non-responder, along with the supporting rationale. Please log into the COMPASS platform and review the tumor’s transcriptomic profile. Your analysis should focus on identifying evidence of immunosuppression—specifically, reduced natural killer cell function, signs of T-cell exhaustion, and decreased B-cell numbers—as well as markers of an active immune response, such as increased macrophage infiltration, heightened interferon-gamma signaling, and stable genomic characteristics. Once your evaluation is complete, please prepare a detailed report, supported by the data, that discusses the potential impact of these findings on the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"I have mRNA TPM data reflecting the patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA), along with the following clinical attributes: female, White, tumor located in the ureter, and an indeterminate tumor mutational burden. Could you evaluate this information to determine whether the patient is likely to respond to Atezolizumab, and provide the rationale behind your assessment?","I have mRNA TPM data reflecting the patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA), along with the following clinical attributes: female, White, tumor located in the ureter, and an indeterminate tumor mutational burden. Could you evaluate this information to determine whether the patient is likely to respond to Atezolizumab, and provide the rationale behind your assessment? Please log into the COMPASS platform and examine the tumor’s transcriptomic data. Focus on identifying markers of immunosuppression—specifically, decreased natural killer cell activity, indications of T-cell exhaustion, and a lower count of B-cells—as well as signs of an active immune response, such as increased macrophage infiltration, elevated interferon-gamma signaling, and stable genomic profiles. Once you have completed your assessment, prepare a detailed, data-supported report discussing the potential implications of these findings on the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"A patient with bladder urothelial carcinoma (BLCA) has undergone mRNA TPM profiling of the tumor immune microenvironment. The patient’s profile includes male sex, white race, kidney tissue sample, and a tumor mutational burden of 2.0 mutations per MB. Based on these clinical and molecular features, can you provide an assessment of whether the patient would likely respond to atezolizumab, including the supporting rationale for your conclusion?","A patient with bladder urothelial carcinoma (BLCA) has undergone mRNA TPM profiling of the tumor immune microenvironment. The patient’s profile includes male sex, white race, kidney tissue sample, and a tumor mutational burden of 2.0 mutations per MB. Based on these clinical and molecular features, can you provide an assessment of whether the patient would likely respond to atezolizumab, including the supporting rationale for your conclusion? Please access the COMPASS platform and review the tumor’s transcriptomic profile. Specifically, evaluate for immunosuppressive features—including reduced natural killer cell activity, evidence of T-cell exhaustion, and decreased B-cell counts—as well as indicators of active immune engagement, such as increased macrophage infiltration, enhanced interferon-gamma signaling, and a stable genomic landscape. Once the analysis is complete, compile a comprehensive, data-driven report discussing how these findings may influence the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"Given processed mRNA TPM data representing the tumor immune microenvironment for a 68-year-old Caucasian male diagnosed with bladder urothelial carcinoma, and noting a tumor mutational burden of 11 mutations per MB, could you assess whether this patient is likely to respond to Atezolizumab? Please include the rationale behind your evaluation.","Given processed mRNA TPM data representing the tumor immune microenvironment for a 68-year-old Caucasian male diagnosed with bladder urothelial carcinoma, and noting a tumor mutational burden of 11 mutations per MB, could you assess whether this patient is likely to respond to Atezolizumab? Please include the rationale behind your evaluation. Please log into the COMPASS platform and review the tumor's transcriptomic profile. Within your evaluation, identify signs of immunosuppression—such as reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts—and also look for markers of active immune involvement, like increased macrophage infiltration, amplified interferon-gamma signaling, and a stable genomic profile. Once your review is complete, prepare a detailed, data-driven report discussing how these findings could affect the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"Based on mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), including the following characteristics: male, White, bladder tissue origin, and a tumor mutational burden of 9.0 mutations per megabase, do you classify this patient as a responder or non-responder to Atezolizumab? Please provide your conclusion along with the underlying rationale.","Based on mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), including the following characteristics: male, White, bladder tissue origin, and a tumor mutational burden of 9.0 mutations per megabase, do you classify this patient as a responder or non-responder to Atezolizumab? Please provide your conclusion along with the underlying rationale. Please access the COMPASS platform and examine the tumor's transcriptomic data. In your review, note any indicators of immunosuppression—such as diminished natural killer cell activity, T-cell exhaustion, and low B-cell counts—as well as markers of active immune engagement, including increased macrophage infiltration, heightened interferon-gamma signaling, and a consistent genomic profile. After your analysis, compile a detailed report supported by the data, outlining how these findings might influence the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"Based on the mRNA TPM profiling of the tumor's immune microenvironment in a patient with Bladder Urothelial Carcinoma, could you evaluate the likelihood of responsiveness to Atezolizumab? The patient is a  male of white race, with tissue sampled from the kidney, and a tumor mutational burden that is currently undetermined.","Based on the mRNA TPM profiling of the tumor's immune microenvironment in a patient with Bladder Urothelial Carcinoma, could you evaluate the likelihood of responsiveness to Atezolizumab? The patient is a  male of white race, with tissue sampled from the kidney, and a tumor mutational burden that is currently undetermined. Access the COMPASS platform and review the tumor’s transcriptomic data. While examining the data, evaluate for signs of immune suppression—such as reduced natural killer cell activity, T-cell exhaustion, and low B-cell counts—as well as markers indicating active immune responses, including elevated macrophage infiltration, increased interferon-gamma signaling, and a stable genomic profile. After completing your analysis, prepare a comprehensive report, using the data to discuss how these findings could impact the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"I have analyzed mRNA TPM data from a patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA) with the following details: male, white, tissue derived from the kidney, and an FMOne tumor mutational burden of 14.0 mutations per MB. Could you assess whether this patient is likely to respond to Atezolizumab and provide your reasoning based on these findings?","I have analyzed mRNA TPM data from a patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA) with the following details: male, white, tissue derived from the kidney, and an FMOne tumor mutational burden of 14.0 mutations per MB. Could you assess whether this patient is likely to respond to Atezolizumab and provide your reasoning based on these findings? Please log in to the COMPASS platform to review the tumor’s transcriptomic dataset. As you analyze the data, assess for evidence of immune suppression—for example, diminished natural killer cell activity, signs of T-cell exhaustion, and decreased B-cell counts—as well as indicators of active immune responses, such as increased macrophage infiltration, heightened interferon-gamma signaling, and a stable genomic profile. Once your evaluation is complete, prepare a detailed report that discusses how these findings may affect the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"Based on mRNA TPM data assessing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), I'm seeking to determine the predicted responsiveness to Atezolizumab. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 18.0 mutations per megabase. Could you provide a conclusion on whether this patient is classified as a responder or non-responder, along with the underlying rationale?
","Based on mRNA TPM data assessing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), I'm seeking to determine the predicted responsiveness to Atezolizumab. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 18.0 mutations per megabase. Could you provide a conclusion on whether this patient is classified as a responder or non-responder, along with the underlying rationale?
 Please access the COMPASS platform and carefully review the tumor’s transcriptomic dataset. In your analysis, evaluate for immune suppression by looking for indications such as reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts. Also, assess for markers of active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and a stable genomic profile. Once you have completed your analysis, compile a detailed report explaining how these findings might influence the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"I have processed mRNA TPM data from a bladder tissue sample of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a 13.0 FMOne mutation burden per MB, white male. Based on this data, can you conclude whether the patient is likely to respond to Atezolizumab, and please explain the reasoning behind your assessment?","I have processed mRNA TPM data from a bladder tissue sample of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a 13.0 FMOne mutation burden per MB, white male. Based on this data, can you conclude whether the patient is likely to respond to Atezolizumab, and please explain the reasoning behind your assessment? Please log in to the COMPASS platform and examine the tumor's transcriptomic data. As you review the dataset, assess for evidence of immune suppression—specifically, look for indicators such as diminished natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts. Additionally, evaluate markers that suggest an active immune response, including heightened macrophage infiltration, increased interferon-gamma signaling, and a stable genomic profile. After completing your analysis, prepare a comprehensive report detailing how these findings could affect the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"I have mRNA TPM data representing the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a Black or African American female, with primary bladder tumor tissue and a tumor mutational burden of 8.0 mutations per MB. Based on this information, could you determine whether the patient is likely to be a responder to atezolizumab, and please provide your supporting rationale?","I have mRNA TPM data representing the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a Black or African American female, with primary bladder tumor tissue and a tumor mutational burden of 8.0 mutations per MB. Based on this information, could you determine whether the patient is likely to be a responder to atezolizumab, and please provide your supporting rationale? Please access the COMPASS platform and review the tumor's transcriptomic data. In your analysis, evaluate for signs of immune suppression—such as decreased natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts—as well as markers of an active immune response, including increased macrophage infiltration, heightened interferon-gamma signaling, and a stable genomic profile. Once completed, prepare a detailed report explaining how these findings may influence the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"For a patient with bladder urothelial carcinoma, mRNA TPM data of the tumor immune microenvironment has been processed to evaluate predicted responsiveness to Atezolizumab. The patient is female, Caucasian, with a primary tumor in the bladder and a tumor mutational burden of 6.0 FMOne mutations per MB. Based on these clinical details, could you help determine if this patient is likely to respond to Atezolizumab and explain the reasoning behind your assessment?","For a patient with bladder urothelial carcinoma, mRNA TPM data of the tumor immune microenvironment has been processed to evaluate predicted responsiveness to Atezolizumab. The patient is female, Caucasian, with a primary tumor in the bladder and a tumor mutational burden of 6.0 FMOne mutations per MB. Based on these clinical details, could you help determine if this patient is likely to respond to Atezolizumab and explain the reasoning behind your assessment? Please log in to the COMPASS platform and examine the tumor's transcriptomic dataset. In your evaluation, look for evidence of immune suppression, such as reduced natural killer cell activity, signs of T-cell exhaustion, and decreased B-cell counts, as well as indicators of an active immune response, including increased macrophage infiltration, enhanced interferon-gamma signaling, and a stable genomic profile. After your review, compile a comprehensive report detailing how these findings could affect the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"I have analyzed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma. The patient is a white male with bladder tissue involvement, and the tumor mutational burden is reported as not available (nan). Based on these clinical attributes, can you provide an evidence-based assessment of whether this patient is likely to respond to atezolizumab, including your supporting rationale?","I have analyzed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma. The patient is a white male with bladder tissue involvement, and the tumor mutational burden is reported as not available (nan). Based on these clinical attributes, can you provide an evidence-based assessment of whether this patient is likely to respond to atezolizumab, including your supporting rationale? Please access the COMPASS platform and review the tumor's transcriptomic dataset. During your analysis, assess for signs of immune suppression—such as diminished activity of natural killer cells, indications of T-cell exhaustion, and lower B-cell counts—as well as evidence of an active immune response, including increased macrophage infiltration, enhanced interferon-gamma signaling, and a preserved genomic profile. Once you have completed your examination, please prepare a detailed report outlining how these findings may influence the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"For a 65-year-old white male with bladder urothelial carcinoma exhibiting a tumor mutational burden of 23 mutations per MB and mRNA TPM data reflecting his tumor immune microenvironment, could you assess his likelihood of responding to Atezolizumab? Please provide your conclusion along with the supporting rationale.","For a 65-year-old white male with bladder urothelial carcinoma exhibiting a tumor mutational burden of 23 mutations per MB and mRNA TPM data reflecting his tumor immune microenvironment, could you assess his likelihood of responding to Atezolizumab? Please provide your conclusion along with the supporting rationale. Please log into the COMPASS platform and examine the tumor transcriptomic dataset. While reviewing the data, evaluate for markers of immune suppression (for example, reduced natural killer cell activity, signs of T-cell exhaustion, and decreased B-cell counts) as well as indicators of an active immune response (such as enhanced macrophage infiltration, increased interferon-gamma signaling, and a preserved genomic profile). Once you have completed your assessment, compile a detailed report that explains how these findings could impact the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"We have mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient’s details are as follows: Sex: Female; Race: White; Sample source: lymph node; Disease: BLCA; and Tumor Mutational Burden: not available. Based on these parameters, can you assess whether this patient is likely to respond to Atezolizumab and explain the rationale behind your conclusion?","We have mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient’s details are as follows: Sex: Female; Race: White; Sample source: lymph node; Disease: BLCA; and Tumor Mutational Burden: not available. Based on these parameters, can you assess whether this patient is likely to respond to Atezolizumab and explain the rationale behind your conclusion? Log into the COMPASS platform and review the tumor transcriptomic dataset. As you analyze the data, assess for signs of immune suppression—such as decreased natural killer cell activity, features indicating T-cell exhaustion, and lower B-cell counts—and also look for evidence of an active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and a stable genomic profile. After completing your review, prepare a detailed report discussing how these findings might influence the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"I have mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with tissue obtained from a lymph node and a tumor mutational burden of 2.0 mutations per MB. Based on these data, could you assess whether this patient is likely to respond to Atezolizumab and explain the reasoning behind your evaluation?","I have mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with tissue obtained from a lymph node and a tumor mutational burden of 2.0 mutations per MB. Based on these data, could you assess whether this patient is likely to respond to Atezolizumab and explain the reasoning behind your evaluation? Please access the COMPASS platform and locate the tumor transcriptomic dataset. As you examine the data, evaluate for indications of immune suppression—such as diminished natural killer cell activity, characteristics of T‐cell exhaustion, and reduced B‐cell counts—and also check for signs of an active immune response, like increased macrophage infiltration, heightened interferon-gamma signaling, and a stable genomic profile. Once your analysis is complete, prepare a comprehensive report that details how these findings may affect the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"In a male patient with bladder urothelial carcinoma (BLCA) of White ethnicity, we have processed mRNA TPM data for the tumor immune microenvironment; however, the tumor mutational burden is not available. Based on these details, can you determine whether the patient is likely to respond to Atezolizumab and provide the supporting rationale?","In a male patient with bladder urothelial carcinoma (BLCA) of White ethnicity, we have processed mRNA TPM data for the tumor immune microenvironment; however, the tumor mutational burden is not available. Based on these details, can you determine whether the patient is likely to respond to Atezolizumab and provide the supporting rationale? Please log into the COMPASS platform and locate the tumor transcriptomic dataset. Carefully review the data for signs of immune suppression—such as reduced natural killer cell activity, markers of T‐cell exhaustion, and lower B‐cell counts—as well as evidence of an active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and a stable genomic profile. Once your evaluation is complete, compile a detailed report explaining how these observations might influence the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"I have mRNA TPM data characterizing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a bladder tumor and a tumor mutational burden of 7.0 mutations per megabase. Could you assess whether this patient is likely to respond to Atezolizumab, and please provide the underlying rationale for your conclusion?","I have mRNA TPM data characterizing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a bladder tumor and a tumor mutational burden of 7.0 mutations per megabase. Could you assess whether this patient is likely to respond to Atezolizumab, and please provide the underlying rationale for your conclusion? Log in to the COMPASS platform and open the tumor transcriptomic dataset. Carefully analyze the data for two groups of signals: first, markers indicating immune suppression—such as decreased natural killer cell activity, signs of T‐cell exhaustion, and reduced B‐cell counts; and second, signals of an active immune response—such as increased macrophage infiltration, higher levels of interferon‐gamma signaling, and a stable genomic profile. Once you have completed your analysis, prepare a comprehensive report detailing how these findings could affect the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a 1.0 mutation/Mb male of Asian descent, with bladder tissue involvement. Based on these attributes, could you please determine if the patient is predicted to be a responder or non-responder to Atezolizumab, and provide your reasoning?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a 1.0 mutation/Mb male of Asian descent, with bladder tissue involvement. Based on these attributes, could you please determine if the patient is predicted to be a responder or non-responder to Atezolizumab, and provide your reasoning? Access the COMPASS platform and load the tumor transcriptomic dataset. Evaluate the data by focusing on two main groups of signals. For immune suppression, look for indicators such as decreased natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts. For an active immune response, assess markers like enhanced macrophage infiltration, increased interferon-gamma signaling, and a stable genomic profile. After completing your analysis, compile a detailed report discussing how these findings may impact the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"For a patient with bladder urothelial carcinoma, we have processed mRNA TPM data of the tumor immune microenvironment along with the following clinical characteristics: male, white, tissue sampled from the ureter, and a tumor mutational burden of 7.0 mutations per MB. Based on these data, can you assess whether this patient is likely to respond to Atezolizumab, and provide the rationale supporting your conclusion?","For a patient with bladder urothelial carcinoma, we have processed mRNA TPM data of the tumor immune microenvironment along with the following clinical characteristics: male, white, tissue sampled from the ureter, and a tumor mutational burden of 7.0 mutations per MB. Based on these data, can you assess whether this patient is likely to respond to Atezolizumab, and provide the rationale supporting your conclusion? Please log into the COMPASS platform and retrieve the tumor transcriptomic dataset. Analyze the data by categorizing the signals into two key groups. In the immune suppression category, assess indicators such as decreased natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts. In the active immune response category, evaluate markers including enhanced macrophage infiltration, increased interferon-gamma signaling, and a stable genomic profile. Once your analysis is complete, prepare a detailed report discussing how these observations might influence the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"Based on the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the associated clinical parameters (male, white, bladder tissue, and a tumor mutational burden of 5.0 mutations/MB), can we determine if this patient is likely to respond to Atezolizumab? Please provide a conclusion supported by the relevant data.","Based on the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the associated clinical parameters (male, white, bladder tissue, and a tumor mutational burden of 5.0 mutations/MB), can we determine if this patient is likely to respond to Atezolizumab? Please provide a conclusion supported by the relevant data. Log into the COMPASS platform and access the tumor transcriptomic dataset. Analyze the dataset by dividing the signals into two distinct groups. For the immune suppression group, examine biomarkers such as reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts. For the active immune response group, assess factors including increased macrophage infiltration, elevated interferon-gamma signaling, and a stable genomic profile. After completing your analysis, prepare a comprehensive report discussing how these findings might impact the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) exhibiting an mRNA TPM profile of the tumor immune microenvironment, and with a Tumor Mutational Burden of 6.0 mutations per megabase, how likely is it that this white male patient will respond to Atezolizumab? Please provide your assessment of his responder status and the supporting rationale.","For a patient with Bladder Urothelial Carcinoma (BLCA) exhibiting an mRNA TPM profile of the tumor immune microenvironment, and with a Tumor Mutational Burden of 6.0 mutations per megabase, how likely is it that this white male patient will respond to Atezolizumab? Please provide your assessment of his responder status and the supporting rationale. Please log in to the COMPASS platform and navigate to the tumor transcriptomic dataset. Divide the dataset into two groups for analysis. In the immune suppression group, evaluate biomarkers such as decreased natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts. In the active immune response group, focus on factors like increased macrophage infiltration, higher levels of interferon-gamma signaling, and a consistent genomic profile. Once you have completed your analysis, compile a comprehensive report detailing how these results may influence the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The key attributes of this patient are: male, white, lung tissue sample, and an undefined tumor mutational burden (reported as ""nan""). Based on the mRNA TPM profile and the available clinical data, can you evaluate whether this patient is likely to be responsive or non-responsive to Atezolizumab, and please explain the reasoning behind your assessment?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The key attributes of this patient are: male, white, lung tissue sample, and an undefined tumor mutational burden (reported as ""nan""). Based on the mRNA TPM profile and the available clinical data, can you evaluate whether this patient is likely to be responsive or non-responsive to Atezolizumab, and please explain the reasoning behind your assessment? Please access the COMPASS platform and locate the tumor transcriptomic dataset. Once you have the dataset, separate it into two distinct groups for subsequent analysis. For the group associated with immune suppression, assess biomarkers including reduced natural killer cell activity, signs of T-cell exhaustion, and diminished B-cell counts. For the group demonstrating an active immune response, examine parameters such as enhanced macrophage infiltration, elevated interferon-gamma signaling, and a uniform genomic profile. After completing your evaluations, please prepare a detailed report that discusses how these findings may affect the patient's treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"Based on a patient dataset that includes mRNA TPM data of the tumor immune microenvironment from a lymph node biopsy in a male, Caucasian patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 2.0 mutations per megabase, could you evaluate and determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and please provide the supporting rationale for your conclusion.","Based on a patient dataset that includes mRNA TPM data of the tumor immune microenvironment from a lymph node biopsy in a male, Caucasian patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 2.0 mutations per megabase, could you evaluate and determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and please provide the supporting rationale for your conclusion. Access the COMPASS platform and retrieve the tumor transcriptomic dataset. Divide the data into two groups for further analysis. For the group showing immune suppression characteristics, evaluate biomarkers such as decreased natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts. For the group exhibiting active immune responses, focus on parameters like increased macrophage infiltration, higher levels of interferon-gamma signaling, and a consistent genomic profile. Once analyses are complete, compile a comprehensive report detailing how these findings could influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"Given the patient has Bladder Urothelial Carcinoma (BLCA) and mRNA TPM data from the tumor immune microenvironment, and considering the following attributes—Sex: M, Race: White, Tissue: bladder, and a tumor mutational burden of 44 mutations per MB—how would you determine if this patient is likely to respond to Atezolizumab? Please provide a clinical interpretation with supporting reasoning.","Given the patient has Bladder Urothelial Carcinoma (BLCA) and mRNA TPM data from the tumor immune microenvironment, and considering the following attributes—Sex: M, Race: White, Tissue: bladder, and a tumor mutational burden of 44 mutations per MB—how would you determine if this patient is likely to respond to Atezolizumab? Please provide a clinical interpretation with supporting reasoning. Please log in to the COMPASS platform and download the tumor transcriptomic dataset. Next, stratify the patients into two distinct groups: one exhibiting features of immune suppression and the other demonstrating active immune responses. For the immune-suppressed group, assess biomarkers such as reduced natural killer cell activity, signs of T-cell exhaustion, and decreased B-cell counts. In contrast, for the group with active immune responses, evaluate indicators like increased macrophage infiltration, higher levels of interferon-gamma signaling, and a stable genomic profile. Conclude by compiling a detailed report that explains how these immunologic profiles may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"Could you please analyze the processed mRNA TPM data from this patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) to determine if they are likely to respond to Atezolizumab? The patient's details are as follows: Male, White, tissue sample from the kidney, diagnosed with BLCA, and exhibiting a tumor mutational burden of 15.0 mutations per megabase. Please provide your conclusion on responder status along with the supporting rationale for your assessment.","Could you please analyze the processed mRNA TPM data from this patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) to determine if they are likely to respond to Atezolizumab? The patient's details are as follows: Male, White, tissue sample from the kidney, diagnosed with BLCA, and exhibiting a tumor mutational burden of 15.0 mutations per megabase. Please provide your conclusion on responder status along with the supporting rationale for your assessment. Access the COMPASS platform and download the tumor transcriptomic dataset. Then, classify the patients into two groups: one with features indicating immune suppression and another with signs of active immune responses. For the immune-suppressed group, evaluate biomarkers such as diminished natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts. For the group with active immune responses, assess parameters like elevated macrophage infiltration, increased interferon-gamma signaling, and a stable genomic profile. Finally, prepare a comprehensive report detailing how these distinct immunologic profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"Given the mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), along with the following clinical details—male, White, tumor tissue from a lymph node, and a tumor mutational burden of 17 mutations per megabase—can you determine whether this patient is likely to respond to Atezolizumab? Please include your supporting rationale.","Given the mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), along with the following clinical details—male, White, tumor tissue from a lymph node, and a tumor mutational burden of 17 mutations per megabase—can you determine whether this patient is likely to respond to Atezolizumab? Please include your supporting rationale. Please access the COMPASS platform and download the tumor transcriptomic dataset. Once obtained, classify the patients into two groups: one demonstrating signs of immune suppression and the other showing evidence of active immune responses. For the immune-suppressed group, assess biomarkers such as reduced natural killer cell activity, indications of T-cell exhaustion, and lower B-cell counts. For the group with active immune responses, evaluate factors including increased macrophage infiltration, heightened interferon-gamma signaling, and a stable genomic profile. Finally, compile a comprehensive report that discusses how these distinct immunologic profiles may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"I have analyzed mRNA TPM data detailing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient's details are: male, White, tissue sample from the kidney, with a tumor mutational burden of 11.0 (FMO mutation per MB). Based on these findings, could you determine whether the patient is predicted to respond to Atezolizumab, and could you explain the reasoning behind your assessment?","I have analyzed mRNA TPM data detailing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient's details are: male, White, tissue sample from the kidney, with a tumor mutational burden of 11.0 (FMO mutation per MB). Based on these findings, could you determine whether the patient is predicted to respond to Atezolizumab, and could you explain the reasoning behind your assessment? Access the COMPASS platform and download the tumor transcriptomic dataset. Next, stratify the patients into two distinct groups: one exhibiting signs of immune suppression and the other showing evidence of active immune responses. For patients in the immune-suppressed group, evaluate biomarkers including reduced natural killer cell activity, markers indicative of T-cell exhaustion, and decreased B-cell counts. In contrast, for patients with active immune responses, examine indicators such as increased macrophage infiltration, elevated interferon-gamma signaling, and a stable genomic profile. Finally, prepare a detailed report discussing how these immunologic differences might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"Given processed mRNA TPM data of the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) who is a white male with bladder tissue involvement and an undefined tumor mutational burden (FMOne mutation burden per MB reported as 'nan'), would you classify this patient as a responder or non-responder to Atezolizumab? Please provide the rationale for your classification based on the molecular and clinical parameters.","Given processed mRNA TPM data of the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) who is a white male with bladder tissue involvement and an undefined tumor mutational burden (FMOne mutation burden per MB reported as 'nan'), would you classify this patient as a responder or non-responder to Atezolizumab? Please provide the rationale for your classification based on the molecular and clinical parameters. Please log in to the COMPASS platform and download the tumor transcriptomic dataset. Once downloaded, stratify the patients into two groups: one group with evidence of immune suppression and another with signs of active immune responses. For the immune-suppressed group, assess biomarkers such as decreased natural killer cell activity, markers of T-cell exhaustion, and reduced B-cell counts. Conversely, for the group with active immune responses, evaluate parameters including increased macrophage infiltration, elevated interferon-gamma signaling, and a stable genomic profile. Finally, prepare a comprehensive report analyzing how these immunologic differences may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment for a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tissue source from the bladder and an undefined tumor mutational burden. Could you please evaluate whether this patient is likely to respond to Atezolizumab therapy, and provide your rationale based on these parameters?","I have processed mRNA TPM data representing the tumor immune microenvironment for a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tissue source from the bladder and an undefined tumor mutational burden. Could you please evaluate whether this patient is likely to respond to Atezolizumab therapy, and provide your rationale based on these parameters? Please access the COMPASS platform and download the tumor transcriptomic dataset. Once you have the data, divide the patients into two distinct groups: one group exhibiting signs of immune suppression and another showing evidence of an active immune response. For the immune-suppressed group, evaluate biomarkers such as reduced natural killer cell activity, markers indicative of T-cell exhaustion, and lower B-cell counts. For the group with active immune responses, assess for increased macrophage infiltration, heightened interferon-gamma signaling, and a stable genomic profile. Finally, compile a detailed report analyzing how these immunological differences might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"For a patient with bladder urothelial carcinoma, we have processed mRNA TPM data reflecting the tumor immune microenvironment. This patient is a white male with bladder tissue involvement and a tumor mutational burden of 12.0 mutations per megabase. Based on these findings, what is your assessment of his predicted response to Atezolizumab, and what evidence supports this evaluation?","For a patient with bladder urothelial carcinoma, we have processed mRNA TPM data reflecting the tumor immune microenvironment. This patient is a white male with bladder tissue involvement and a tumor mutational burden of 12.0 mutations per megabase. Based on these findings, what is your assessment of his predicted response to Atezolizumab, and what evidence supports this evaluation? Please log in to the COMPASS platform and download the tumor transcriptomic dataset. Next, stratify the patients into two groups: one group displaying markers of immune suppression and another with active immune responses. For the immune-suppressed group, examine indicators such as decreased natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts. In contrast, for the active immune response group, evaluate features like increased macrophage infiltration, heightened interferon-gamma signaling, and a genomically stable profile. Finally, prepare a comprehensive report that explores how these differing immunological characteristics could impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient details are as follows: male, White, bladder tissue, and a tumor mutational burden of 6.0 FMOne mutations per MB. Based on these parameters, could you provide an evaluation of whether this patient is likely to respond to atezolizumab treatment, including your supporting rationale?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient details are as follows: male, White, bladder tissue, and a tumor mutational burden of 6.0 FMOne mutations per MB. Based on these parameters, could you provide an evaluation of whether this patient is likely to respond to atezolizumab treatment, including your supporting rationale? Please access the COMPASS platform and download the tumor transcriptomic dataset. Then, divide the patients into two groups: one group that exhibits markers of immune suppression and another that shows signs of an active immune response. For the immune-suppressed group, assess markers such as reduced natural killer cell activity, evidence of T-cell exhaustion, and decreased B-cell counts. For the group with active immune responses, evaluate features such as increased macrophage infiltration, heightened interferon-gamma signaling, and a genomically stable profile. Finally, compile a detailed report discussing how these distinct immunological profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,I have processed mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA) and want to evaluate his likely response to Atezolizumab. The patient is a 5.0 mutations per MB tumor mutational burden white male with bladder tissue involvement in BLCA. Can you assess whether he is likely to be a responder or non-responder to Atezolizumab and provide the rationale for your conclusion?,"I have processed mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA) and want to evaluate his likely response to Atezolizumab. The patient is a 5.0 mutations per MB tumor mutational burden white male with bladder tissue involvement in BLCA. Can you assess whether he is likely to be a responder or non-responder to Atezolizumab and provide the rationale for your conclusion? Access the COMPASS platform to download the tumor transcriptomic dataset. Next, stratify the patient cohort into two groups based on their immunological profiles. One group should be characterized by markers indicative of immune suppression, such as diminished natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts, while the other group should display markers of an active immune response, including increased macrophage infiltration, elevated interferon-gamma signaling, and a genomically stable profile. After stratification, prepare a comprehensive report analyzing how these distinct immune profiles might affect treatment responses.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"I have processed mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) to evaluate their likely response to Atezolizumab. The patient is a white male with a reported tumor mutational burden of 8.0 (FMOne mutations per MB), and tumor tissue information is not available. Based on these details, could you determine if the patient is more likely to be a responder or a non-responder to Atezolizumab, and please provide your reasoning?","I have processed mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) to evaluate their likely response to Atezolizumab. The patient is a white male with a reported tumor mutational burden of 8.0 (FMOne mutations per MB), and tumor tissue information is not available. Based on these details, could you determine if the patient is more likely to be a responder or a non-responder to Atezolizumab, and please provide your reasoning? Please log into the COMPASS platform and download the tumor transcriptomic dataset. Once you have the dataset, divide the patient cohort into two groups based on their immune profiles. The first group should include patients with indicators of an immunosuppressive environment, such as reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts. The second group should consist of patients exhibiting an active immune response, evidenced by increased macrophage infiltration, higher interferon-gamma signaling, and a genomically stable profile. After categorizing the groups, prepare a detailed report evaluating how these distinct immune profiles could influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"Based on processed mRNA TPM data of the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA), how would you evaluate the likelihood of a favorable response to Atezolizumab? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 8.0 mutations per MB. Could you provide your assessment of this patient being a responder or non-responder and outline the supporting rationale?","Based on processed mRNA TPM data of the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA), how would you evaluate the likelihood of a favorable response to Atezolizumab? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 8.0 mutations per MB. Could you provide your assessment of this patient being a responder or non-responder and outline the supporting rationale? Please access the COMPASS platform to download the tumor transcriptomic dataset. Once you have the dataset, sort the patients into two groups based on their immune profiles. For the first group, select patients exhibiting an immunosuppressive profile, indicated by reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts. For the second group, include patients showing an active immune response, as demonstrated by increased macrophage infiltration, elevated interferon-gamma signaling, and genomic stability. After grouping the patients, prepare a comprehensive report assessing how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"Based on mRNA TPM data from a patient's tumor immune microenvironment in a case of bladder urothelial carcinoma (BLCA), could you evaluate the predicted responsiveness to Atezolizumab? The patient is a male with unknown race, the tumor originates in the bladder, and the tumor mutational burden is 0.0 mutations per MB. Please provide your conclusion regarding whether this patient is likely to be a responder or non-responder, and detail the supporting reasoning.","Based on mRNA TPM data from a patient's tumor immune microenvironment in a case of bladder urothelial carcinoma (BLCA), could you evaluate the predicted responsiveness to Atezolizumab? The patient is a male with unknown race, the tumor originates in the bladder, and the tumor mutational burden is 0.0 mutations per MB. Please provide your conclusion regarding whether this patient is likely to be a responder or non-responder, and detail the supporting reasoning. Please log in to the COMPASS platform and download the transcriptomic dataset for tumors. Next, classify the patients into two groups based on their immune profiles. The first group should consist of patients with an immunosuppressive phenotype—those exhibiting reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts. The second group should include patients with an active immune profile, characterized by increased macrophage infiltration, heightened interferon-gamma signaling, and genomic stability. After grouping the patients, prepare a comprehensive report that evaluates how these distinct immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a tumor mutational burden of 5.0 mutations per megabase, and the sampled tissue is from the kidney. Could you provide an assessment of whether this patient is likely to respond to Atezolizumab, including your supporting rationale?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a tumor mutational burden of 5.0 mutations per megabase, and the sampled tissue is from the kidney. Could you provide an assessment of whether this patient is likely to respond to Atezolizumab, including your supporting rationale? Log in to the COMPASS platform and download the transcriptomic dataset for tumors. Then, categorize the patients into two groups based on their immune profiles. The first group should include patients with an immunosuppressive phenotype, defined by reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts. The second group should comprise patients with an active immune profile, indicated by increased macrophage infiltration, enhanced interferon-gamma signaling, and maintained genomic stability. Finally, compile a detailed report evaluating how these distinct immune profiles could potentially impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"I have mRNA TPM data representing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, with the tissue sample taken from the kidney, and a tumor mutational burden of 6.0 mutations per megabase. Based on these clinical details, could you please assess whether this patient is likely to respond to Atezolizumab and explain your reasoning?","I have mRNA TPM data representing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, with the tissue sample taken from the kidney, and a tumor mutational burden of 6.0 mutations per megabase. Based on these clinical details, could you please assess whether this patient is likely to respond to Atezolizumab and explain your reasoning? Please access the COMPASS platform and download the transcriptomic dataset for tumors. Next, divide the patients into two groups according to their immune characteristics. One group should consist of patients exhibiting an immunosuppressive profile, which is determined by diminished natural killer cell activity, markers of T-cell exhaustion, and lower counts of B-cells. The other group should include patients with an active immune profile, characterized by enhanced macrophage infiltration, increased interferon-gamma signaling, and maintained genomic stability. Finally, prepare a comprehensive report that examines how these different immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"Given the processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), could you please evaluate the predicted treatment response to Atezolizumab? The patient’s details are as follows: Female, White, tissue sample from the kidney, and tumor mutational burden data is not available. Please provide a conclusion on whether this patient is likely to respond to Atezolizumab, including your supporting reasoning.","Given the processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), could you please evaluate the predicted treatment response to Atezolizumab? The patient’s details are as follows: Female, White, tissue sample from the kidney, and tumor mutational burden data is not available. Please provide a conclusion on whether this patient is likely to respond to Atezolizumab, including your supporting reasoning. Please log into the COMPASS platform and download the transcriptomic dataset for tumors. Then, stratify the patients into two groups based on their immune profiles: one group should include patients with an immunosuppressive profile, defined by reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts; the other group should consist of patients with an active immune profile, characterized by increased macrophage infiltration, enhanced interferon-gamma signaling, and maintained genomic stability. Finally, prepare a detailed report analyzing how these distinct immune profiles could affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"In a patient with Bladder Urothelial Carcinoma who has undergone mRNA TPM profiling of the tumor immune microenvironment—with a tumor mutational burden of 59 mutations/MB, male sex, white race, and a tumor originating in the ureter—can current predictive models determine whether this patient is likely to respond to Atezolizumab? Please provide a detailed explanation supporting your conclusion.","In a patient with Bladder Urothelial Carcinoma who has undergone mRNA TPM profiling of the tumor immune microenvironment—with a tumor mutational burden of 59 mutations/MB, male sex, white race, and a tumor originating in the ureter—can current predictive models determine whether this patient is likely to respond to Atezolizumab? Please provide a detailed explanation supporting your conclusion. Please access the COMPASS platform and download the transcriptomic dataset for tumor samples. Next, stratify the patient cohort into two groups based on their immune characteristics. One group should comprise patients with an immunosuppressive profile, indicated by reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts. The other group should include patients with an active immune profile, marked by increased macrophage infiltration, elevated interferon-gamma signaling, and preserved genomic stability. Finally, prepare a comprehensive report analyzing how these differing immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"I have mRNA TPM data reflecting the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a 13.0 mutation per MB tumor mutational burden male of white race with kidney tissue involvement. Based on these details, could you assess whether this patient is predicted to be a responder to Atezolizumab, and provide supporting reasoning for your conclusion?","I have mRNA TPM data reflecting the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a 13.0 mutation per MB tumor mutational burden male of white race with kidney tissue involvement. Based on these details, could you assess whether this patient is predicted to be a responder to Atezolizumab, and provide supporting reasoning for your conclusion? Please log into the COMPASS platform and download the transcriptomic data from the tumor samples. Once you have the data, divide the patient cohort into two groups based on immune characteristics. One group should consist of patients with an immunosuppressive profile, which is indicated by diminished natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts. The other group should include patients with an active immune profile, characterized by increased macrophage infiltration, higher levels of interferon-gamma signaling, and maintained genomic stability. Finally, compile a detailed report analyzing how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"Based on mRNA TPM data reflecting the tumor immune microenvironment and the patient’s clinical profile (female, race: other, ureter tissue involvement, Bladder Urothelial Carcinoma, and a tumor mutational burden of 12.0 mutations/MB), what is the predicted response to Atezolizumab? Please provide a conclusion on whether the patient is likely to be a responder or non-responder, along with the supporting scientific rationale.","Based on mRNA TPM data reflecting the tumor immune microenvironment and the patient’s clinical profile (female, race: other, ureter tissue involvement, Bladder Urothelial Carcinoma, and a tumor mutational burden of 12.0 mutations/MB), what is the predicted response to Atezolizumab? Please provide a conclusion on whether the patient is likely to be a responder or non-responder, along with the supporting scientific rationale. Please access the COMPASS platform and download the transcriptomic data for the tumor samples. Once you have the data, stratify the patients into two groups based on their immune profiles. The first group should include patients exhibiting an immunosuppressive profile, characterized by reduced natural killer cell activity, indications of T-cell exhaustion, and lowered B-cell counts. The second group should consist of patients with an active immune profile, marked by higher levels of macrophage infiltration, increased interferon-gamma signaling, and stable genomic features. After grouping the patients, prepare a detailed report analyzing how these distinct immune profiles could influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"Based on my analysis of the patient's mRNA TPM data from the tumor immune microenvironment in the context of bladder urothelial carcinoma (BLCA)—noting that the patient is a white male with lymph node tissue involvement and a tumor mutational burden of 4.0 mutations per megabase—could you determine whether he is likely to respond to Atezolizumab? Please provide a conclusion, including your supporting reasoning.","Based on my analysis of the patient's mRNA TPM data from the tumor immune microenvironment in the context of bladder urothelial carcinoma (BLCA)—noting that the patient is a white male with lymph node tissue involvement and a tumor mutational burden of 4.0 mutations per megabase—could you determine whether he is likely to respond to Atezolizumab? Please provide a conclusion, including your supporting reasoning. Please log into the COMPASS platform and download the transcriptomic dataset corresponding to the tumor samples. After obtaining the data, stratify the patients into two cohorts based on their immune profiles. The first cohort should comprise patients with an immunosuppressive profile, identified by diminished natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts. In contrast, the second cohort should include patients with an active immune profile, characterized by elevated macrophage infiltration, increased interferon-gamma signaling, and stable genomic markers. Once the patients have been grouped, compile a comprehensive report evaluating the potential impact of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"For a male, white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 11 mutations per megabase, whose mRNA TPM data was used to characterize the tumor immune microenvironment, does the evidence suggest a likely positive response to Atezolizumab treatment? Please provide your assessment along with the rationale for classifying the patient as a responder or non-responder.","For a male, white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 11 mutations per megabase, whose mRNA TPM data was used to characterize the tumor immune microenvironment, does the evidence suggest a likely positive response to Atezolizumab treatment? Please provide your assessment along with the rationale for classifying the patient as a responder or non-responder. Please access the COMPASS platform and download the transcriptomic dataset for the tumor samples. Once you have the data, divide the patients into two groups based on their immune profiles. One group should include patients with an immunosuppressive profile, as evidenced by reduced natural killer cell activity, T-cell exhaustion, and decreased B-cell counts. The other group should consist of patients showing an active immune profile, characterized by increased macrophage infiltration, heightened interferon-gamma signaling, and stable genomic markers. Finally, prepare a detailed report assessing how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a White male with bladder tissue involvement and a tumor mutational burden of 5 mutations per MB. Based on these parameters, could you provide an assessment of the patient’s predicted responsiveness to Atezolizumab, including your rationale?","I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a White male with bladder tissue involvement and a tumor mutational burden of 5 mutations per MB. Based on these parameters, could you provide an assessment of the patient’s predicted responsiveness to Atezolizumab, including your rationale? Please log in to the COMPASS platform and download the transcriptomic data for the tumor samples. Once you have the data, classify the patients into two groups based on their immune characteristics. Group one should include patients exhibiting an immunosuppressive profile, indicated by diminished natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts. Group two should consist of patients displaying an active immune response, marked by increased macrophage infiltration, enhanced interferon-gamma signaling, and stable genomic markers. Finally, prepare a detailed report that evaluates how these distinct immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"Given the mRNA TPM data for the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you provide an assessment of the patient's likely responsiveness to Atezolizumab? The patient is a white female with tissue sampled from the kidney, and the tumor mutational burden is reported as ""nan"" mutations per megabase. Please include your clinical reasoning for classifying the patient as a responder or non-responder.","Given the mRNA TPM data for the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you provide an assessment of the patient's likely responsiveness to Atezolizumab? The patient is a white female with tissue sampled from the kidney, and the tumor mutational burden is reported as ""nan"" mutations per megabase. Please include your clinical reasoning for classifying the patient as a responder or non-responder. Access the COMPASS platform and download the transcriptomic data for the tumor samples. Next, stratify the patients into two groups based on their immune characteristics. For the first group, include patients showing an immunosuppressive profile defined by reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts. The second group should comprise patients with an active immune response, indicated by increased macrophage infiltration, boosted interferon-gamma signaling, and stable genomic markers. Finally, compile a detailed report assessing how these immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"Given the mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA), could you assess the predicted responsiveness to Atezolizumab? The patient is a  male of White race, with the tumor originating from the ureter and a tumor mutational burden of 5.0 mutations per MB. Based on this profile, is the patient likely to be categorized as a responder or non-responder, and what is the rationale behind your conclusion?","Given the mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA), could you assess the predicted responsiveness to Atezolizumab? The patient is a  male of White race, with the tumor originating from the ureter and a tumor mutational burden of 5.0 mutations per MB. Based on this profile, is the patient likely to be categorized as a responder or non-responder, and what is the rationale behind your conclusion? Please log in to the COMPASS platform and download the tumor sample transcriptomic data. After obtaining the data, classify the patients into two groups based on their immune profiles. For the first group, include patients who exhibit an immunosuppressive profile, characterized by diminished natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts. For the second group, include patients who display an active immune response, indicated by increased macrophage infiltration, enhanced interferon-gamma signaling, and stable genomic markers. Finally, prepare a detailed report evaluating the potential impact of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"For a patient with Bladder Urothelial Carcinoma (BLCA) who has an mRNA TPM profile of the tumor immune microenvironment, how do the following characteristics—male sex, Native Hawaiian or other Pacific Islander race, a non-standard tissue sample type, and a Tumor Mutational Burden of 19.0 mutations per megabase—affect the predicted response to Atezolizumab therapy? Please provide your assessment on the likelihood of response along with the supporting rationale.","For a patient with Bladder Urothelial Carcinoma (BLCA) who has an mRNA TPM profile of the tumor immune microenvironment, how do the following characteristics—male sex, Native Hawaiian or other Pacific Islander race, a non-standard tissue sample type, and a Tumor Mutational Burden of 19.0 mutations per megabase—affect the predicted response to Atezolizumab therapy? Please provide your assessment on the likelihood of response along with the supporting rationale. Please access the COMPASS platform and download the transcriptomic data for tumor samples. Once obtained, sort the patients into two distinct groups based on their immune characteristics. Group 1 should consist of patients with an immunosuppressive profile, marked by reduced natural killer cell function, evidence of T-cell exhaustion, and decreased B-cell counts. Group 2 should include patients with an active immune response, as demonstrated by increased macrophage infiltration, heightened interferon-gamma signaling, and stable genomic markers. Finally, compile a comprehensive report assessing how these immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"Given the mRNA TPM data for a bladder urothelial carcinoma (BLCA) patient with the following characteristics – Sex: M, Race: WHITE, Tissue: bladder, and a tumor mutational burden reported as ""nan"" – could you evaluate the likelihood of response to Atezolizumab therapy based on the tumor immune microenvironment profile, and provide the rationale for your determination?","Given the mRNA TPM data for a bladder urothelial carcinoma (BLCA) patient with the following characteristics – Sex: M, Race: WHITE, Tissue: bladder, and a tumor mutational burden reported as ""nan"" – could you evaluate the likelihood of response to Atezolizumab therapy based on the tumor immune microenvironment profile, and provide the rationale for your determination? Please log into the COMPASS platform and download the transcriptomic data for tumor samples. Then, stratify the patients into two groups based on their immune profiles. The first group should include patients exhibiting an immunosuppressive profile, characterized by reduced natural killer cell function, signs of T-cell exhaustion, and decreased B-cell counts. The second group should comprise patients displaying an active immune response, as indicated by increased macrophage infiltration, heightened interferon-gamma signaling, and stable genomic markers. Finally, prepare a detailed report evaluating how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-563d62-ar-563d623.pkl. "
BLCA,,,,NR,"We have mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) who is a white female with a bladder tumor. The tumor mutational burden is not available. Based on this information, could you please assess the predicted responsiveness to Atezolizumab and explain whether the patient is more likely to be a responder or non-responder?","We have mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) who is a white female with a bladder tumor. The tumor mutational burden is not available. Based on this information, could you please assess the predicted responsiveness to Atezolizumab and explain whether the patient is more likely to be a responder or non-responder? Please access the COMPASS platform and securely log in to download the transcriptomic dataset for tumor samples. After retrieving the data, stratify the patients into two cohorts based on their immune profiles. Group one should include patients showing an immunosuppressive profile—characterized by diminished natural killer cell function, evidence of T-cell exhaustion, and lower B-cell counts. Group two should consist of patients with an active immune response, as indicated by increased macrophage infiltration, elevated interferon-gamma signaling, and stable genomic markers. Finally, compile a comprehensive report analyzing how these distinct immune profiles could potentially affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"Given a patient with bladder urothelial carcinoma, for whom mRNA TPM data of the tumor immune microenvironment have been analyzed, can you determine the likelihood of a response to atezolizumab? The patient details are as follows: male, white, kidney tissue sample, and a tumor mutational burden of 33.0 mutations/MB. Please provide your conclusion along with the rationale supporting the classification as either a responder or non-responder.","Given a patient with bladder urothelial carcinoma, for whom mRNA TPM data of the tumor immune microenvironment have been analyzed, can you determine the likelihood of a response to atezolizumab? The patient details are as follows: male, white, kidney tissue sample, and a tumor mutational burden of 33.0 mutations/MB. Please provide your conclusion along with the rationale supporting the classification as either a responder or non-responder. Please log in securely to the COMPASS platform and download the tumor transcriptomic dataset. Once obtained, stratify the patients into two cohorts based on their immune profiles. The first cohort should comprise patients with an immunosuppressive profile—characterized by reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell levels. The second cohort should include patients exhibiting an active immune response, indicated by increased macrophage infiltration, heightened interferon-gamma signaling, and stable genomic markers. Finally, prepare a detailed report analyzing how these differing immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"I have processed mRNA TPM data to evaluate the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a 32-year-old white male with a tumor mutational burden of 32.0 mutations per megabase. Could you please provide an assessment of this patient’s predicted response to Atezolizumab therapy, indicating whether he is likely to be a responder or non-responder, and explain the reasoning behind your conclusion?","I have processed mRNA TPM data to evaluate the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a 32-year-old white male with a tumor mutational burden of 32.0 mutations per megabase. Could you please provide an assessment of this patient’s predicted response to Atezolizumab therapy, indicating whether he is likely to be a responder or non-responder, and explain the reasoning behind your conclusion? Please securely log in to the COMPASS platform and download the tumor transcriptomic dataset. Once you have the dataset, divide the patients into two groups based on their immune characteristics. The first group should include patients demonstrating an immunosuppressive profile, which you can identify by reduced natural killer cell activity, evidence of T-cell exhaustion, and lower levels of B cells. The second group should consist of patients showing an active immune response, as indicated by increased macrophage infiltration, stronger interferon-gamma signaling, and stable genomic markers. Lastly, prepare a comprehensive report that examines how these different immune profiles could affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"A patient with Bladder Urothelial Carcinoma (BLCA) has been evaluated using mRNA TPM data of the tumor immune microenvironment. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 2.0 mutations per MB. Based on these characteristics, is this patient likely to be a responder or non-responder to Atezolizumab, and what is the rationale for this assessment?","A patient with Bladder Urothelial Carcinoma (BLCA) has been evaluated using mRNA TPM data of the tumor immune microenvironment. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 2.0 mutations per MB. Based on these characteristics, is this patient likely to be a responder or non-responder to Atezolizumab, and what is the rationale for this assessment? Please log in securely to the COMPASS platform and download the tumor transcriptomic dataset. After obtaining the dataset, categorize the patients into two groups based on their immune profiles. Group one should include patients with an immunosuppressive phenotype, characterized by diminished natural killer cell activity, signs of T-cell exhaustion, and lower B cell levels. Group two should comprise patients exhibiting an active immune response, as evidenced by elevated macrophage infiltration, enhanced interferon-gamma signaling, and consistent genomic markers. Finally, compile a comprehensive report that evaluates how these distinct immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"Based on the processed mRNA TPM data of the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you assess the predicted responsiveness to Atezolizumab? The patient is a male of OTHER race, with bladder tissue involvement and a tumor mutational burden of 14.0 mutations per megabase. Please provide your conclusion on whether this patient is likely to be a responder or non-responder, along with the supporting rationale.","Based on the processed mRNA TPM data of the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you assess the predicted responsiveness to Atezolizumab? The patient is a male of OTHER race, with bladder tissue involvement and a tumor mutational burden of 14.0 mutations per megabase. Please provide your conclusion on whether this patient is likely to be a responder or non-responder, along with the supporting rationale. Please access the COMPASS platform using secure login credentials to download the tumor transcriptomic dataset. Once the dataset is obtained, stratify the patients into two groups based on their immune profiles. The first group should consist of patients showing an immunosuppressive profile, identified by reduced natural killer cell activity, evidence of T-cell exhaustion, and decreased B-cell counts. The second group should include patients with an active immune response, characterized by increased macrophage infiltration, enhanced interferon-gamma signaling, and consistent genomic markers. After grouping, please prepare a detailed report analyzing how these immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"A patient with bladder urothelial carcinoma has been evaluated using mRNA TPM data from their tumor immune microenvironment. The patient is male, identified as White, with tissue details and tumor mutational burden information not available. Based on this data, can you determine whether the patient is more likely to be a responder or a non-responder to Atezolizumab, and explain the reasoning behind your conclusion?","A patient with bladder urothelial carcinoma has been evaluated using mRNA TPM data from their tumor immune microenvironment. The patient is male, identified as White, with tissue details and tumor mutational burden information not available. Based on this data, can you determine whether the patient is more likely to be a responder or a non-responder to Atezolizumab, and explain the reasoning behind your conclusion? Log in securely to the COMPASS platform to download the tumor transcriptomic dataset. After obtaining the dataset, please divide the patients into two groups based on their immune characteristics. One group should include patients with an immunosuppressive profile, which is defined by lower natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts. The other group should consist of patients showing an active immune response, identified by increased macrophage infiltration, enhanced interferon-gamma signaling, and stable genomic markers. Finally, prepare a comprehensive report detailing how these immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"Given mRNA TPM data for the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you assess whether the patient is likely to respond to Atezolizumab? The patient is a 9.0 TMB (mutations per MB) White male with bladder tissue involvement. Please provide your conclusion on responder status along with the rationale behind your assessment.","Given mRNA TPM data for the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you assess whether the patient is likely to respond to Atezolizumab? The patient is a 9.0 TMB (mutations per MB) White male with bladder tissue involvement. Please provide your conclusion on responder status along with the rationale behind your assessment. Please follow these steps:

1. Log in securely to the COMPASS platform and download the tumor transcriptomic dataset.
2. Once the dataset is obtained, classify the patients into two groups based on their immune profiles. One group should consist of patients with an immunosuppressive profile, defined by lower natural killer cell activity, evidence of T-cell exhaustion, and decreased B-cell counts. The other group should include patients exhibiting an active immune response, characterized by increased macrophage infiltration, enhanced interferon-gamma signaling, and stable genomic markers.
3. Prepare a detailed report that discusses how these distinct immune profiles might affect treatment outcomes.

This approach should ensure a thorough analysis while maintaining the scientific accuracy and clinical relevance of the findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"Based on mRNA TPM data reflecting the tumor immune microenvironment in this patient with Bladder Urothelial Carcinoma (BLCA), can you assess her predicted response to Atezolizumab? The patient is a female of Asian descent with tumor tissue from the ureter and a tumor mutational burden of 12 mutations per megabase. Please provide your conclusion on whether she is likely to be a responder or non-responder, along with the supporting rationale.","Based on mRNA TPM data reflecting the tumor immune microenvironment in this patient with Bladder Urothelial Carcinoma (BLCA), can you assess her predicted response to Atezolizumab? The patient is a female of Asian descent with tumor tissue from the ureter and a tumor mutational burden of 12 mutations per megabase. Please provide your conclusion on whether she is likely to be a responder or non-responder, along with the supporting rationale. Please complete the following steps:

1. Securely log into the COMPASS platform and download the tumor transcriptomic dataset.
2. After retrieving the dataset, stratify the patients into two groups based on their immune characteristics. The first group should include patients with an immunosuppressive profile, defined by reduced natural killer cell activity, indicators of T-cell exhaustion, and lower B-cell counts. The second group should consist of patients with an active immune response, identified by increased macrophage infiltration, stronger interferon-gamma signaling, and stable genomic markers.
3. Develop a comprehensive report detailing how these differing immune profiles could influence treatment outcomes.

This structured approach will ensure a precise and clinically relevant analysis of the data.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) who is male and white, with the primary tissue being the bladder and an unknown FMOne mutation burden per MB, could you evaluate the mRNA TPM data representing the tumor immune microenvironment to determine whether the patient is likely to respond to Atezolizumab? Please include the clinical rationale behind the predicted responder or non-responder classification.","For a patient with Bladder Urothelial Carcinoma (BLCA) who is male and white, with the primary tissue being the bladder and an unknown FMOne mutation burden per MB, could you evaluate the mRNA TPM data representing the tumor immune microenvironment to determine whether the patient is likely to respond to Atezolizumab? Please include the clinical rationale behind the predicted responder or non-responder classification. Please follow these steps:

1. Log into the COMPASS platform using secure credentials and download the tumor transcriptomic dataset.
2. Once you have the dataset, categorize the patients into two groups based on their immune profiles: 
 a. Group one should include patients exhibiting an immunosuppressive profile, characterized by low natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.
 b. Group two should consist of patients showing an active immune response, marked by increased macrophage infiltration, enhanced interferon-gamma signaling, and consistent genomic markers.
3. Prepare a detailed report that evaluates how these distinct immune profiles may affect treatment outcomes.

This methodical process is intended to facilitate a clear, clinically relevant analysis of the data.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"Based on the processed mRNA TPM data reflecting the tumor immune microenvironment in a male, White patient with Bladder Urothelial Carcinoma (BLCA) and an FMOne mutation burden of 11.0 mutations per MB, can we determine if he is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Based on the processed mRNA TPM data reflecting the tumor immune microenvironment in a male, White patient with Bladder Urothelial Carcinoma (BLCA) and an FMOne mutation burden of 11.0 mutations per MB, can we determine if he is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. Please complete the following steps:

1. Log in to the COMPASS platform with your secure credentials and download the provided tumor transcriptomic dataset.

2. Divide the dataset into two patient groups based on their immune profiles:
 a. Group 1: Patients with an immunosuppressive profile, indicated by diminished natural killer cell activity, signs of T-cell exhaustion, and decreased B-cell counts.
 b. Group 2: Patients with an active immune response, characterized by increased macrophage infiltration, enhanced interferon-gamma signaling, and consistent genomic markers.

3. Generate a comprehensive report that examines how these differing immune profiles might influence treatment outcomes.

These steps are designed to enable a systematic and clinically applicable analysis of the data.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"I have analyzed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  male, White individual with liver tissue involvement and a tumor mutational burden of 10.0 mutations per megabase. Can you assess the predicted response of this patient to Atezolizumab, and provide your conclusion on whether the patient is likely to be a responder or a non-responder, including the scientific reasoning supporting your determination?","I have analyzed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  male, White individual with liver tissue involvement and a tumor mutational burden of 10.0 mutations per megabase. Can you assess the predicted response of this patient to Atezolizumab, and provide your conclusion on whether the patient is likely to be a responder or a non-responder, including the scientific reasoning supporting your determination? Please follow these steps:

1. Sign in securely to the COMPASS platform using your credentials and download the designated tumor transcriptomic dataset.

2. Stratify the dataset into two patient groups based on their immune profiles:
 a. Group 1 will include patients exhibiting an immunosuppressive profile, defined by reduced natural killer cell activity, markers indicative of T-cell exhaustion, and lower B-cell counts.
 b. Group 2 will consist of patients showing an active immune response, characterized by increased macrophage infiltration, heightened interferon-gamma signaling, and stable genomic indicators.

3. Prepare a detailed report analyzing how these distinct immune profiles may affect treatment outcomes.

These steps are intended to facilitate a systematic, clinically relevant evaluation of the data.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"For a patient with bladder urothelial carcinoma (BLCA), we have mRNA TPM data from the tumor immune microenvironment along with the following clinical details: Male, White, originating from bladder tissue, and a tumor mutational burden of 12.0 mutations per MB. Based on this information, could you evaluate and determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include your reasoning in the assessment.","For a patient with bladder urothelial carcinoma (BLCA), we have mRNA TPM data from the tumor immune microenvironment along with the following clinical details: Male, White, originating from bladder tissue, and a tumor mutational burden of 12.0 mutations per MB. Based on this information, could you evaluate and determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include your reasoning in the assessment. Please sign in securely to the COMPASS platform using your credentials and download the designated tumor transcriptomic dataset. Once you have the data, divide the patient cohort into two groups based on their immune profiles:

1. Group 1: Patients displaying an immunosuppressive profile, characterized by reduced natural killer cell activity, evidence of T-cell exhaustion markers, and decreased B-cell counts.
2. Group 2: Patients demonstrating an active immune response, marked by increased macrophage infiltration, elevated interferon-gamma signaling, and stable genomic indicators.

Finally, compile a detailed report evaluating how these differences in immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,I have mRNA TPM data reflecting the tumor immune microenvironment of a female patient diagnosed with Bladder Urothelial Carcinoma (BLCA) whose tumor mutational burden is 13.0 mutations per MB. Given these details—including her tissue origin (bladder) and unknown race—could you assess whether this patient is likely to respond to Atezolizumab and provide the supporting rationale for your conclusion?,"I have mRNA TPM data reflecting the tumor immune microenvironment of a female patient diagnosed with Bladder Urothelial Carcinoma (BLCA) whose tumor mutational burden is 13.0 mutations per MB. Given these details—including her tissue origin (bladder) and unknown race—could you assess whether this patient is likely to respond to Atezolizumab and provide the supporting rationale for your conclusion? Please log in securely to the COMPASS platform using your credentials and download the specified tumor transcriptomic dataset. Next, divide the patient cohort into two distinct groups based on their immune profiles:

• Group 1: Patients with an immunosuppressive profile, identified by diminished natural killer cell activity, the presence of T-cell exhaustion markers, and reduced B-cell counts.

• Group 2: Patients with an active immune response, characterized by increased macrophage infiltration, elevated interferon-gamma signaling, and stable genomic markers.

Finally, prepare a comprehensive report assessing how these immune profile differences may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"Based on the mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), can you assess the likelihood of a response to Atezolizumab? The patient is a White male with a kidney tissue sample and a tumor mutational burden of 6.0 mutations per MB. Please explain your reasoning and conclude whether the patient is likely to be classified as a responder or non-responder.","Based on the mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), can you assess the likelihood of a response to Atezolizumab? The patient is a White male with a kidney tissue sample and a tumor mutational burden of 6.0 mutations per MB. Please explain your reasoning and conclude whether the patient is likely to be classified as a responder or non-responder. Please access the COMPASS platform using your secure login credentials and download the designated tumor transcriptomic dataset. Once you have the data, stratify the patient cohort into two groups based on their immune characteristics as follows:

• Group 1: Patients displaying an immunosuppressive profile, which includes decreased natural killer cell activity, the presence of T-cell exhaustion markers, and lower B-cell counts.

• Group 2: Patients showing an active immune response, indicated by increased macrophage infiltration, enhanced interferon-gamma signaling, and stable genomic markers.

Finally, prepare a detailed report analyzing how differences in these immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the likelihood of response to Atezolizumab. The patient’s details are as follows: Male, White, tumor sampled from the ureter, and a tumor mutational burden of 21 mutations per megabase. Could you provide your assessment on whether this patient should be classified as a responder or non-responder, along with your supporting rationale?","I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the likelihood of response to Atezolizumab. The patient’s details are as follows: Male, White, tumor sampled from the ureter, and a tumor mutational burden of 21 mutations per megabase. Could you provide your assessment on whether this patient should be classified as a responder or non-responder, along with your supporting rationale? Please log in to the COMPASS platform with your secure credentials and download the designated tumor transcriptomic dataset. Once you have the dataset, classify the patient cohort into two groups based on their immune profiles:

• Group 1: Patients with an immunosuppressive profile, characterized by reduced natural killer cell activity, the presence of T-cell exhaustion markers, and lower B-cell counts.

• Group 2: Patients with an active immune response, indicated by increased macrophage infiltration, enhanced interferon-gamma signaling, and stable genomic markers.

After stratifying the groups, prepare a detailed report evaluating how these immune profile differences may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"For a patient with Bladder Urothelial Carcinoma (BLCA) characterized by a male sex, white race, bladder tissue involvement, and a tumor mutational burden of 14.0 mutations per MB, can the mRNA TPM data for the tumor immune microenvironment be used to predict responsiveness to Atezolizumab? Please provide your conclusion on responder versus non-responder status along with the supporting rationale.","For a patient with Bladder Urothelial Carcinoma (BLCA) characterized by a male sex, white race, bladder tissue involvement, and a tumor mutational burden of 14.0 mutations per MB, can the mRNA TPM data for the tumor immune microenvironment be used to predict responsiveness to Atezolizumab? Please provide your conclusion on responder versus non-responder status along with the supporting rationale. Log in to the COMPASS platform using your secure credentials. After logging in, download the specific tumor transcriptomic dataset provided. Once you have the dataset, please categorize the patients into two groups based on their immune profiles:

• Group 1: Patients showing an immunosuppressive profile, which includes reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.

• Group 2: Patients exhibiting an active immune response, characterized by increased macrophage infiltration, enhanced interferon-gamma signaling, and stable genomic markers.

After grouping the patients, compile a detailed report evaluating how these differences in immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient's characteristics are as follows: male sex, white race, tissue sample from the bladder, and a tumor mutational burden of 9.0 mutations per megabase. Based on these data, could you please provide an evaluation of the patient's predicted responsiveness to Atezolizumab, including a determination of responder versus non-responder status and the clinical rationale supporting this assessment?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient's characteristics are as follows: male sex, white race, tissue sample from the bladder, and a tumor mutational burden of 9.0 mutations per megabase. Based on these data, could you please provide an evaluation of the patient's predicted responsiveness to Atezolizumab, including a determination of responder versus non-responder status and the clinical rationale supporting this assessment? Please access the COMPASS platform using your secure credentials. After signing in, download the designated tumor transcriptomic dataset. With the dataset in hand, classify the patients into two distinct groups based on their immune profiles:

• Group 1: Patients with an immunosuppressive profile, which includes diminished natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.

• Group 2: Patients with an active immune response, characterized by increased macrophage infiltration, heightened interferon-gamma signaling, and stable genomic markers.

Once you have completed the classification, prepare a comprehensive report that evaluates how these differences in immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"I have processed mRNA TPM data to evaluate the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient details are as follows: male, white, bladder tissue, and a tumor mutational burden of 27 mutations per MB. Based on these findings, could you please determine whether this patient is likely to respond to Atezolizumab and explain the underlying rationale?","I have processed mRNA TPM data to evaluate the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient details are as follows: male, white, bladder tissue, and a tumor mutational burden of 27 mutations per MB. Based on these findings, could you please determine whether this patient is likely to respond to Atezolizumab and explain the underlying rationale? Please log into the COMPASS platform using your secure credentials. Once logged in, download the designated tumor transcriptomic dataset. Using this dataset, stratify the patients into two groups according to their immune profiles:

• Group 1: Patients exhibiting an immunosuppressive profile, which is indicated by reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.

• Group 2: Patients demonstrating an active immune response, as shown by increased macrophage infiltration, enhanced interferon-gamma signaling, and stable genomic markers.

After you complete the classification, compile a detailed report that assesses the potential impact of these distinct immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"Based on the available processed mRNA TPM data representing the tumor immune microenvironment in a case of Bladder Urothelial Carcinoma, could you please determine whether this patient (Female, White, with lymph node tissue involvement and an indeterminate tumor mutational burden) is likely to respond to Atezolizumab treatment? Please include your reasoning in support of your conclusion.","Based on the available processed mRNA TPM data representing the tumor immune microenvironment in a case of Bladder Urothelial Carcinoma, could you please determine whether this patient (Female, White, with lymph node tissue involvement and an indeterminate tumor mutational burden) is likely to respond to Atezolizumab treatment? Please include your reasoning in support of your conclusion. Please access the COMPASS platform with your secure login details. After signing in, download the specified tumor transcriptomic dataset. Then, using the dataset, classify patients into two groups based on their immune profiles:

• Group 1: Patients with an immunosuppressive profile characterized by reduced natural killer cell activity, signs of T-cell exhaustion, and decreased B-cell counts.

• Group 2: Patients with an active immune response indicated by increased macrophage infiltration, elevated interferon-gamma signaling, and stable genomic markers.

Once the classification is complete, please prepare a comprehensive report that evaluates how these distinct immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"Based on mRNA TPM data of the tumor immune microenvironment and the following patient information—sex: female, race: White, tissue: kidney, diagnosis: bladder urothelial carcinoma, and a tumor mutational burden of 5.0 mutations/MB—can you determine whether this patient is likely to respond to atezolizumab and provide the rationale for your conclusion?","Based on mRNA TPM data of the tumor immune microenvironment and the following patient information—sex: female, race: White, tissue: kidney, diagnosis: bladder urothelial carcinoma, and a tumor mutational burden of 5.0 mutations/MB—can you determine whether this patient is likely to respond to atezolizumab and provide the rationale for your conclusion? Please log in to the COMPASS platform using your secure credentials. Once you are signed in, download the relevant tumor transcriptomic dataset. Based on this dataset, classify patients into two groups according to their immune profiles:

• Group 1: Patients showing an immunosuppressive profile, characterized by reduced natural killer cell activity, evidence of T‐cell exhaustion, and decreased B‐cell counts.

• Group 2: Patients demonstrating an active immune response, as indicated by increased macrophage infiltration, elevated interferon‐gamma signaling, and stable genomic markers.

After completing the classification, prepare a detailed report discussing how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"Based on mRNA TPM data of the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), how would you assess the predicted response to Atezolizumab? The patient is a white male with a primary bladder tumor, and the tumor mutational burden (FMOne mutation burden per MB) data is not available. Could you provide a conclusion on whether this patient is likely to be a responder or non-responder, along with the supporting clinical reasoning?","Based on mRNA TPM data of the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), how would you assess the predicted response to Atezolizumab? The patient is a white male with a primary bladder tumor, and the tumor mutational burden (FMOne mutation burden per MB) data is not available. Could you provide a conclusion on whether this patient is likely to be a responder or non-responder, along with the supporting clinical reasoning? Log in to the COMPASS platform with your secure credentials. Once you have accessed the system, download the tumor transcriptomic dataset provided. Using this dataset, stratify the patients into two groups based on their immune profiles:

• Group 1: Patients exhibiting an immunosuppressive profile, which includes features such as lower natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.

• Group 2: Patients displaying an active immune response, characterized by enhanced macrophage infiltration, increased interferon-gamma signaling, and stable genomic markers.

Once you have completed the classification, compile a detailed report that discusses the potential impact of these differing immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"I have analyzed mRNA TPM data depicting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a white male with bladder tissue involvement and a tumor mutational burden of 14.0 mutations per megabase. Based on this information, could you please assess whether the patient is likely to respond to Atezolizumab, and provide the rationale behind your conclusion?","I have analyzed mRNA TPM data depicting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a white male with bladder tissue involvement and a tumor mutational burden of 14.0 mutations per megabase. Based on this information, could you please assess whether the patient is likely to respond to Atezolizumab, and provide the rationale behind your conclusion? Please log in to the COMPASS platform using your secure credentials. After accessing the system, download the available tumor transcriptomic dataset. Utilize this dataset to categorize patients into two groups based on their immune profiles:

• Group 1: Patients who have an immunosuppressive profile, evidenced by reduced natural killer cell activity, indications of T-cell exhaustion, and decreased B-cell counts.

• Group 2: Patients who exhibit an active immune response, as reflected by enhanced macrophage infiltration, elevated interferon-gamma signaling, and stable genomic markers.

After classifying the patients, prepare a comprehensive report that examines how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"Using mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), please evaluate the likelihood of a positive response to Atezolizumab. The patient is a 4.0 FMOne mutation burden per MB, White male with bladder tissue involvement. Based on these clinical and molecular features, would you consider him a responder or non-responder, and what is your rationale?","Using mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), please evaluate the likelihood of a positive response to Atezolizumab. The patient is a 4.0 FMOne mutation burden per MB, White male with bladder tissue involvement. Based on these clinical and molecular features, would you consider him a responder or non-responder, and what is your rationale? Please access the COMPASS platform using your secure login credentials. Once you have logged in, download the tumor transcriptomic dataset. Using this dataset, stratify the patients into two groups based on their immune profiles:

• Group 1: Patients with an immunosuppressive profile, characterized by diminished natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.

• Group 2: Patients with an active immune response, demonstrated by increased macrophage infiltration, higher interferon-gamma signaling, and the presence of stable genomic markers.

After the classification is complete, compile a detailed report that evaluates the potential impact of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"Given mRNA TPM data from the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and considering the following details – male, white, bladder tissue origin, and a tumor mutational burden of 5 mutations per MB – can you determine whether this patient is likely to respond to Atezolizumab, and provide the clinical rationale supporting your assessment?","Given mRNA TPM data from the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and considering the following details – male, white, bladder tissue origin, and a tumor mutational burden of 5 mutations per MB – can you determine whether this patient is likely to respond to Atezolizumab, and provide the clinical rationale supporting your assessment? Please log in securely to the COMPASS platform and download the tumor transcriptomic dataset. Next, use this dataset to classify patients into two groups based on their immune profiles as follows:

• Group 1 (Immunosuppressive Profile): Patients exhibiting reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.  
• Group 2 (Active Immune Response): Patients showing increased macrophage infiltration, enhanced interferon-gamma signaling, and stable genomic markers.

After categorizing the patients, prepare a comprehensive report that assesses how these differing immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"Given the mRNA TPM data profiling the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), can you assess the predicted responsiveness to Atezolizumab? The patient is a 15.0 mutations/MB female of White race with bladder tissue involvement. Please provide your conclusion on whether she is likely to be a responder or non-responder, along with the rationale for your assessment.","Given the mRNA TPM data profiling the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), can you assess the predicted responsiveness to Atezolizumab? The patient is a 15.0 mutations/MB female of White race with bladder tissue involvement. Please provide your conclusion on whether she is likely to be a responder or non-responder, along with the rationale for your assessment. Please access the COMPASS platform using secure credentials and download the tumor transcriptomic dataset. Using this dataset, categorize patients based on their immune profiles into two groups:

• Group 1 (""Immunosuppressive Profile""): Patients with diminished natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.
• Group 2 (""Active Immune Response""): Patients with increased macrophage infiltration, heightened interferon-gamma signaling, and consistent genomic markers.

Following this classification, compile a detailed report discussing how these distinct immune profiles could potentially affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"I have analyzed mRNA TPM data that characterizes the tumor immune microenvironment of a male patient with bladder urothelial carcinoma (BLCA). The patient is White, has bladder tissue affected, and exhibits a tumor mutational burden of 13.0 mutations per megabase. Based on this information, could you determine whether the patient is likely to respond to atezolizumab, and please provide the clinical reasoning behind your assessment.","I have analyzed mRNA TPM data that characterizes the tumor immune microenvironment of a male patient with bladder urothelial carcinoma (BLCA). The patient is White, has bladder tissue affected, and exhibits a tumor mutational burden of 13.0 mutations per megabase. Based on this information, could you determine whether the patient is likely to respond to atezolizumab, and please provide the clinical reasoning behind your assessment. Please log into the COMPASS platform using your secure credentials and download the tumor transcriptomic dataset available there. Once you have the data, classify the patients into two groups based on their immune profiles as follows:

• Group 1 (""Immunosuppressive Profile""): Patients who exhibit reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.
• Group 2 (""Active Immune Response""): Patients who show increased macrophage presence, enhanced interferon-gamma signaling, and consistent genomic markers.

After completing the classification, prepare a comprehensive report that analyzes how these distinct immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"For a female patient with bladder urothelial carcinoma (BLCA), a white racial background, and a tumor mutational burden of 14 mutations per megabase, does the processed mRNA TPM data from the tumor immune microenvironment suggest that she is likely to respond to Atezolizumab? Please include the rationale supporting your conclusion.","For a female patient with bladder urothelial carcinoma (BLCA), a white racial background, and a tumor mutational burden of 14 mutations per megabase, does the processed mRNA TPM data from the tumor immune microenvironment suggest that she is likely to respond to Atezolizumab? Please include the rationale supporting your conclusion. Please log into the COMPASS platform using your secure credentials to download the tumor transcriptomic dataset. Then, classify the patients into two groups based on their immune profiles as follows:

• Group 1 (""Immunosuppressive Profile""): Patients with decreased natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
• Group 2 (""Active Immune Response""): Patients with an increased number of macrophages, heightened interferon-gamma signaling, and consistent genomic markers.

After completing the classification, generate a detailed report examining how these distinct immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"For a BLCA patient with processed mRNA TPM data of the tumor immune microenvironment, characterized as a 17.0 TMB (FMO mutation burden per MB) male of Black or African American descent with bladder tissue involvement, how would you assess the likelihood of response to Atezolizumab? Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with your supporting rationale.","For a BLCA patient with processed mRNA TPM data of the tumor immune microenvironment, characterized as a 17.0 TMB (FMO mutation burden per MB) male of Black or African American descent with bladder tissue involvement, how would you assess the likelihood of response to Atezolizumab? Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with your supporting rationale. Please access the COMPASS platform with your secure login credentials to retrieve the tumor transcriptomic dataset. Next, divide the patients into two specific groups based on their immune profiles:

• Group 1 (""Immunosuppressive Profile""): Patients exhibiting reduced natural killer cell activity, evidence of T-cell exhaustion, and diminished B-cell counts.
• Group 2 (""Active Immune Response""): Patients characterized by elevated macrophage numbers, increased interferon-gamma signaling, and stable genomic markers.

Once you have completed the classification, please prepare a comprehensive report that analyzes the potential effects of these distinct immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"I have processed mRNA TPM data analyzing the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma. The patient is a white male, with bladder tissue involved, and has a tumor mutational burden of 7.0 FMOne mutations per MB. Based on these clinical and molecular parameters, could you assess whether this patient is likely to respond to Atezolizumab? Please include your rationale in support of your conclusion.","I have processed mRNA TPM data analyzing the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma. The patient is a white male, with bladder tissue involved, and has a tumor mutational burden of 7.0 FMOne mutations per MB. Based on these clinical and molecular parameters, could you assess whether this patient is likely to respond to Atezolizumab? Please include your rationale in support of your conclusion. Please log into the COMPASS platform using your secure credentials and retrieve the tumor transcriptomic dataset. Next, stratify the patients into two groups based on their immune profiles:

• Group 1 (""Immunosuppressive Profile""): Patients who show reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
• Group 2 (""Active Immune Response""): Patients who exhibit an increased number of macrophages, enhanced interferon-gamma signaling, and stable genomic markers.

Once you have completed the classification, prepare a detailed report that assesses how these different immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"Based on the mRNA TPM data for this patient's bladder urothelial carcinoma, including details such as male sex, white race, bladder tissue origin, and a tumor mutational burden of 5.0 mutations/MB, could you provide an evidence-based assessment of the likelihood of response to Atezolizumab, along with the supporting rationale?","Based on the mRNA TPM data for this patient's bladder urothelial carcinoma, including details such as male sex, white race, bladder tissue origin, and a tumor mutational burden of 5.0 mutations/MB, could you provide an evidence-based assessment of the likelihood of response to Atezolizumab, along with the supporting rationale? Log into the COMPASS platform with your secure credentials and access the tumor transcriptomic dataset. Once you have the dataset, classify patients into two distinct groups based on their immune profiles:

• Group 1 – Immunosuppressive Profile: This group includes patients with reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.
• Group 2 – Active Immune Response: This group comprises patients with an increased number of macrophages, enhanced interferon-gamma signaling, and stable genomic markers.

After completing the classification, prepare a comprehensive report that evaluates how these immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"Based on processed mRNA TPM data of the tumor immune microenvironment for a male, white patient with bladder urothelial carcinoma (BLCA) whose tissue sample was obtained from the lung and a tumor mutational burden of 20 mutations per megabase, could you please evaluate his likelihood of responding to Atezolizumab? Please include your reasoning and specify whether he is more likely to be classified as a responder or non-responder.","Based on processed mRNA TPM data of the tumor immune microenvironment for a male, white patient with bladder urothelial carcinoma (BLCA) whose tissue sample was obtained from the lung and a tumor mutational burden of 20 mutations per megabase, could you please evaluate his likelihood of responding to Atezolizumab? Please include your reasoning and specify whether he is more likely to be classified as a responder or non-responder. Please log in to the COMPASS platform using your secure credentials to retrieve the tumor transcriptomic dataset. Then, classify the patients into two groups based on their immune profiles as follows:

• Group 1 – Immunosuppressive Profile: This subgroup includes patients exhibiting reduced natural killer cell activity, signs of T-cell exhaustion, and decreased B-cell counts.  
• Group 2 – Active Immune Response: This subgroup consists of patients with increased macrophage counts, enhanced interferon-gamma signaling, and stable genomic markers.

After completing the classification, prepare a detailed report assessing how these distinct immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"Given a patient diagnosed with bladder urothelial carcinoma (male, White) who has mRNA TPM data representing their tumor immune microenvironment and a tumor mutational burden of 3.0 mutations/MB, can you assess whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Given a patient diagnosed with bladder urothelial carcinoma (male, White) who has mRNA TPM data representing their tumor immune microenvironment and a tumor mutational burden of 3.0 mutations/MB, can you assess whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. Log in to the COMPASS platform using your secure credentials to access the tumor transcriptomic dataset. Next, categorize the patients into two groups based on their immune characteristics:

• Group 1 – Immunosuppressive Profile: Patients in this group show evidence of reduced natural killer cell activity, T-cell exhaustion, and lower B-cell counts.  
• Group 2 – Active Immune Response: Patients here demonstrate increased macrophage numbers, enhanced interferon-gamma signaling, and stable genomic markers.

After completing the classification, generate a comprehensive report outlining how these differing immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma. The patient is a Black or African American male whose tissue sample was taken from a lymph node. Tumor mutational burden data (FMO mutation burden per MB) is not available. Based on these findings, can we determine if this patient is likely to respond to atezolizumab treatment, and what is the rationale behind this assessment?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma. The patient is a Black or African American male whose tissue sample was taken from a lymph node. Tumor mutational burden data (FMO mutation burden per MB) is not available. Based on these findings, can we determine if this patient is likely to respond to atezolizumab treatment, and what is the rationale behind this assessment? Please access the COMPASS platform using your secure credentials to retrieve the tumor transcriptomic dataset. Once logged in, classify the patients into the following two groups based on their immune profiles:

• Group 1 – Immunosuppressive Profile: This group includes patients with diminished natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.  
• Group 2 – Active Immune Response: This group comprises patients showing higher numbers of macrophages, increased interferon-gamma signaling, and stable genomic markers.

After completing the classification, prepare a detailed report discussing the potential impact of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"Based on the processed mRNA TPM data of the tumor immune microenvironment for a patient with bladder urothelial carcinoma, can you assess the likelihood of response to Atezolizumab? The patient is a White male, with bladder tissue affected, and the tumor mutational burden data is unavailable (nan). Please provide a conclusion regarding whether this patient should be classified as a responder or non-responder, along with the supporting rationale.","Based on the processed mRNA TPM data of the tumor immune microenvironment for a patient with bladder urothelial carcinoma, can you assess the likelihood of response to Atezolizumab? The patient is a White male, with bladder tissue affected, and the tumor mutational burden data is unavailable (nan). Please provide a conclusion regarding whether this patient should be classified as a responder or non-responder, along with the supporting rationale. Please log into the COMPASS platform using your secure credentials to retrieve the tumor transcriptomic dataset. Once you have accessed the data, classify the patients into two groups based on their immune profiles:

1. Immunosuppressive Profile: Patients in this group exhibit reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
2. Active Immune Response: Patients in this group display increased macrophage numbers, elevated interferon-gamma signaling, and stable genomic markers.

After completing the classification, prepare a comprehensive report that evaluates the potential effects of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"Given this patient's mRNA TPM data for Bladder Urothelial Carcinoma, where she is a white female with a tumor mutational burden of 8.0 mutations per megabase, can we predict her likely response to Atezolizumab? Please provide your assessment on whether she would be classified as a responder or non-responder, including the supporting reasoning based on her tumor immune microenvironment profile.","Given this patient's mRNA TPM data for Bladder Urothelial Carcinoma, where she is a white female with a tumor mutational burden of 8.0 mutations per megabase, can we predict her likely response to Atezolizumab? Please provide your assessment on whether she would be classified as a responder or non-responder, including the supporting reasoning based on her tumor immune microenvironment profile. Please log into the COMPASS platform with your secure credentials to access the tumor transcriptomic dataset. Once you have obtained the data, categorize the patients into two groups based on their immune profiles:

• Immunosuppressive Profile: Patients with this profile show decreased natural killer cell activity, indications of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response: Patients in this group exhibit increased macrophage numbers, enhanced interferon-gamma signaling, and stable genomic markers.

After completing the classifications, prepare a detailed report that evaluates how these immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"Based on mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), and considering the patient’s details (male, White, kidney tissue, with a tumor mutational burden of 6.0 mutations per megabase), can you please assess whether this patient is likely to respond to Atezolizumab? Please include the clinical rationale supporting your conclusion.","Based on mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), and considering the patient’s details (male, White, kidney tissue, with a tumor mutational burden of 6.0 mutations per megabase), can you please assess whether this patient is likely to respond to Atezolizumab? Please include the clinical rationale supporting your conclusion. Please sign in to the COMPASS platform using your secure credentials to retrieve the tumor transcriptomic dataset. Once you have accessed the data, stratify the patients into two groups based on their immune profiles as follows:

• Immunosuppressive Profile: Patients in this category demonstrate reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response: Patients in this group show increased macrophage presence, enhanced interferon-gamma signaling, and stable genomic markers.

After categorizing the patients, compile a comprehensive report analyzing the potential impact of these distinct immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"I have processed mRNA TPM data representing a patient's tumor immune microenvironment in a case of bladder urothelial carcinoma. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 17 mutations per megabase. Based on this information, could you determine if he is likely to respond to Atezolizumab and explain the rationale behind your conclusion?","I have processed mRNA TPM data representing a patient's tumor immune microenvironment in a case of bladder urothelial carcinoma. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 17 mutations per megabase. Based on this information, could you determine if he is likely to respond to Atezolizumab and explain the rationale behind your conclusion? Please log in to the COMPASS platform using your secure credentials to access the tumor transcriptomic dataset. Once logged in, segregate the patients into two distinct groups based on their immune profiles:

• Immunosuppressive Profile: These patients exhibit diminished natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts.
• Active Immune Response: These patients demonstrate increased macrophage activity, heightened interferon-gamma signaling, and consistent genomic markers.

After classification, please prepare a detailed report evaluating how these divergent immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"Based on the processed mRNA TPM data representing the patient’s tumor immune microenvironment for bladder urothelial carcinoma (BLCA)—with the following attributes: male, White, kidney tissue involved, and a tumor mutational burden of 6.0 mutations per MB—could you provide a clinical assessment of the patient's predicted response to Atezolizumab, along with the supporting rationale for classifying the patient as a likely responder or non-responder?","Based on the processed mRNA TPM data representing the patient’s tumor immune microenvironment for bladder urothelial carcinoma (BLCA)—with the following attributes: male, White, kidney tissue involved, and a tumor mutational burden of 6.0 mutations per MB—could you provide a clinical assessment of the patient's predicted response to Atezolizumab, along with the supporting rationale for classifying the patient as a likely responder or non-responder? Log in to the COMPASS platform using your secure credentials to access the tumor transcriptomic dataset. Once logged in, please categorize the patients into two groups based on their immune profiles:

1. Immunosuppressive Profile: Patients with reduced natural killer cell activity, clear signs of T-cell exhaustion, and lower B-cell counts.
2. Active Immune Response: Patients characterized by increased macrophage activity, elevated interferon-gamma signaling, and consistent genomic markers.

After completing the classification, compile a detailed report that evaluates the potential impact of these differing immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"Based on mRNA TPM data profiling the tumor immune microenvironment for Bladder Urothelial Carcinoma, could you assess the likelihood of response to Atezolizumab for a male, white patient whose tumor sample was obtained from a lymph node and exhibits a tumor mutational burden of 1.0 FMOne mutation per MB? Please provide your rationale for classifying this patient as a responder or non-responder.","Based on mRNA TPM data profiling the tumor immune microenvironment for Bladder Urothelial Carcinoma, could you assess the likelihood of response to Atezolizumab for a male, white patient whose tumor sample was obtained from a lymph node and exhibits a tumor mutational burden of 1.0 FMOne mutation per MB? Please provide your rationale for classifying this patient as a responder or non-responder. Please access the COMPASS platform using your secure login credentials to retrieve the tumor transcriptomic dataset. After logging in, sort the patients into two groups based on their immune characteristics:

1. Immunosuppressive Group: This includes patients who exhibit diminished natural killer cell activity, evident T-cell exhaustion, and reduced B-cell counts.
2. Active Immune Response Group: This consists of patients who show increased macrophage activity, higher levels of interferon-gamma signaling, and consistent genomic markers.

Once the classification is complete, prepare a detailed report assessing how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, and the tissue sampled was from the kidney. The Tumor Mutational Burden (mutations per MB) is not available. Based on these findings, could you assess whether this patient is predicted to be a responder or non-responder to Atezolizumab, and provide the rationale for your prediction?","I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, and the tissue sampled was from the kidney. The Tumor Mutational Burden (mutations per MB) is not available. Based on these findings, could you assess whether this patient is predicted to be a responder or non-responder to Atezolizumab, and provide the rationale for your prediction? Please log in to the COMPASS platform using your secure credentials and retrieve the tumor transcriptomic dataset. Once you have accessed the dataset, classify the patients into two groups based on their immune profiles:

• Immunosuppressive Group: Include patients with reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.

• Active Immune Response Group: Include patients showing enhanced macrophage activity, elevated interferon-gamma signaling, and consistent genomic markers.

After classifying the patients, compile a comprehensive report evaluating how these differing immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"Based on the mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), along with the following clinical details—sex: female; race: White; tissue: kidney; and a tumor mutational burden of 7.0 mutations per megabase—could you provide an assessment on whether this patient is more likely to be a responder or non-responder to Atezolizumab? Please include your supporting rationale.","Based on the mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), along with the following clinical details—sex: female; race: White; tissue: kidney; and a tumor mutational burden of 7.0 mutations per megabase—could you provide an assessment on whether this patient is more likely to be a responder or non-responder to Atezolizumab? Please include your supporting rationale. Please access the COMPASS platform using your secure login credentials to obtain the tumor transcriptomic dataset. After you have the dataset, please stratify the patients into two groups based on their immune profiles:

1. Immunosuppressive Group: Patients should be assigned to this group if they exhibit diminished natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
2. Active Immune Response Group: Patients showing increased macrophage activity, higher interferon-gamma signaling, and consistent genomic markers should be classified under this group.

Following the categorization, prepare a detailed report analyzing how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"For a female white patient with Bladder Urothelial Carcinoma exhibiting a tumor mutational burden of 21.0 mutations per MB and mRNA TPM data characterizing the tumor immune microenvironment from bladder tissue, can we determine the likelihood of a favorable response to Atezolizumab? Please provide your conclusion along with supporting scientific rationale.","For a female white patient with Bladder Urothelial Carcinoma exhibiting a tumor mutational burden of 21.0 mutations per MB and mRNA TPM data characterizing the tumor immune microenvironment from bladder tissue, can we determine the likelihood of a favorable response to Atezolizumab? Please provide your conclusion along with supporting scientific rationale. Please log in to the COMPASS platform with your secure credentials to download the tumor transcriptomic dataset. Next, classify the patients into two groups based on their immune profiles:

1. Immunosuppressive Group: Include patients with reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.
2. Active Immune Response Group: Include patients showing enhanced macrophage activity, elevated interferon-gamma signaling, and consistent genomic markers.

After stratifying the patients, please compile a comprehensive report that evaluates how these distinct immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"I have analyzed the patient's mRNA TPM data that characterizes the tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA). The patient is a  male of white ethnicity, with a tumor located in the ureter and a tumor mutational burden of 7.0 mutations per megabase. Could you evaluate the likelihood of a positive response to Atezolizumab in this context and provide the reasoning behind your assessment?","I have analyzed the patient's mRNA TPM data that characterizes the tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA). The patient is a  male of white ethnicity, with a tumor located in the ureter and a tumor mutational burden of 7.0 mutations per megabase. Could you evaluate the likelihood of a positive response to Atezolizumab in this context and provide the reasoning behind your assessment? Log in to the COMPASS platform using your secure credentials to access and download the tumor transcriptomic dataset. Once downloaded, stratify the patients into two distinct groups based on their immune profiles:

1. Immunosuppressive Group: This group should include patients who exhibit decreased natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.
2. Active Immune Response Group: This group should consist of patients with increased macrophage activity, higher levels of interferon-gamma signaling, and consistent genomic markers.

After categorization, prepare a detailed report assessing how these different immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"Considering the processed mRNA TPM data for the patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with the following clinical details—male, White, lung tissue sample, and a tumor mutational burden of 6.0 mutations per megabase—can you determine whether this patient is predicted to respond to Atezolizumab? Please provide your conclusion and the rationale behind it.","Considering the processed mRNA TPM data for the patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with the following clinical details—male, White, lung tissue sample, and a tumor mutational burden of 6.0 mutations per megabase—can you determine whether this patient is predicted to respond to Atezolizumab? Please provide your conclusion and the rationale behind it. Please log in to the COMPASS platform using your secure credentials to access and download the tumor transcriptomic dataset. Once you have the dataset, stratify the patients into two groups based on their immune profiles:

1. Immunosuppressive Group: Include patients with reduced natural killer cell activity, evidence of T‐cell exhaustion, and decreased B-cell counts.
2. Active Immune Response Group: Include patients who exhibit increased macrophage activity, elevated interferon-gamma signaling, and stable genomic markers.

After grouping the patients, prepare a detailed report evaluating how these distinct immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"A patient with Bladder Urothelial Carcinoma has mRNA TPM data characterizing the tumor immune microenvironment. The patient is male, white, and the sample was obtained from kidney tissue, with a tumor mutational burden of 6.0 mutations per megabase. Based on these data, can you determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please provide your conclusion with the supporting rationale.","A patient with Bladder Urothelial Carcinoma has mRNA TPM data characterizing the tumor immune microenvironment. The patient is male, white, and the sample was obtained from kidney tissue, with a tumor mutational burden of 6.0 mutations per megabase. Based on these data, can you determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please provide your conclusion with the supporting rationale. Please access the COMPASS platform using your secure login credentials to download the tumor transcriptomic dataset. Once you have obtained the dataset, categorize the patients into two groups based on their immune characteristics:

1. Immunosuppressive Group: Patients in this group should have reduced natural killer (NK) cell activity, signs of T‐cell exhaustion, and decreased B‐cell counts.
2. Active Immune Response Group: Patients in this group should demonstrate increased macrophage activity, elevated interferon‐gamma signaling, and stable genomic markers.

After stratifying the patients, prepare a detailed report analyzing how these differing immune profiles could potentially affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) who is being considered for Atezolizumab treatment. The patient details are: sex: male; race: white; tissue: bladder; and tumor mutational burden data is currently unavailable (nan). Based on this information, could you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your assessment?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) who is being considered for Atezolizumab treatment. The patient details are: sex: male; race: white; tissue: bladder; and tumor mutational burden data is currently unavailable (nan). Based on this information, could you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your assessment? Please log into the COMPASS platform using your secure credentials and download the tumor transcriptomic dataset. Once you have the dataset, classify patients into two groups according to their immune characteristics:

1. Immunosuppressive Group: This group should include patients exhibiting reduced natural killer (NK) cell activity, evidence of T‐cell exhaustion, and decreased B‐cell counts.
2. Active Immune Response Group: This group should consist of patients showing increased macrophage activity, elevated interferon‐gamma signaling, and preservation of key genomic markers.

After you have stratified the patients, please compile a comprehensive report that discusses how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"Based on the patient's tumor immune microenvironment mRNA TPM data for Bladder Urothelial Carcinoma (BLCA) and the clinical details provided (Male, White, bladder tissue, and tumor mutational burden of 3.0 FMOne mutations per MB), could you assess whether this patient is predicted to be a responder or non-responder to Atezolizumab, including your supporting rationale?","Based on the patient's tumor immune microenvironment mRNA TPM data for Bladder Urothelial Carcinoma (BLCA) and the clinical details provided (Male, White, bladder tissue, and tumor mutational burden of 3.0 FMOne mutations per MB), could you assess whether this patient is predicted to be a responder or non-responder to Atezolizumab, including your supporting rationale? Please access the COMPASS platform using your secure login credentials to download the tumor transcriptomic dataset. Next, stratify patients into two groups based on their immune profiles:

1. Immunosuppressive Group: Patients with reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
2. Active Immune Response Group: Patients exhibiting heightened macrophage activity, increased interferon-gamma signaling, and preservation of key genomic markers.

After stratifying the patients, prepare a detailed report analyzing how these distinct immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"I have processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) and need to assess the likelihood of response to Atezolizumab. The patient is a male of Asian descent, with a bladder tumor and a tumor mutational burden of 5.0 mutations per megabase. Could you help determine whether this patient is likely to be classified as a responder or non-responder to Atezolizumab, and explain your reasoning based on these clinical and molecular attributes?","I have processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) and need to assess the likelihood of response to Atezolizumab. The patient is a male of Asian descent, with a bladder tumor and a tumor mutational burden of 5.0 mutations per megabase. Could you help determine whether this patient is likely to be classified as a responder or non-responder to Atezolizumab, and explain your reasoning based on these clinical and molecular attributes? Please log into the COMPASS platform using your secure credentials and download the tumor transcriptomic dataset. Then, divide the patients into two groups based on their immune profiles:

1. Immunosuppressive Group: This group includes patients with diminished natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts.
2. Active Immune Response Group: This group includes patients with increased macrophage activity, elevated interferon-gamma signaling, and maintenance of essential genomic markers.

Once you have completed the stratification, compile a comprehensive report that evaluates the potential impact of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"Based on mRNA TPM data profiling that represents the immune microenvironment of a bladder tumor in a patient with Bladder Urothelial Carcinoma (BLCA), how should we interpret the likelihood of response to Atezolizumab? The patient is a white male with a bladder tumor, and the Tumor Mutational Burden (FMOne mutations per MB) is not available. Considering these details, is the patient predicted to be a responder or non-responder, and what reasoning supports this conclusion?","Based on mRNA TPM data profiling that represents the immune microenvironment of a bladder tumor in a patient with Bladder Urothelial Carcinoma (BLCA), how should we interpret the likelihood of response to Atezolizumab? The patient is a white male with a bladder tumor, and the Tumor Mutational Burden (FMOne mutations per MB) is not available. Considering these details, is the patient predicted to be a responder or non-responder, and what reasoning supports this conclusion? Please access the COMPASS platform using your secure login and download the tumor transcriptomic dataset. Next, stratify the patients into two groups based on their immune characteristics:

• Immunosuppressive Group: This group should include patients who show decreased natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.

• Active Immune Response Group: This group should include patients with enhanced macrophage activity, higher levels of interferon-gamma signaling, and preservation of key genomic markers.

After completing the stratification, please prepare a detailed report analyzing how these immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"Based on the processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (tumor located in the ureter), who is a White female with a tumor mutational burden of 12.0 mutations per megabase, could you assess whether this patient is likely to respond to Atezolizumab therapy and provide your supporting rationale?","Based on the processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (tumor located in the ureter), who is a White female with a tumor mutational burden of 12.0 mutations per megabase, could you assess whether this patient is likely to respond to Atezolizumab therapy and provide your supporting rationale? Please log in securely to the COMPASS platform and download the tumor transcriptomic dataset. Once you have the dataset, divide the patients into two groups based on their immune profiles:

1. Immunosuppressive Group: Patients in this group should show reduced activity of natural killer cells, evidence of T-cell exhaustion, and decreased B-cell counts.
2. Active Immune Response Group: Patients in this group should exhibit increased macrophage activity, higher levels of interferon-gamma signaling, and maintenance of key genomic markers.

After grouping the patients, prepare a detailed report analyzing how these immune characteristics could impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"Based on the processed mRNA TPM data reflecting the tumor immune microenvironment in this male, White patient with bladder urothelial carcinoma (primary tissue: ureter) and with unavailable tumor mutational burden information, can you provide a scientifically supported conclusion on whether the patient is predicted to respond to Atezolizumab? Please include the underlying rationale for your assessment.","Based on the processed mRNA TPM data reflecting the tumor immune microenvironment in this male, White patient with bladder urothelial carcinoma (primary tissue: ureter) and with unavailable tumor mutational burden information, can you provide a scientifically supported conclusion on whether the patient is predicted to respond to Atezolizumab? Please include the underlying rationale for your assessment. Please access the COMPASS platform securely and download the tumor transcriptomic dataset. After obtaining the dataset, stratify the patients into two groups based on their immune profiles:

1. Immunosuppressive Group: This group should include patients who demonstrate reduced activity of natural killer cells, signs of T-cell exhaustion, and lower levels of B cells.
2. Active Immune Response Group: This group should consist of patients with increased macrophage activity, elevated interferon-gamma signaling, and preservation of key genomic markers.

Following the stratification, compile a comprehensive report evaluating how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) and obtained details on her tumor immune microenvironment. The patient is a 5.0 TMB (mutations per megabase) white female with bladder tissue involvement. Can you provide your conclusion regarding this patient's likelihood to respond to Atezolizumab, and explain the rationale behind your assessment?","I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) and obtained details on her tumor immune microenvironment. The patient is a 5.0 TMB (mutations per megabase) white female with bladder tissue involvement. Can you provide your conclusion regarding this patient's likelihood to respond to Atezolizumab, and explain the rationale behind your assessment? Please log in to the COMPASS platform securely and download the tumor transcriptomic dataset. Once you have the dataset, classify the patients into two groups based on their immune profiles:

1. Immunosuppressive Group: Include patients who exhibit low natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell levels.
2. Active Immune Response Group: Include patients who show increased macrophage activity, elevated interferon-gamma signaling, and preservation of key genomic markers.

After stratification, prepare a detailed report assessing how these differing immune profiles could potentially affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"Given mRNA TPM data representing a bladder urothelial carcinoma tumor immune microenvironment, can you evaluate whether a 60-year-old white male patient with a lymph node tumor and a tumor mutational burden of 4.0 mutations/MB is predicted to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Given mRNA TPM data representing a bladder urothelial carcinoma tumor immune microenvironment, can you evaluate whether a 60-year-old white male patient with a lymph node tumor and a tumor mutational burden of 4.0 mutations/MB is predicted to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. Please log in securely to the COMPASS platform and download the tumor transcriptomic dataset. Once you have the dataset, classify the patients into two groups based on specific immune profile criteria:

• Immunosuppressive Group: This group should include patients exhibiting low activity of natural killer cells, markers of T-cell exhaustion, and reduced B-cell levels.

• Active Immune Response Group: This group should include patients demonstrating increased macrophage activity, elevated interferon-gamma signaling, and preserved key genomic markers.

After categorizing the patients into these groups, compile a detailed report that analyzes how these different immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"Based on the mRNA TPM analysis of this patient's tumor immune microenvironment for Bladder Urothelial Carcinoma, and considering the following clinical and molecular characteristics—male sex, White ethnicity, bladder tissue origin, and a tumor mutational burden of 8.0 mutations per megabase—can you determine whether this patient is likely to respond to Atezolizumab? Please provide your rationale.","Based on the mRNA TPM analysis of this patient's tumor immune microenvironment for Bladder Urothelial Carcinoma, and considering the following clinical and molecular characteristics—male sex, White ethnicity, bladder tissue origin, and a tumor mutational burden of 8.0 mutations per megabase—can you determine whether this patient is likely to respond to Atezolizumab? Please provide your rationale. Please log in securely to the COMPASS platform and download the tumor transcriptomic dataset. Next, classify the patients into two groups according to their immune profiles:

1. Immunosuppressive Group – Include patients who show low natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell levels.
2. Active Immune Response Group – Include patients who exhibit increased macrophage activity, elevated interferon-gamma signaling, and preservation of key genomic markers.

Once the patients have been categorized, compile a comprehensive report analyzing the potential impact of these different immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"Can you evaluate the predicted response to Atezolizumab for a patient with Bladder Urothelial Carcinoma based on processed mRNA TPM data from their tumor immune microenvironment? The patient is a white male with a bladder tumor, and the tumor mutational burden measurement was not determined (n/a). Please provide your assessment of whether the patient is likely to be a responder or non-responder, including the rationale for your conclusion.","Can you evaluate the predicted response to Atezolizumab for a patient with Bladder Urothelial Carcinoma based on processed mRNA TPM data from their tumor immune microenvironment? The patient is a white male with a bladder tumor, and the tumor mutational burden measurement was not determined (n/a). Please provide your assessment of whether the patient is likely to be a responder or non-responder, including the rationale for your conclusion. Please securely log in to the COMPASS platform and download the tumor transcriptomic dataset. Then, stratify the patients into two groups based on their immune profiles as follows:

1. Immunosuppressive Group – patients displaying low natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts.
2. Active Immune Response Group – patients with increased macrophage activity, heightened interferon-gamma signaling, and maintained key genomic markers.

After categorization, please prepare a detailed report analyzing how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"I have processed the mRNA TPM data reflecting the tumor immune microenvironment of a BLCA patient. The patient is a male, African American with bladder tissue involvement, diagnosed with Bladder Urothelial Carcinoma, and has a tumor mutational burden of 1.0 mutations per megabase. Based on these parameters, could you please assess whether this patient is likely to be a responder or non-responder to Atezolizumab, and provide the supporting rationale for your conclusion?","I have processed the mRNA TPM data reflecting the tumor immune microenvironment of a BLCA patient. The patient is a male, African American with bladder tissue involvement, diagnosed with Bladder Urothelial Carcinoma, and has a tumor mutational burden of 1.0 mutations per megabase. Based on these parameters, could you please assess whether this patient is likely to be a responder or non-responder to Atezolizumab, and provide the supporting rationale for your conclusion? Please log in securely to the COMPASS platform and download the tumor transcriptomic dataset. Once downloaded, divide the patients into two groups based on their immune profiles:

1. Immunosuppressive Group: Patients with low natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.
2. Active Immune Response Group: Patients showing increased macrophage activity, enhanced interferon-gamma signaling, and preserved key genomic markers.

After categorizing the patients, prepare a detailed report analyzing how these distinct immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"I have analyzed the mRNA TPM data for a patient with bladder urothelial carcinoma (BLCA) and obtained detailed tumor immune microenvironment information. The patient is a  male of Asian descent, with a kidney tissue sample and a tumor mutational burden of 11.0 FMOne mutations per MB. Based on this profile, could you determine whether the patient is likely to respond to Atezolizumab and provide the underlying rationale?","I have analyzed the mRNA TPM data for a patient with bladder urothelial carcinoma (BLCA) and obtained detailed tumor immune microenvironment information. The patient is a  male of Asian descent, with a kidney tissue sample and a tumor mutational burden of 11.0 FMOne mutations per MB. Based on this profile, could you determine whether the patient is likely to respond to Atezolizumab and provide the underlying rationale? Please access the COMPASS platform securely and download the tumor transcriptomic dataset. Once you have the dataset, stratify the patients into two groups based on their immune profiles:

1. Immunosuppressive Group: Patients exhibiting low natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts.
2. Active Immune Response Group: Patients with elevated macrophage activity, increased interferon-gamma signaling, and maintenance of key genomic markers.

After categorizing the patients, compile a comprehensive report that examines how these differing immune profiles could potentially impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a  male of White race, and the tissue sample was derived from the kidney. The tumor mutational burden is 8.0 mutations per megabase. Based on this information, can you evaluate the likelihood of a positive response to Atezolizumab therapy, and explain your rationale for classifying this patient as a responder or non-responder?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a  male of White race, and the tissue sample was derived from the kidney. The tumor mutational burden is 8.0 mutations per megabase. Based on this information, can you evaluate the likelihood of a positive response to Atezolizumab therapy, and explain your rationale for classifying this patient as a responder or non-responder? Please log in to the COMPASS platform using secure access and download the transcriptomic dataset related to tumors. Then, classify the patients into two groups according to their immune characteristics:

1. Immunosuppressive Group: Patients who demonstrate low natural killer cell activity, signs of T-cell exhaustion, and decreased B-cell counts.
2. Active Immune Response Group: Patients with heightened macrophage activity, increased signaling of interferon-gamma, and preserved key genomic markers.

After sorting the patients, prepare a detailed report analyzing how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"Given mRNA TPM data of the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA), and considering the following clinical details—sex: female; race: White; tissue: bladder; tumor mutational burden (FMO, mutations per MB): 7.0—could you provide an assessment on whether this patient is likely to respond or not respond to treatment with atezolizumab, including the rationale behind this prediction?","Given mRNA TPM data of the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA), and considering the following clinical details—sex: female; race: White; tissue: bladder; tumor mutational burden (FMO, mutations per MB): 7.0—could you provide an assessment on whether this patient is likely to respond or not respond to treatment with atezolizumab, including the rationale behind this prediction? Please securely access the COMPASS platform and download the tumor-related transcriptomic dataset. Once downloaded, categorize the patients into two groups based on their immune profiles:

1. Immunosuppressive Group: Identified by low natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts.
2. Active Immune Response Group: Characterized by enhanced macrophage activity, increased interferon-gamma signaling, and preservation of key genomic markers.

After grouping the patients, compile a comprehensive report that examines how these differing immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"Based on the processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), and considering the following patient characteristics—Sex: Male, Race: White, Tissue: Other, and an undefined Tumor Mutational Burden (FMOne mutation burden per MB: nan)—can you determine whether this patient is likely to respond to Atezolizumab? Please provide a conclusion along with the supporting scientific rationale.","Based on the processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), and considering the following patient characteristics—Sex: Male, Race: White, Tissue: Other, and an undefined Tumor Mutational Burden (FMOne mutation burden per MB: nan)—can you determine whether this patient is likely to respond to Atezolizumab? Please provide a conclusion along with the supporting scientific rationale. Please log in securely to the COMPASS platform and retrieve the tumor-related transcriptomic dataset. Once you have the dataset, stratify the patients into the following two groups based on their immune biomarkers:

• Immunosuppressive Group – Patients showing low natural killer cell activity, signs of T-cell exhaustion, and diminished B-cell counts.
• Active Immune Response Group – Patients demonstrating increased macrophage activity, elevated interferon-gamma signaling, and maintenance of critical genomic markers.

After organizing the data into these groups, please prepare a detailed report evaluating the potential impact of these distinct immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a male patient with White ethnicity, diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 mutations/MB. Based on these details, could you provide an assessment of whether this patient is likely to respond to Atezolizumab, including your reasoning?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a male patient with White ethnicity, diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 mutations/MB. Based on these details, could you provide an assessment of whether this patient is likely to respond to Atezolizumab, including your reasoning? Please access the secure COMPASS platform and download the tumor transcriptomic dataset. Next, classify patients into two groups based on their immune biomarker profiles:

• Immunosuppressive Group: Patients with reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.  
• Active Immune Response Group: Patients with heightened macrophage activity, increased interferon-gamma signaling, and preserved key genomic markers.

Once the groups are established, compile a comprehensive report analyzing how these immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"I have mRNA TPM data that characterizes the immune tumor microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, and the tissue sample analyzed is from the lung, with a tumor mutational burden of 8.0 FMOne mutations per MB. Based on these parameters, could you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and explain your reasoning?","I have mRNA TPM data that characterizes the immune tumor microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, and the tissue sample analyzed is from the lung, with a tumor mutational burden of 8.0 FMOne mutations per MB. Based on these parameters, could you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and explain your reasoning? Access the secure COMPASS platform to download the tumor transcriptomic dataset. Next, stratify the patients into two groups based on their immune biomarker profiles:

• Immunosuppressive Group: Patients exhibiting reduced activity of natural killer cells, signs of T-cell exhaustion, and decreased B-cell counts.  
• Active Immune Response Group: Patients displaying increased macrophage activity, elevated interferon-gamma signaling, and preservation of key genomic markers.

After grouping the patients, prepare a detailed report evaluating the potential impact of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"Based on the patient's detailed profile, including an mRNA TPM analysis of the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), with the following attributes: female, white, primary bladder tumor, and a tumor mutational burden of 14.0 mutations/Mb, could you assess whether these findings indicate a likelihood of response to Atezolizumab? Please provide your rationale for the predicted outcome.","Based on the patient's detailed profile, including an mRNA TPM analysis of the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), with the following attributes: female, white, primary bladder tumor, and a tumor mutational burden of 14.0 mutations/Mb, could you assess whether these findings indicate a likelihood of response to Atezolizumab? Please provide your rationale for the predicted outcome. Please log in to the secure COMPASS platform and download the tumor transcriptomic dataset. Once the data is obtained, divide the patients into two distinct groups based on their immune biomarker profiles:

1. Immunosuppressive Group: Patients should be classified into this group if they present with reduced activity of natural killer cells, evidence of T-cell exhaustion, and lower B-cell counts.  
2. Active Immune Response Group: Patients exhibiting increased macrophage activity, higher interferon-gamma signaling, and maintenance of significant genomic markers should be categorized here.

After categorizing the patients, compile a comprehensive report assessing how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"Based on the mRNA TPM profiling of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), with the following clinical characteristics—sex: male, race: white, bladder tissue involvement, and a tumor mutational burden of 13.0 mutations per MB—how would you assess the likelihood of responsiveness to Atezolizumab? Please provide your conclusion as to whether this patient is classified as a responder or non-responder, along with the supporting rationale.","Based on the mRNA TPM profiling of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), with the following clinical characteristics—sex: male, race: white, bladder tissue involvement, and a tumor mutational burden of 13.0 mutations per MB—how would you assess the likelihood of responsiveness to Atezolizumab? Please provide your conclusion as to whether this patient is classified as a responder or non-responder, along with the supporting rationale. Please access the secure COMPASS platform and download the tumor transcriptomic dataset. Once downloaded, stratify the patients into two groups based on their immune biomarker profiles as follows:

1. Immunosuppressive Group: Include patients who exhibit decreased natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
2. Active Immune Response Group: Include patients who show elevated macrophage activity, increased interferon-gamma signaling, and maintain significant genomic markers.

After grouping the patients, prepare a detailed report evaluating how these distinct immune profiles may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"A patient with bladder urothelial carcinoma (BLCA) has been assessed using mRNA TPM data to characterize the tumor immune microenvironment. The patient is an Asian male with a bladder tumor and a tumor mutational burden of 14.0 FMOne mutations per MB. Could you provide your evaluation on whether he is likely to respond to atezolizumab therapy, including the rationale for your conclusion?","A patient with bladder urothelial carcinoma (BLCA) has been assessed using mRNA TPM data to characterize the tumor immune microenvironment. The patient is an Asian male with a bladder tumor and a tumor mutational burden of 14.0 FMOne mutations per MB. Could you provide your evaluation on whether he is likely to respond to atezolizumab therapy, including the rationale for your conclusion? Please log in to the secure COMPASS platform and download the tumor transcriptomic dataset. Once you have the dataset, categorize the patients into two groups based on their immune biomarker profiles:

1. Immunosuppressive Group: Patients who display reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.
2. Active Immune Response Group: Patients who exhibit increased macrophage activity, enhanced interferon-gamma signaling, and preserved genomic markers.

After categorizing the patients, develop a comprehensive report that assesses how these differing immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"Based on the mRNA TPM data analysis for a patient with Bladder Urothelial Carcinoma (BLCA), can you help assess the predicted response to Atezolizumab? The patient details are as follows: Male, White, tissue sampled from the kidney, with a tumor mutational burden of 7.0 mutations per megabase. Please provide a conclusion on whether this patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting rationale.","Based on the mRNA TPM data analysis for a patient with Bladder Urothelial Carcinoma (BLCA), can you help assess the predicted response to Atezolizumab? The patient details are as follows: Male, White, tissue sampled from the kidney, with a tumor mutational burden of 7.0 mutations per megabase. Please provide a conclusion on whether this patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting rationale. Please access the secure COMPASS platform and download the tumor transcriptomics dataset. Once you have the dataset, classify the patients into two groups based on their immune biomarker profiles:

• Immunosuppressive Group – patients showing diminished natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.
• Active Immune Response Group – patients with increased macrophage activity, elevated interferon-gamma signaling, and preserved genomic markers.

After grouping the patients, prepare a detailed report analyzing how these varying immune profiles may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"Given a patient's mRNA TPM data that characterizes the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA)—specifically, a 6.0 mutations/MB tumor mutational burden, male sex, and White race with bladder tissue involvement—could you please evaluate the data to determine whether this patient is predicted to respond to Atezolizumab, and explain the reasoning behind the classification?","Given a patient's mRNA TPM data that characterizes the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA)—specifically, a 6.0 mutations/MB tumor mutational burden, male sex, and White race with bladder tissue involvement—could you please evaluate the data to determine whether this patient is predicted to respond to Atezolizumab, and explain the reasoning behind the classification? Please log into the secure COMPASS platform and download the tumor transcriptomics dataset. Using this dataset, divide the patients into two categories based on their immune biomarker profiles:

• Immunosuppressive Group – patients with reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response Group – patients exhibiting heightened macrophage activity, increased interferon-gamma signaling, and intact genomic markers.

After categorizing the patients, compile a comprehensive report that analyzes how these differences in immune profiles could influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"I am reviewing mRNA TPM data that characterizes the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient’s profile is as follows: Male, White, tissue of origin is kidney, and a tumor mutational burden of 6.0 mutations per megabase. Could you assess the likelihood that this patient will respond to Atezolizumab and provide the rationale behind classification as a responder or non-responder?","I am reviewing mRNA TPM data that characterizes the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient’s profile is as follows: Male, White, tissue of origin is kidney, and a tumor mutational burden of 6.0 mutations per megabase. Could you assess the likelihood that this patient will respond to Atezolizumab and provide the rationale behind classification as a responder or non-responder? Please access the secure COMPASS platform to retrieve the tumor transcriptomics dataset. Once obtained, stratify the patients into two groups based on their immune biomarker profiles as follows:

• Immunosuppressive Group – these patients exhibit reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response Group – these patients show increased macrophage activity, elevated interferon-gamma signaling, and intact genomic markers.

After categorizing the patients, please prepare a detailed report that examines how these distinct immune profiles may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and need to evaluate the predicted response to Atezolizumab. The patient is male, White, with a primary tumor located in the bladder, a BLCA diagnosis, and a tumor mutational burden of 5 mutations per megabase. Based on these parameters, could you determine if this patient is likely to be a responder or non-responder to Atezolizumab and provide a detailed explanation of your reasoning?","I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and need to evaluate the predicted response to Atezolizumab. The patient is male, White, with a primary tumor located in the bladder, a BLCA diagnosis, and a tumor mutational burden of 5 mutations per megabase. Based on these parameters, could you determine if this patient is likely to be a responder or non-responder to Atezolizumab and provide a detailed explanation of your reasoning? Please log in to the secure COMPASS platform and download the tumor transcriptomics dataset. Once you have the data, divide the patients into two groups based on their immune biomarker profiles:

• Immunosuppressive Group – patients with reduced natural killer cell function, signs of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response Group – patients with increased macrophage activity, heightened interferon-gamma signaling, and preserved genomic markers.

After grouping the patients, compile a comprehensive report analyzing how these distinct immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"I have analyzed mRNA TPM data of the tumor immune microenvironment from a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a high tumor mutational burden (49 mutations/MB). Could you please assess whether this patient is likely to be a responder or non-responder to atezolizumab, and explain the reasoning behind your conclusion?","I have analyzed mRNA TPM data of the tumor immune microenvironment from a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a high tumor mutational burden (49 mutations/MB). Could you please assess whether this patient is likely to be a responder or non-responder to atezolizumab, and explain the reasoning behind your conclusion? Please sign in to the secure COMPASS platform to download the tumor transcriptomics dataset. Once you have the data, stratify the patients into two groups based on their immune biomarker profiles:

• Immunosuppressive Group: Patients who exhibit reduced natural killer cell function, evidence of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response Group: Patients who show increased macrophage activity, elevated interferon-gamma signaling, and maintained genomic markers.

After grouping the patients, please prepare a detailed report analyzing how these differing immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"Based on processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), can you help determine if this patient is likely to be a responder to Atezolizumab? Key clinical details include: male, white, primary bladder tissue involvement, and a tumor mutational burden of 12.0 mutations per MB. Please provide your assessment along with the rationale behind your conclusion.","Based on processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), can you help determine if this patient is likely to be a responder to Atezolizumab? Key clinical details include: male, white, primary bladder tissue involvement, and a tumor mutational burden of 12.0 mutations per MB. Please provide your assessment along with the rationale behind your conclusion. Log in to the secure COMPASS platform to download the tumor transcriptomics dataset. Once you have accessed the data, divide the patients into two groups based on their immune biomarker profiles:

• Immunosuppressive Group: Patients with decreased natural killer cell function, signs of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response Group: Patients with increased macrophage activity, heightened interferon-gamma signaling, and maintained genomic markers.

After categorizing the patients, compile a comprehensive report that examines how these distinct immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"A patient with bladder urothelial carcinoma (BLCA) has been evaluated using processed mRNA TPM data that characterizes the tumor immune microenvironment. The patient is a white male with bladder tissue involvement, and the FMOne mutation burden per megabase is not available. Based on this information, could you assess whether this patient is likely to respond to atezolizumab therapy, and please provide your rationale for classifying him as a responder or non-responder?","A patient with bladder urothelial carcinoma (BLCA) has been evaluated using processed mRNA TPM data that characterizes the tumor immune microenvironment. The patient is a white male with bladder tissue involvement, and the FMOne mutation burden per megabase is not available. Based on this information, could you assess whether this patient is likely to respond to atezolizumab therapy, and please provide your rationale for classifying him as a responder or non-responder? Please access the secure COMPASS platform and download the tumor transcriptomics dataset. Next, divide the patients into the following two groups based on their immune biomarker profiles:

• Immunosuppressive Group – Patients exhibiting reduced natural killer cell function, indications of T-cell exhaustion, and lower B-cell counts.  
• Active Immune Response Group – Patients showing increased macrophage activity, enhanced interferon-gamma signaling, and stable genomic markers.

After grouping the patients, prepare a detailed report to analyze how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"For a male white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations per megabase, and with available mRNA TPM data detailing the tumor immune microenvironment, could you assess the likely response to atezolizumab by classifying the patient as a responder or non-responder and provide the rationale behind this determination?","For a male white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations per megabase, and with available mRNA TPM data detailing the tumor immune microenvironment, could you assess the likely response to atezolizumab by classifying the patient as a responder or non-responder and provide the rationale behind this determination? Access the secure COMPASS platform to download the tumor transcriptomics dataset. Next, stratify the patient cohort into two groups based on their immune biomarker profiles:

• Immunosuppressive Group – Patients with diminished natural killer cell function, signs of T-cell exhaustion, and decreased B-cell counts.  
• Active Immune Response Group – Patients with heightened macrophage activity, increased interferon-gamma signaling, and stable genomic markers.

Once you have created these groups, compile a detailed report analyzing how these distinct immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) and would like to assess their predicted responsiveness to Atezolizumab. The patient is a male, Black or African American, with kidney tissue involvement, and has an FMOne tumor mutational burden of 11.0 mutations per megabase. Based on these attributes, could you provide a conclusion on whether this patient is more likely to be a responder or a non-responder to Atezolizumab, including the supporting rationale?","I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) and would like to assess their predicted responsiveness to Atezolizumab. The patient is a male, Black or African American, with kidney tissue involvement, and has an FMOne tumor mutational burden of 11.0 mutations per megabase. Based on these attributes, could you provide a conclusion on whether this patient is more likely to be a responder or a non-responder to Atezolizumab, including the supporting rationale? Please log in to the secure COMPASS platform and download the tumor transcriptomics dataset. Then, divide the patient cohort into two groups based on their immune biomarker characteristics:

• Immunosuppressive Group: This includes patients exhibiting reduced natural killer cell function, evidence of T-cell exhaustion, and lower B-cell counts.  
• Active Immune Response Group: This includes patients showing elevated macrophage activity, increased interferon-gamma signaling, and stable genomic markers.

After classifying the patients, prepare a comprehensive report detailing how these differing immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"Based on processed mRNA TPM data from the patient's tumor immune microenvironment in a case of bladder urothelial carcinoma (BLCA), can you determine if the patient—a white male with primary bladder involvement and an unspecified tumor mutational burden—is likely to respond to Atezolizumab? Please include the rationale behind your conclusion.","Based on processed mRNA TPM data from the patient's tumor immune microenvironment in a case of bladder urothelial carcinoma (BLCA), can you determine if the patient—a white male with primary bladder involvement and an unspecified tumor mutational burden—is likely to respond to Atezolizumab? Please include the rationale behind your conclusion. Please access the secure COMPASS platform and download the tumor transcriptomics dataset. Then, categorize the patient cohort into two groups based on specific immune biomarker profiles:

• Immunosuppressive Group: Patients in this group display reduced natural killer cell function, signs of T-cell exhaustion, and lower B-cell counts.  
• Active Immune Response Group: Patients here exhibit heightened macrophage activity, increased interferon-gamma signaling, and stable genomic markers.

Once you have completed the classification, please compile a detailed report analyzing how these distinct immune profiles could potentially affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"For a patient with bladder urothelial carcinoma and available mRNA TPM data reflecting the tumor immune microenvironment, can you help determine the likelihood of a positive response to atezolizumab? The patient is a ₁M, white individual with a ureter sample, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Please provide a conclusion on whether this patient is likely to be a responder or non-responder, along with the supporting rationale.","For a patient with bladder urothelial carcinoma and available mRNA TPM data reflecting the tumor immune microenvironment, can you help determine the likelihood of a positive response to atezolizumab? The patient is a ₁M, white individual with a ureter sample, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Please provide a conclusion on whether this patient is likely to be a responder or non-responder, along with the supporting rationale. Please log into the secure COMPASS platform and download the tumor transcriptomics dataset. Next, stratify the patient group into two categories based on their immune biomarker profiles:

1. Immunosuppressive Group: Patients who demonstrate diminished natural killer cell function, evidence of T-cell exhaustion, and decreased B-cell counts.
2. Active Immune Response Group: Patients who show increased macrophage activity, enhanced interferon-gamma signaling, and maintain stable genomic markers.

After completing the classification, prepare a comprehensive report evaluating the potential impact of these distinct immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"For a patient with bladder urothelial carcinoma characterized by the following attributes: male, white, bladder tissue origin, and an FMOne mutation burden of 17 mutations per megabase, can we determine whether they are more likely to respond to Atezolizumab? Please include the rationale that supports this prediction based on the mRNA TPM data and the tumor immune microenvironment.","For a patient with bladder urothelial carcinoma characterized by the following attributes: male, white, bladder tissue origin, and an FMOne mutation burden of 17 mutations per megabase, can we determine whether they are more likely to respond to Atezolizumab? Please include the rationale that supports this prediction based on the mRNA TPM data and the tumor immune microenvironment. Please access the secure COMPASS platform and download the tumor transcriptomics dataset. Once downloaded, categorize the patients into two groups based on their immune biomarker profiles:

1. Immunosuppressive Group: Patients who exhibit reduced natural killer cell function, signs of T-cell exhaustion, and lower B-cell counts.
2. Active Immune Response Group: Patients characterized by increased macrophage activity, enhanced interferon-gamma signaling, and stable genomic markers.

After completing the classification, compile a detailed report assessing how these distinct immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"Based on the processed mRNA TPM data of the tumor immune microenvironment for a male White patient with bladder tissue involvement in Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 22.0 (FMOne mutation burden per MB), can you determine whether this patient is likely to respond to Atezolizumab? Please include your reasoning for the classification as a responder or non-responder.","Based on the processed mRNA TPM data of the tumor immune microenvironment for a male White patient with bladder tissue involvement in Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 22.0 (FMOne mutation burden per MB), can you determine whether this patient is likely to respond to Atezolizumab? Please include your reasoning for the classification as a responder or non-responder. Please log into the secure COMPASS platform to download the tumor transcriptomics dataset. After obtaining the dataset, please stratify the patients into two groups based on their immune biomarker profiles:

1. Immunosuppressive Group: Patients who demonstrate diminished natural killer cell function, evidence of T-cell exhaustion, and reduced B-cell counts.
2. Active Immune Response Group: Patients exhibiting heightened macrophage activity, increased interferon-gamma signaling, and stable genomic markers.

Once the classification is complete, prepare a comprehensive report evaluating the potential impact of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"Based on mRNA TPM data from the tumor immune microenvironment of a white male with bladder urothelial carcinoma (BLCA) and an unavailable tumor mutational burden (FMO mutation burden per MB: nan), can we predict his likelihood of responding to Atezolizumab? Please provide an interpretation with supporting rationale.","Based on mRNA TPM data from the tumor immune microenvironment of a white male with bladder urothelial carcinoma (BLCA) and an unavailable tumor mutational burden (FMO mutation burden per MB: nan), can we predict his likelihood of responding to Atezolizumab? Please provide an interpretation with supporting rationale. Please access the secure COMPASS platform and download the tumor transcriptomics dataset. Once you have the dataset, classify the patients into two groups based on their immune biomarker profiles. Group 1 should include patients with reduced natural killer cell function, signs of T-cell exhaustion, and decreased B-cell counts (the Immunosuppressive Group). Group 2 should consist of patients with heightened macrophage activity, increased interferon-gamma signaling, and stable genomic markers (the Active Immune Response Group). After completing the classification, prepare a detailed report assessing how these immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"A patient with Bladder Urothelial Carcinoma (BLCA) has processed mRNA TPM data characterizing the tumor immune microenvironment. The patient is male, of a non-Caucasian race (OTHER), with tissue reported as kidney, and has a tumor mutational burden of 18.0 mutations per MB. Based on these data, can you provide an assessment of the predicted responsiveness to Atezolizumab, including the rationale for classifying this patient as a responder or non-responder?","A patient with Bladder Urothelial Carcinoma (BLCA) has processed mRNA TPM data characterizing the tumor immune microenvironment. The patient is male, of a non-Caucasian race (OTHER), with tissue reported as kidney, and has a tumor mutational burden of 18.0 mutations per MB. Based on these data, can you provide an assessment of the predicted responsiveness to Atezolizumab, including the rationale for classifying this patient as a responder or non-responder? Please log in to the secure COMPASS platform and download the tumor transcriptomics dataset. Once you have the data, please categorize patients into two groups based on their immune biomarker profiles. Group 1 should include patients demonstrating reduced natural killer cell function, evidence of T-cell exhaustion, and lower B-cell counts (the Immunosuppressive Group). Conversely, Group 2 should comprise patients showing enhanced macrophage activity, elevated interferon-gamma signaling, and stable genomic markers (the Active Immune Response Group). After completing this classification, generate a comprehensive report analyzing how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a White male, with a kidney tissue sample and a tumor mutational burden of 5 mutations per megabase. Based on these findings, can you determine whether the patient is likely to respond to Atezolizumab, and please provide your supporting rationale?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a White male, with a kidney tissue sample and a tumor mutational burden of 5 mutations per megabase. Based on these findings, can you determine whether the patient is likely to respond to Atezolizumab, and please provide your supporting rationale? Please access the secure COMPASS platform and download the tumor transcriptomics dataset. Next, stratify the patients into two groups based on their immune biomarker profiles as follows:

• Group 1 (Immunosuppressive Group): Patients with diminished natural killer cell function, signs of T-cell exhaustion, and reduced B-cell counts.

• Group 2 (Active Immune Response Group): Patients with increased macrophage activity, heightened interferon-gamma signaling, and stable genomic markers.

After categorizing the patients, prepare a detailed report evaluating how these distinct immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"I have processed mRNA TPM data characterizing the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 4.0 mutations per megabase. Based on these details, can you provide a conclusion on whether this patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting scientific rationale?","I have processed mRNA TPM data characterizing the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 4.0 mutations per megabase. Based on these details, can you provide a conclusion on whether this patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting scientific rationale? Please log into the secure COMPASS platform and download the tumor transcriptomics dataset. Once downloaded, stratify the patients into two groups based on their immune biomarker profiles:

• Group 1 (Immunosuppressive Profile): Patients exhibiting reduced natural killer cell function, evidence of T-cell exhaustion, and lower B-cell counts.

• Group 2 (Active Immune Response): Patients showing increased macrophage activity, enhanced interferon-gamma signaling, and stable genomic markers.

After grouping the patients accordingly, prepare a comprehensive report that evaluates how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"We have processed mRNA TPM data from a patient’s tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA). The patient is a white male with kidney tissue sampling and a tumor mutational burden of 5.0 mutations per MB. Could you assess whether this patient is likely to respond to Atezolizumab, and provide the supporting rationale for your conclusion?","We have processed mRNA TPM data from a patient’s tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA). The patient is a white male with kidney tissue sampling and a tumor mutational burden of 5.0 mutations per MB. Could you assess whether this patient is likely to respond to Atezolizumab, and provide the supporting rationale for your conclusion? Access the secure COMPASS platform and download the tumor transcriptomics dataset. Next, stratify the patients into two groups based on their immune biomarker profiles. For Group 1, include patients who show reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts, indicating an immunosuppressive profile. For Group 2, group patients with heightened macrophage activity, increased interferon-gamma signaling, and consistent genomic markers, reflecting an active immune response. Finally, prepare a comprehensive report assessing how these differing immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"Based on the patient's tumor immune microenvironment mRNA TPM profile, along with the clinical details provided (male, white, kidney tissue, diagnosed with Bladder Urothelial Carcinoma, and a tumor mutational burden of 12.0 mutations per megabase), can we determine whether this patient is likely to be a responder to Atezolizumab? Please provide a conclusion supported by your reasoning.","Based on the patient's tumor immune microenvironment mRNA TPM profile, along with the clinical details provided (male, white, kidney tissue, diagnosed with Bladder Urothelial Carcinoma, and a tumor mutational burden of 12.0 mutations per megabase), can we determine whether this patient is likely to be a responder to Atezolizumab? Please provide a conclusion supported by your reasoning. Please log into the secure COMPASS platform and download the tumor transcriptomics dataset. After obtaining the dataset, classify the patients into two groups based on their immune biomarkers. For the first group, include patients with reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts, which together suggest an immunosuppressive profile. For the second group, include those with increased macrophage activity, elevated interferon-gamma signaling, and uniform genomic markers, which indicate an active immune response. Finally, compile a detailed report evaluating how these distinct immune profiles could impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), and I am interested in determining the predicted response to Atezolizumab. The patient details are: Sex: Male; Race: White; Tissue specimen: liver; Tumor Mutational Burden (per MB): not available. Based on the available data, could you provide a conclusion on whether this patient is likely to be a responder or non-responder to Atezolizumab, and explain the supporting rationale?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), and I am interested in determining the predicted response to Atezolizumab. The patient details are: Sex: Male; Race: White; Tissue specimen: liver; Tumor Mutational Burden (per MB): not available. Based on the available data, could you provide a conclusion on whether this patient is likely to be a responder or non-responder to Atezolizumab, and explain the supporting rationale? Please access the secure COMPASS platform and download the tumor transcriptomics dataset. Once you have the data, divide the patients into two groups based on their immune biomarkers. Group 1 should consist of patients exhibiting signs of an immunosuppressive profile, as evidenced by reduced natural killer cell activity, markers of T-cell exhaustion, and lower B-cell counts. Group 2 should comprise patients who display an active immune response, characterized by increased macrophage activity, elevated interferon-gamma signaling, and consistent genomic markers. Finally, prepare a comprehensive report that evaluates how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA) to evaluate predicted responsiveness to Atezolizumab. The patient is a White female with kidney tissue involvement, and the tumor mutational burden (FMOne mutation burden per MB) is not available (nan). Based on these clinical and molecular parameters, could you determine whether this patient is more likely to be a responder or a non-responder to Atezolizumab, and explain the reasoning behind your assessment?","I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA) to evaluate predicted responsiveness to Atezolizumab. The patient is a White female with kidney tissue involvement, and the tumor mutational burden (FMOne mutation burden per MB) is not available (nan). Based on these clinical and molecular parameters, could you determine whether this patient is more likely to be a responder or a non-responder to Atezolizumab, and explain the reasoning behind your assessment? Please log into the secure COMPASS platform and retrieve the tumor transcriptomics dataset. After downloading the data, stratify the patients into two groups based on their immune biomarker profiles. For Group 1, include those patients showing an immunosuppressive profile, which should be defined by decreased natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts. For Group 2, include patients who appear to have an active immune response, indicated by heightened macrophage activity, increased interferon-gamma signaling, and the presence of consistent genomic markers. Finally, compile a detailed report that assesses how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"For a male, White patient with bladder urothelial carcinoma and a tumor mutational burden of 10 mutations per megabase, how likely is it that they will respond to Atezolizumab based on the processed mRNA TPM data reflecting their tumor immune microenvironment? Please classify the patient as a responder or non-responder, and provide the supporting rationale for your conclusion.","For a male, White patient with bladder urothelial carcinoma and a tumor mutational burden of 10 mutations per megabase, how likely is it that they will respond to Atezolizumab based on the processed mRNA TPM data reflecting their tumor immune microenvironment? Please classify the patient as a responder or non-responder, and provide the supporting rationale for your conclusion. Log into the secure COMPASS platform and locate the tumor transcriptomics dataset. Once you have downloaded the data, divide the patients into two groups based on their immune biomarker profiles. Group 1 should consist of patients with an immunosuppressive profile, characterized by decreased natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts. Group 2 should include patients with an active immune response, as indicated by increased macrophage activity, enhanced interferon-gamma signaling, and consistent genomic markers. Finally, prepare a detailed report evaluating the potential impact of these distinct immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"Given the patient's mRNA TPM data from the tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA), along with the relevant clinical attributes (Sex: F; Race: White; Tissue: bladder; Tumor Mutational Burden: 6.0 mutations/Mb), could you please determine whether the patient is likely to respond to Atezolizumab and provide the rationale behind the assessment?","Given the patient's mRNA TPM data from the tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA), along with the relevant clinical attributes (Sex: F; Race: White; Tissue: bladder; Tumor Mutational Burden: 6.0 mutations/Mb), could you please determine whether the patient is likely to respond to Atezolizumab and provide the rationale behind the assessment? Access the secure COMPASS system and retrieve the tumor transcriptomics dataset. Once the data is downloaded, categorize the patients into two groups according to their immune biomarker profiles. For Group 1, include patients who demonstrate an immunosuppressive profile, defined by reduced natural killer cell activity, signs of T‐cell exhaustion, and lower B‐cell counts. For Group 2, include patients with active immune responses, indicated by increased macrophage activity, heightened interferon-gamma signaling, and consistent genomic markers. Finally, compile a comprehensive report examining how these variations in immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"Using the processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA), could you please assess the predicted response to Atezolizumab treatment? Patient details: Female, White; tissue: bladder; tumor mutational burden (FMOne mutation burden per MB) is not available. Based on these data, is this patient likely to be a responder or a non-responder, and what is the supporting rationale?","Using the processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA), could you please assess the predicted response to Atezolizumab treatment? Patient details: Female, White; tissue: bladder; tumor mutational burden (FMOne mutation burden per MB) is not available. Based on these data, is this patient likely to be a responder or a non-responder, and what is the supporting rationale? Please access the secure COMPASS system and download the tumor transcriptomics dataset. After obtaining the dataset, classify the patients into two distinct groups based on their immune biomarker profiles. For the first group, include patients who exhibit an immunosuppressive profile—this should be characterized by reduced natural killer cell activity, evidence of T‐cell exhaustion, and lower B‐cell counts. For the second group, include patients who display active immune responses, as indicated by increased macrophage activity, heightened interferon-gamma signaling, and the presence of consistent genomic markers. Finally, prepare a detailed report that evaluates how these differences in immune profiles may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,Can you evaluate the predicted response to Atezolizumab for a patient with bladder urothelial carcinoma (BLCA) based on processed mRNA TPM data of the tumor immune microenvironment? The patient is a white female with bladder tissue involvement and a tumor mutational burden of 15 mutations per megabase. Please classify the patient as a likely responder or non-responder and provide the supporting rationale for your conclusion.,"Can you evaluate the predicted response to Atezolizumab for a patient with bladder urothelial carcinoma (BLCA) based on processed mRNA TPM data of the tumor immune microenvironment? The patient is a white female with bladder tissue involvement and a tumor mutational burden of 15 mutations per megabase. Please classify the patient as a likely responder or non-responder and provide the supporting rationale for your conclusion. Access the secure COMPASS system and download the tumor transcriptomics dataset. Once downloaded, sort the patients into two groups based on their immune biomarker profiles. Place patients with reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts into the immunosuppressed group. Place patients with increased macrophage activity, elevated interferon-gamma signaling, and consistent genomic markers into the active immune response group. Finally, prepare a detailed report discussing how these immune profile differences could affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"I have processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) to evaluate the tumor immune microenvironment. The patient is a  male of White race with a lymph node tissue sample and a tumor mutational burden of 8.0 mutations per megabase. Based on these characteristics, could you assess the likelihood of a favorable response to Atezolizumab and explain your reasoning?","I have processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) to evaluate the tumor immune microenvironment. The patient is a  male of White race with a lymph node tissue sample and a tumor mutational burden of 8.0 mutations per megabase. Based on these characteristics, could you assess the likelihood of a favorable response to Atezolizumab and explain your reasoning? Please log into the secure COMPASS system and download the tumor transcriptomics dataset. After obtaining the data, classify the patients into two groups based on their immune biomarker profiles. Patients exhibiting reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts should be categorized as immunosuppressed. In contrast, patients showing increased macrophage activity, elevated interferon-gamma signaling, and stable genomic markers should be classified as having an active immune response. Once the groups have been defined, compile a detailed report discussing how these differences in immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"Given the processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), and considering the patient's characteristics (male, white, bladder tissue with a tumor mutational burden of 6.0 mutations/MB), what is the predicted response to Atezolizumab? Please provide a detailed conclusion and your supporting reasoning regarding whether this patient is likely to respond to the treatment.","Given the processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), and considering the patient's characteristics (male, white, bladder tissue with a tumor mutational burden of 6.0 mutations/MB), what is the predicted response to Atezolizumab? Please provide a detailed conclusion and your supporting reasoning regarding whether this patient is likely to respond to the treatment. Log into the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the data, divide the patients into two groups based on their immune biomarker profiles. Classify patients with decreased natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts as immunosuppressed. Conversely, assign patients with increased macrophage activity, higher interferon-gamma signaling, and stable genomic markers to the active immune response group. Finally, generate a detailed report that explores how these immune profile differences might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"I have processed mRNA TPM data from a patient's Bladder Urothelial Carcinoma tumor immune microenvironment. The patient is a white male with a bladder tumor and a tumor mutational burden of 19.0 mutations/MB. Based on these factors, what is the predicted response to Atezolizumab, and could you provide the rationale behind classifying this patient as a responder or non-responder?","I have processed mRNA TPM data from a patient's Bladder Urothelial Carcinoma tumor immune microenvironment. The patient is a white male with a bladder tumor and a tumor mutational burden of 19.0 mutations/MB. Based on these factors, what is the predicted response to Atezolizumab, and could you provide the rationale behind classifying this patient as a responder or non-responder? Access the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the data, segregate the patients into two groups according to their immune biomarker profiles. Patients exhibiting reduced natural killer cell activity, evidence of T-cell exhaustion, and diminished B-cell counts should be categorized as immunosuppressed. In contrast, those with elevated macrophage activity, increased interferon-gamma signaling, and stable genomic markers should be classified as having an active immune response. Finally, prepare a comprehensive report that analyzes how these differing immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"Given mRNA TPM data for a male, White patient with Bladder Urothelial Carcinoma (tissue: other) and a tumor mutational burden of 12.0 mutations per megabase, what is the predicted response to Atezolizumab, and what evidence supports classifying this patient as a responder or non-responder?","Given mRNA TPM data for a male, White patient with Bladder Urothelial Carcinoma (tissue: other) and a tumor mutational burden of 12.0 mutations per megabase, what is the predicted response to Atezolizumab, and what evidence supports classifying this patient as a responder or non-responder? Please log into the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the data, divide the patients into two groups based on their immune biomarker profiles. Group one should include patients showing signs of immunosuppression, such as reduced natural killer cell activity, indications of T-cell exhaustion, and lower B-cell counts. The other group should consist of patients with an active immune response, characterized by increased macrophage activity, higher interferon-gamma signaling, and stable genomic markers. Finally, compile a detailed report that evaluates how these distinct immune profiles could influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the predicted response to Atezolizumab. The patient’s clinical characteristics include: male, White, tissue sampled from the kidney, BLCA diagnosis, and an unavailable Tumor Mutational Burden. Could you please provide an assessment regarding whether this patient is more likely to respond to Atezolizumab, along with the rationale supporting your conclusion?","I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the predicted response to Atezolizumab. The patient’s clinical characteristics include: male, White, tissue sampled from the kidney, BLCA diagnosis, and an unavailable Tumor Mutational Burden. Could you please provide an assessment regarding whether this patient is more likely to respond to Atezolizumab, along with the rationale supporting your conclusion? Please access the secure COMPASS system and download the tumor transcriptomics data. After obtaining the dataset, stratify the patients into two groups based on their immune biomarker profiles. The first group should include patients exhibiting signs of immunosuppression—for example, those with diminished natural killer cell activity, clear markers of T-cell exhaustion, and reduced B-cell counts. The second group should consist of patients with an active immune response, indicated by increased macrophage activity, elevated interferon-gamma signaling, and stable genomic markers. Once this grouping is complete, please prepare a comprehensive report analyzing how these differing immune profiles may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"A patient with Bladder Urothelial Carcinoma (BLCA), a white male with a tumor mutational burden of 3.0 mutations/MB, has mRNA TPM data available reflecting the tumor immune microenvironment. Based on this profile, how might we predict his responsiveness to Atezolizumab, and what clinical rationale supports this assessment?","A patient with Bladder Urothelial Carcinoma (BLCA), a white male with a tumor mutational burden of 3.0 mutations/MB, has mRNA TPM data available reflecting the tumor immune microenvironment. Based on this profile, how might we predict his responsiveness to Atezolizumab, and what clinical rationale supports this assessment? Access the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the data, divide the patients into two groups according to their immune biomarker profiles. Group one should include patients demonstrating immunosuppression—characterized by reduced natural killer cell activity, markers of T-cell exhaustion, and lower B-cell counts. Group two should comprise patients showing an active immune response, evidenced by heightened macrophage activity, increased interferon-gamma signaling, and consistent genomic markers. Finally, prepare a detailed report evaluating how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"Based on the patient's mRNA TPM data reflecting the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with the clinical details provided (male, white, lymph node tissue involvement, and a tumor mutational burden of 18.0 mutations/MB), can you assess whether this patient is likely to respond to Atezolizumab and explain the rationale behind the prediction?","Based on the patient's mRNA TPM data reflecting the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with the clinical details provided (male, white, lymph node tissue involvement, and a tumor mutational burden of 18.0 mutations/MB), can you assess whether this patient is likely to respond to Atezolizumab and explain the rationale behind the prediction? Please log into the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the dataset, stratify the patients into two groups based on their immune biomarker profiles. The first group should include patients exhibiting signs of immunosuppression, such as decreased natural killer cell activity, markers indicative of T-cell exhaustion, and lower B-cell counts. The second group should consist of patients with an active immune response, demonstrated by increased macrophage activity, elevated interferon-gamma signaling, and consistent genomic markers. Finally, compile a comprehensive report that assesses how these distinct immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"Given the mRNA TPM data for this patient's tumor immune microenvironment and considering the following clinical details—Sex: Male, Race: White, Tissue: Kidney, Diagnosis: Bladder Urothelial Carcinoma (BLCA), and a Tumor Mutational Burden of 15 mutations per MB—could you evaluate the likelihood of a positive response to Atezolizumab and explain your reasoning?","Given the mRNA TPM data for this patient's tumor immune microenvironment and considering the following clinical details—Sex: Male, Race: White, Tissue: Kidney, Diagnosis: Bladder Urothelial Carcinoma (BLCA), and a Tumor Mutational Burden of 15 mutations per MB—could you evaluate the likelihood of a positive response to Atezolizumab and explain your reasoning? Access the secure COMPASS system to download the tumor transcriptomics dataset. Next, categorize the patients into two groups based on their immune biomarker profiles. The first group should include individuals showing evidence of immunosuppression, characterized by reduced natural killer cell activity, markers of T-cell exhaustion, and lower B-cell counts. The second group should consist of patients with an active immune response, indicated by heightened macrophage activity, increased interferon-gamma signaling, and specific genomic markers. Finally, prepare a detailed report evaluating how these differing immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"I have analyzed mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) that characterizes the tumor immune microenvironment. The patient is a white male with a lymph node sample, and the tumor mutational burden is currently unavailable. Could you provide an assessment of whether this patient is likely to respond to Atezolizumab, including the supporting rationale?","I have analyzed mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) that characterizes the tumor immune microenvironment. The patient is a white male with a lymph node sample, and the tumor mutational burden is currently unavailable. Could you provide an assessment of whether this patient is likely to respond to Atezolizumab, including the supporting rationale? Please log into the secure COMPASS system and download the tumor transcriptomics dataset. Then, stratify the patients into two groups based on their immune biomarker profiles. The first group should include patients showing signs of immunosuppression—for example, reduced natural killer cell activity, markers indicating T-cell exhaustion, and lower B-cell counts. The second group should consist of patients with an active immune response, as evidenced by increased macrophage activity, higher interferon-gamma signaling, and the presence of specific genomic markers. Finally, compile a detailed report assessing how these distinct immune profiles could impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"Based on the mRNA TPM data for this patient with Bladder Urothelial Carcinoma (BLCA) and the following clinical details – female, white, primary tumor in the bladder, and an unavailable tumor mutational burden (reported as 'nan') – could you assess whether this patient is predicted to be a responder or non-responder to Atezolizumab? Please provide your reasoning.","Based on the mRNA TPM data for this patient with Bladder Urothelial Carcinoma (BLCA) and the following clinical details – female, white, primary tumor in the bladder, and an unavailable tumor mutational burden (reported as 'nan') – could you assess whether this patient is predicted to be a responder or non-responder to Atezolizumab? Please provide your reasoning. Please access the secure COMPASS system and download the tumor transcriptomics dataset. Once downloaded, classify the patients into two distinct groups according to their immune biomarker profiles. 

1. The first group should include patients exhibiting evidence of immunosuppression—such as diminished natural killer cell activity, indicators of T-cell exhaustion, and reduced B-cell counts.
2. The second group should comprise patients demonstrating an active immune response, characterized by increased macrophage activity, elevated interferon-gamma signaling, and the presence of specific genomic markers.

After stratifying the patients, prepare a comprehensive report that evaluates how these different immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"I have processed mRNA TPM data reflecting a patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA). The patient is a white male with a kidney tissue sample and a tumor mutational burden of 6.0 mutations per MB. Could you assess the predicted response to Atezolizumab and provide a conclusion on whether the patient is likely to be a responder or non-responder, including the rationale behind your assessment?","I have processed mRNA TPM data reflecting a patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA). The patient is a white male with a kidney tissue sample and a tumor mutational burden of 6.0 mutations per MB. Could you assess the predicted response to Atezolizumab and provide a conclusion on whether the patient is likely to be a responder or non-responder, including the rationale behind your assessment? Please log in to the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the dataset, stratify the patients into two groups based on their immune biomarker profiles as follows:

1. Group 1: Patients showing signs of immunosuppression, such as reduced natural killer cell activity, indicators of T-cell exhaustion, and decreased B-cell counts.
2. Group 2: Patients with an active immune response, indicated by increased macrophage activity, enhanced interferon-gamma signaling, and the presence of certain genomic markers.

After classifying the patients, please prepare a detailed report analyzing how these different immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"I have processed mRNA TPM data that characterizes the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient's details are as follows: female, white, kidney tissue sample, with an indeterminate tumor mutational burden (FMOne mutation burden per MB reported as 'nan'). Could you provide an evaluation of her predicted response to Atezolizumab, including the supporting rationale?","I have processed mRNA TPM data that characterizes the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient's details are as follows: female, white, kidney tissue sample, with an indeterminate tumor mutational burden (FMOne mutation burden per MB reported as 'nan'). Could you provide an evaluation of her predicted response to Atezolizumab, including the supporting rationale? Please access the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the dataset, stratify the patient samples into two groups based on their immune biomarker profiles:

• Group 1: Patients displaying immunosuppressive features—characterized by diminished natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.
• Group 2: Patients exhibiting an active immune response—indicated by increased macrophage activity, enhanced interferon-gamma signaling, and specific genomic markers.

After stratification, please compile a detailed report analyzing how these distinct immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"Given the mRNA TPM data capturing the tumor immune microenvironment in a patient with bladder urothelial carcinoma—with the following attributes: male, Black or African American, primary tumor tissue from the ureter, and an unavailable tumor mutational burden (FMOne mutation burden per MB recorded as ""nan"")—could you determine whether this patient is predicted to be a responder or non-responder to atezolizumab? Please include the clinical rationale supporting your conclusion.","Given the mRNA TPM data capturing the tumor immune microenvironment in a patient with bladder urothelial carcinoma—with the following attributes: male, Black or African American, primary tumor tissue from the ureter, and an unavailable tumor mutational burden (FMOne mutation burden per MB recorded as ""nan"")—could you determine whether this patient is predicted to be a responder or non-responder to atezolizumab? Please include the clinical rationale supporting your conclusion. Please log in to the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the dataset, divide the patient samples into two distinct groups based on their immune biomarker profiles:

• Group 1 should include patients with immunosuppressive characteristics, such as reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.

• Group 2 should consist of patients showing an active immune response, evidenced by increased macrophage activity, heightened interferon-gamma signaling, and specific genomic markers.

After grouping the samples, prepare a comprehensive report to analyze the potential effects of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"I have analyzed mRNA TPM data for a white female patient diagnosed with bladder urothelial carcinoma (BLCA), with available tumor immune microenvironment data from bladder tissue and unavailable tumor mutational burden information. Could you provide an assessment of whether this patient is likely to respond to Atezolizumab, along with the rationale behind this prediction?","I have analyzed mRNA TPM data for a white female patient diagnosed with bladder urothelial carcinoma (BLCA), with available tumor immune microenvironment data from bladder tissue and unavailable tumor mutational burden information. Could you provide an assessment of whether this patient is likely to respond to Atezolizumab, along with the rationale behind this prediction? Access the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the dataset, stratify the patient samples into two groups based on their immune biomarker profiles:

• Group 1: Patients exhibiting immunosuppressive features—specifically, reduced natural killer cell activity, indications of T-cell exhaustion, and decreased B-cell counts.

• Group 2: Patients showing active immune responses, as evidenced by increased macrophage activity, elevated interferon-gamma signaling, and the presence of specific genomic markers.

After dividing the samples, prepare a detailed report examining how these immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"I have analyzed mRNA TPM data for a white male patient with Bladder Urothelial Carcinoma (BLCA) using a ureter tissue sample. The patient exhibits a tumor mutational burden of 4.0 mutations per megabase. Based on these parameters, could you determine whether the patient is predicted to be a responder or a non-responder to Atezolizumab, and explain the rationale behind this classification?","I have analyzed mRNA TPM data for a white male patient with Bladder Urothelial Carcinoma (BLCA) using a ureter tissue sample. The patient exhibits a tumor mutational burden of 4.0 mutations per megabase. Based on these parameters, could you determine whether the patient is predicted to be a responder or a non-responder to Atezolizumab, and explain the rationale behind this classification? Please log into the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the dataset, categorize the patient samples into two distinct groups based on their immune biomarker profiles:

• Group 1: Patients showing immunosuppressive characteristics, including low natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell levels.

• Group 2: Patients displaying active immune responses, indicated by heightened macrophage activity, increased interferon-gamma signaling, and specific genomic markers.

After the stratification, compile a comprehensive report analyzing how these differing immune profiles could affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"Given the mRNA TPM data for this patient’s tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), along with the details provided (male, Caucasian, bladder tissue with BLCA diagnosis, and a tumor mutational burden of 14.0 mutations per MB), how would you assess the predicted responsiveness to Atezolizumab? Please provide your conclusion on whether this patient is likely to be a responder or non-responder, along with the rationale behind your assessment.","Given the mRNA TPM data for this patient’s tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), along with the details provided (male, Caucasian, bladder tissue with BLCA diagnosis, and a tumor mutational burden of 14.0 mutations per MB), how would you assess the predicted responsiveness to Atezolizumab? Please provide your conclusion on whether this patient is likely to be a responder or non-responder, along with the rationale behind your assessment. Log into the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the data, please classify the patient samples into two distinct groups based on their immune biomarker profiles:

• Group 1: Patients exhibiting immunosuppressive traits—specifically, low natural killer cell activity, evidence of T-cell exhaustion, and diminished B-cell counts.

• Group 2: Patients demonstrating active immune responses—characterized by elevated macrophage activity, increased interferon-gamma signaling, and the presence of specific genomic markers.

After grouping the patients, prepare a detailed report analyzing how these different immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"In a patient with Bladder Urothelial Carcinoma (BLCA) characterized by a male, white demographic, lung tissue sample, and a tumor mutational burden of 7.0 mutations per megabase, mRNA TPM profiling of the tumor immune microenvironment has been performed. Based on these parameters, what is the predicted responsiveness to Atezolizumab, and what is the rationale behind classifying this patient as a responder or non-responder?","In a patient with Bladder Urothelial Carcinoma (BLCA) characterized by a male, white demographic, lung tissue sample, and a tumor mutational burden of 7.0 mutations per megabase, mRNA TPM profiling of the tumor immune microenvironment has been performed. Based on these parameters, what is the predicted responsiveness to Atezolizumab, and what is the rationale behind classifying this patient as a responder or non-responder? Please access the secure COMPASS system and download the tumor transcriptomics dataset. Then, review the patient data and assign the samples to two groups based on their immune biomarker profiles:

• Group 1: Patients with immunosuppressive characteristics—specifically, those exhibiting low natural killer cell activity, T-cell exhaustion, and reduced B-cell counts.

• Group 2: Patients with active immune responses—identified by increased macrophage activity, elevated interferon-gamma signaling, and the presence of particular genomic markers.

Once the patients have been categorized, prepare a comprehensive report evaluating how these distinct immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"I have processed mRNA TPM data that characterizes the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white female, with tissue sampled from the lung, and a tumor mutational burden of 3.0 mutations per megabase. Based on these attributes, can you determine whether the patient is likely to respond to Atezolizumab? Please provide your conclusion along with supporting clinical reasoning.","I have processed mRNA TPM data that characterizes the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white female, with tissue sampled from the lung, and a tumor mutational burden of 3.0 mutations per megabase. Based on these attributes, can you determine whether the patient is likely to respond to Atezolizumab? Please provide your conclusion along with supporting clinical reasoning. Please log in to the secure COMPASS system and download the tumor transcriptomics dataset. Once you have the data, review the patient information and assign each sample to one of two groups based on their immune biomarker profiles:

• Group 1: Patients with immunosuppressive features—characterized by low natural killer cell activity, T-cell exhaustion, and decreased B-cell counts.

• Group 2: Patients with active immune responses—identified by increased macrophage activity, elevated interferon-gamma signaling, and specific genomic markers.

After categorizing the patients, please prepare a detailed report exploring how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"I have processed mRNA TPM data representing the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA) and wish to assess the predicted response to Atezolizumab. The patient is a white male with a bladder tissue origin and exhibits a tumor mutational burden of 11.0 mutations per MB. Based on these characteristics, could you provide an evaluation of whether this patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting rationale?","I have processed mRNA TPM data representing the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA) and wish to assess the predicted response to Atezolizumab. The patient is a white male with a bladder tissue origin and exhibits a tumor mutational burden of 11.0 mutations per MB. Based on these characteristics, could you provide an evaluation of whether this patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting rationale? Please access the secure COMPASS system and download the tumor transcriptomics dataset. Once you have obtained the data, review the patient records and categorize each sample into one of two groups based on their immune biomarker profiles as follows:

• Group 1: Patients showing immunosuppressive characteristics, which include low natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.

• Group 2: Patients exhibiting active immune responses, indicated by increased macrophage activity, heightened interferon-gamma signaling, and specific genomic markers.

After sorting the patients into these groups, prepare a comprehensive report discussing how these distinct immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"Based on the processed mRNA TPM data for tumor immune microenvironment analysis in a patient with bladder urothelial carcinoma (BLCA), can you determine if the patient is likely to respond to Atezolizumab treatment? The patient is a white female, with bladder tissue affected by BLCA, and has a tumor mutational burden of 4.0 mutations per MB. Please provide your conclusion along with supporting rationale regarding her responsiveness to the therapy.","Based on the processed mRNA TPM data for tumor immune microenvironment analysis in a patient with bladder urothelial carcinoma (BLCA), can you determine if the patient is likely to respond to Atezolizumab treatment? The patient is a white female, with bladder tissue affected by BLCA, and has a tumor mutational burden of 4.0 mutations per MB. Please provide your conclusion along with supporting rationale regarding her responsiveness to the therapy. Please log in to the secure COMPASS system and download the tumor transcriptomics dataset. After obtaining the data, review each patient record and classify the samples into two groups based on their immune biomarker profiles:

• Group 1: Patients with immunosuppressive features, such as reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.

• Group 2: Patients with active immune responses, as indicated by elevated macrophage activity, increased interferon-gamma signaling, and the presence of specific genomic markers.

Once the samples have been categorized, compile a detailed report analyzing how these differing immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"I have analyzed mRNA TPM expression data from the tumor immune microenvironment of a  White female patient diagnosed with Bladder Urothelial Carcinoma (BLCA), using tissue from the bladder. Although the tumor mutational burden data (FMOne mutation burden per MB) is unavailable, I would like to assess her predicted responsiveness to Atezolizumab. Could you please help determine whether she is classified as a responder or non-responder, and provide the supporting rationale for this classification?","I have analyzed mRNA TPM expression data from the tumor immune microenvironment of a  White female patient diagnosed with Bladder Urothelial Carcinoma (BLCA), using tissue from the bladder. Although the tumor mutational burden data (FMOne mutation burden per MB) is unavailable, I would like to assess her predicted responsiveness to Atezolizumab. Could you please help determine whether she is classified as a responder or non-responder, and provide the supporting rationale for this classification? Please access the secure COMPASS system and download the tumor transcriptomics dataset. After obtaining the data, review each patient's record and categorize the samples into two groups based on their immune biomarker profiles. Specifically:

• Group 1: Patients exhibiting immunosuppressive features, including decreased natural killer cell activity, markers of T-cell exhaustion, and lower B-cell counts.

• Group 2: Patients showing evidence of active immune responses, such as increased macrophage activity, elevated interferon-gamma signaling, and the presence of specific genomic markers.

Once the categorization is complete, please prepare a detailed report analyzing how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"For a patient with Bladder Urothelial Carcinoma (BLCA) whose tumor immune microenvironment has been characterized through mRNA TPM data, what is the predicted responsiveness to Atezolizumab? The patient is male, White, with bladder tissue involvement, and has a Tumor Mutational Burden reported as nan (FMOne mutation burden per MB). Could you provide a conclusion regarding responder status along with the underlying rationale?","For a patient with Bladder Urothelial Carcinoma (BLCA) whose tumor immune microenvironment has been characterized through mRNA TPM data, what is the predicted responsiveness to Atezolizumab? The patient is male, White, with bladder tissue involvement, and has a Tumor Mutational Burden reported as nan (FMOne mutation burden per MB). Could you provide a conclusion regarding responder status along with the underlying rationale? Please log into the secure COMPASS system and download the tumor transcriptomics dataset. Once you have obtained the data, review each patient record and classify the samples into two groups based on their immune biomarker profiles:

• Group 1: Patients presenting immunosuppressive features, such as reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.

• Group 2: Patients with indicators of an active immune response, including heightened macrophage activity, increased interferon-gamma signaling, and specific genomic markers.

After completing the categorization, compile a detailed report evaluating how these distinct immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"I have analyzed a patient’s mRNA TPM data derived from their tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a tumor mutational burden of 18.0 FMOne mutations per MB, and the tissue sample is classified as ""other."" Based on this information, can you determine if the patient is likely to respond to Atezolizumab, and provide the clinical reasoning behind your conclusion?","I have analyzed a patient’s mRNA TPM data derived from their tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a tumor mutational burden of 18.0 FMOne mutations per MB, and the tissue sample is classified as ""other."" Based on this information, can you determine if the patient is likely to respond to Atezolizumab, and provide the clinical reasoning behind your conclusion? Access the secure COMPASS system and download the tumor transcriptomics dataset. Then, for each patient record, review and classify the samples into two distinct groups based on immune biomarker profiles:

• Group 1: Patients exhibiting immunosuppressive characteristics, such as decreased natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.

• Group 2: Patients showing features of an active immune response, including increased macrophage activity, elevated interferon-gamma signaling, and specific genomic markers.

After grouping the samples, prepare a comprehensive report that evaluates how these different immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"I have analyzed the mRNA TPM data reflecting the tumor immune microenvironment of a white male patient with bladder urothelial carcinoma (BLCA), who exhibits a tumor mutational burden of 19 mutations per megabase. Could you assess the patient's predicted responsiveness to Atezolizumab, indicating whether they are likely to be classified as a responder or non-responder, and provide the rationale for your conclusion?","I have analyzed the mRNA TPM data reflecting the tumor immune microenvironment of a white male patient with bladder urothelial carcinoma (BLCA), who exhibits a tumor mutational burden of 19 mutations per megabase. Could you assess the patient's predicted responsiveness to Atezolizumab, indicating whether they are likely to be classified as a responder or non-responder, and provide the rationale for your conclusion? Please log in to the secure COMPASS system and download the tumor transcriptomics dataset. For each patient record, examine the immune biomarker data and categorize the samples into two groups:

1. Immunosuppressed Group: Identify patients with reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
2. Active Immune Response Group: Identify patients with increased macrophage activity, enhanced interferon-gamma signaling, and specific genomic markers indicating immune activation.

After classifying the samples, prepare a detailed report that assesses how these different immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"Given the mRNA TPM data of a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA), which includes the following attributes: male sex, white race, bladder tissue, and a tumor mutational burden of 35 mutations per MB, can you provide a conclusion on whether this patient is predicted to respond to Atezolizumab? Please include the supporting rationale for your assessment.","Given the mRNA TPM data of a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA), which includes the following attributes: male sex, white race, bladder tissue, and a tumor mutational burden of 35 mutations per MB, can you provide a conclusion on whether this patient is predicted to respond to Atezolizumab? Please include the supporting rationale for your assessment. Please access the secure COMPASS system and download the transcriptomics dataset for the tumor samples. For each patient, review the immune biomarker information and assign the samples into one of two categories:

1. Immunosuppressed Group: Patients showing decreased natural killer cell activity, indications of T-cell exhaustion, and lower B-cell counts.
2. Active Immune Response Group: Patients exhibiting increased macrophage activity, elevated interferon-gamma signaling, and specific genetic markers of immune activation.

Once you have categorized the samples, compile a detailed report that explores how these distinct immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"A patient with Bladder Urothelial Carcinoma (BLCA) has been profiled using mRNA TPM data of the tumor immune microenvironment. The patient is a white male whose tissue sample originates from the kidney and exhibits a tumor mutational burden of 5.0 mutations per megabase. Based on these data, can we determine whether this patient is likely to respond to Atezolizumab? Please provide a clinical assessment including the rationale for classifying him as a responder or non-responder.","A patient with Bladder Urothelial Carcinoma (BLCA) has been profiled using mRNA TPM data of the tumor immune microenvironment. The patient is a white male whose tissue sample originates from the kidney and exhibits a tumor mutational burden of 5.0 mutations per megabase. Based on these data, can we determine whether this patient is likely to respond to Atezolizumab? Please provide a clinical assessment including the rationale for classifying him as a responder or non-responder. Please log into the secure COMPASS system and download the transcriptomics data related to tumor samples. For each patient, evaluate the immune biomarker data and classify the samples into one of the following groups:

1. Immunosuppressed Group: Patients who demonstrate reduced natural killer cell activity, signs of T-cell exhaustion, and decreased B-cell counts.
2. Active Immune Response Group: Patients who display increased macrophage activity, heightened interferon-gamma signaling, and specific genetic markers associated with immune activation.

After categorizing the samples, prepare a comprehensive report analyzing how these distinct immune profiles could influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"A patient with bladder urothelial carcinoma (BLCA) has been evaluated using mRNA TPM data of the tumor immune microenvironment. The patient is a 5.0 FMOne mutation burden per MB, white male with bladder tissue involvement. Based on these factors, can you determine whether the patient is predicted to respond to Atezolizumab, and please detail the rationale for your conclusion?","A patient with bladder urothelial carcinoma (BLCA) has been evaluated using mRNA TPM data of the tumor immune microenvironment. The patient is a 5.0 FMOne mutation burden per MB, white male with bladder tissue involvement. Based on these factors, can you determine whether the patient is predicted to respond to Atezolizumab, and please detail the rationale for your conclusion? Please access the secure COMPASS system and download the transcriptomics data corresponding to tumor samples. Then, for each patient, analyze the immune biomarker data and group the samples into one of the following categories:

• Immunosuppressed Group: Patients exhibiting reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response Group: Patients with increased macrophage activity, elevated interferon-gamma signaling, and specific genetic markers that indicate immune activation.

Once the samples have been categorized, compile a detailed report evaluating how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"Based on the mRNA TPM data for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and considering the following details—male, white, primary bladder tissue, and a tumor mutational burden of 16.0 mutations per MB—can you determine whether the patient is more likely to respond to Atezolizumab, and please explain the rationale behind this classification?","Based on the mRNA TPM data for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and considering the following details—male, white, primary bladder tissue, and a tumor mutational burden of 16.0 mutations per MB—can you determine whether the patient is more likely to respond to Atezolizumab, and please explain the rationale behind this classification? Please log into the secure COMPASS system to download the transcriptomic data for tumor samples. For each patient, evaluate the immune biomarker profile and classify the sample into one of the following categories:

• Immunosuppressed Group: Patients if they show reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response Group: Patients if they exhibit elevated macrophage activity, increased interferon-gamma signaling, along with specific genetic markers of immune activation.

After categorizing the samples, prepare a detailed report that discusses how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"Based on mRNA TPM data from the tumor immune microenvironment of a male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8.0 mutations/Mb, how likely is the patient to respond to Atezolizumab therapy, and what factors support this assessment?","Based on mRNA TPM data from the tumor immune microenvironment of a male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8.0 mutations/Mb, how likely is the patient to respond to Atezolizumab therapy, and what factors support this assessment? Please access the secure COMPASS system and download the transcriptomic data for the tumor samples. For each patient, review the immune biomarker data and assign each sample to one of two groups:

• Immunosuppressed: Characterized by reduced natural killer cell activity, evidence of T-cell exhaustion, and decreased B-cell counts.
• Active Immune Response: Indicated by heightened macrophage activity, increased interferon-gamma signaling, and the presence of specific genetic markers associated with immune activation.

After completing the categorization, prepare a comprehensive report that examines the potential impact of these distinct immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"Given mRNA TPM data assessing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), how would you interpret this patient's predicted response to Atezolizumab? The patient is a 5.0 mutations/MB TMB, white, male, with bladder tissue involvement. Please provide your conclusion on responder versus non-responder status and the supporting rationale.","Given mRNA TPM data assessing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), how would you interpret this patient's predicted response to Atezolizumab? The patient is a 5.0 mutations/MB TMB, white, male, with bladder tissue involvement. Please provide your conclusion on responder versus non-responder status and the supporting rationale. Please log into the secure COMPASS system and download the transcriptomic data for the tumor samples. For each patient, carefully review the immune biomarker information and classify each sample into one of two groups:

• Immunosuppressed: This group includes samples with reduced natural killer cell activity, indications of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response: This group includes samples showing increased macrophage activity, elevated interferon-gamma signaling, and the presence of specific genetic markers that suggest immune activation.

After assigning the samples to the appropriate groups, generate a detailed report that analyzes how these varying immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) whose mRNA TPM data reflect the tumor immune microenvironment, and with the following clinical attributes—female, white, kidney tissue origin, and a tumor mutational burden of 5.0 mutations per megabase—could you assess the patient’s predicted response to Atezolizumab and provide the supporting rationale for classifying them as a responder or non-responder?","For a patient with Bladder Urothelial Carcinoma (BLCA) whose mRNA TPM data reflect the tumor immune microenvironment, and with the following clinical attributes—female, white, kidney tissue origin, and a tumor mutational burden of 5.0 mutations per megabase—could you assess the patient’s predicted response to Atezolizumab and provide the supporting rationale for classifying them as a responder or non-responder? Please access the secure COMPASS system and download the transcriptomic data for the tumor samples. For each patient, examine the immune biomarker data meticulously, then classify each sample into one of two categories:

• Immunosuppressed: Samples with decreased natural killer cell activity, evidence of T-cell exhaustion, and reduced B-cell counts.
• Active Immune Response: Samples with increased macrophage activity, heightened interferon-gamma signaling, and the presence of specific genetic markers indicating immune activation.

After completing the classifications, compile a detailed report discussing how these different immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"For a patient with bladder urothelial carcinoma profiled via mRNA TPM analysis of the tumor immune microenvironment, who is female, White, and has a tumor mutational burden of 7.0 mutations per MB, what is the estimated likelihood of response to Atezolizumab, and what factors primarily contribute to this assessment?","For a patient with bladder urothelial carcinoma profiled via mRNA TPM analysis of the tumor immune microenvironment, who is female, White, and has a tumor mutational burden of 7.0 mutations per MB, what is the estimated likelihood of response to Atezolizumab, and what factors primarily contribute to this assessment? Please log in to the secure COMPASS system and download the transcriptomic data for the tumor samples. For each patient, carefully evaluate the immune biomarker information and assign each sample to one of the following categories:

• Immunosuppressed: Indicated by reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response: Indicated by increased macrophage activity, elevated interferon-gamma signaling, and the presence of specific genetic markers that signal immune activation.

After categorizing the samples, prepare a comprehensive report that discusses how these distinct immune profiles could potentially influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"I have processed mRNA TPM data characterizing the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with bladder tissue involvement, and the FMOne tumor mutational burden per megabase is not available (NaN). Based on this information, could you provide an assessment of whether this patient is likely to respond to Atezolizumab, including your supporting rationale?","I have processed mRNA TPM data characterizing the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with bladder tissue involvement, and the FMOne tumor mutational burden per megabase is not available (NaN). Based on this information, could you provide an assessment of whether this patient is likely to respond to Atezolizumab, including your supporting rationale? Please access the secure COMPASS system to download the transcriptomic data for the tumor samples. For each patient, review the detailed immune biomarker information and categorize each sample as either:

• Immunosuppressed – characterized by reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response – characterized by increased macrophage activity, elevated interferon-gamma signaling, and the presence of specific genetic markers indicative of immune activation.

Once the samples have been classified, compile a detailed report discussing how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 9.0 mutations per megabase. Based on this data, could you please assess his predicted responsiveness to Atezolizumab and explain the reasoning behind classifying him as a responder or non-responder?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 9.0 mutations per megabase. Based on this data, could you please assess his predicted responsiveness to Atezolizumab and explain the reasoning behind classifying him as a responder or non-responder? Please log in to the secure COMPASS system and download the transcriptomic data for the tumor samples. For each patient, review the detailed immune biomarker data and classify the samples into one of two categories:

• Immunosuppressed: Samples showing reduced natural killer cell activity, evidence of T-cell exhaustion, and decreased B-cell counts.
• Active Immune Response: Samples exhibiting increased macrophage activity, elevated interferon-gamma signaling, and specific genetic markers of immune activation.

After classifying the samples, prepare a comprehensive report that discusses how these immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"Given a patient with bladder urothelial carcinoma (BLCA) whose processed mRNA TPM data reflects their tumor immune microenvironment, can you evaluate their predicted response to Atezolizumab? The patient is a white female with bladder tissue involvement and a tumor mutational burden of 20 mutations per megabase. Please determine if this patient is likely to be a responder or non-responder to the treatment and provide the supporting clinical rationale.","Given a patient with bladder urothelial carcinoma (BLCA) whose processed mRNA TPM data reflects their tumor immune microenvironment, can you evaluate their predicted response to Atezolizumab? The patient is a white female with bladder tissue involvement and a tumor mutational burden of 20 mutations per megabase. Please determine if this patient is likely to be a responder or non-responder to the treatment and provide the supporting clinical rationale. Please log in to the secure COMPASS system and download the transcriptomic data for the tumor samples. For each patient, review the detailed immune biomarker information and classify the samples into one of two categories:

• Immunosuppressed: Defined by reduced natural killer cell activity, evidence of T‐cell exhaustion, and decreased B‐cell counts.
• Active Immune Response: Defined by increased macrophage activity, elevated interferon‐gamma signaling, and presence of specific genetic markers indicating immune activation.

Once the classification is complete, prepare a thorough report that evaluates how these immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"I have mRNA TPM data from a bladder urothelial carcinoma patient's tumor immune microenvironment (sampled from a lymph node). The patient is a white female with a tumor mutational burden of 10 mutations per megabase. Based on this information, could you help determine whether the patient is predicted to respond to Atezolizumab, and explain the rationale behind your assessment?","I have mRNA TPM data from a bladder urothelial carcinoma patient's tumor immune microenvironment (sampled from a lymph node). The patient is a white female with a tumor mutational burden of 10 mutations per megabase. Based on this information, could you help determine whether the patient is predicted to respond to Atezolizumab, and explain the rationale behind your assessment? Log in to the secure COMPASS system and download the transcriptomic data for the tumor samples. Then, for each patient, review the detailed immune biomarker data and classify the samples into one of these two groups:

• Immunosuppressed: characterized by reduced natural killer cell activity, signs of T‐cell exhaustion, and lower B‐cell counts.
• Active Immune Response: characterized by increased macrophage activity, enhanced interferon‐gamma signaling, and specific genetic markers that indicate immune activation.

After classifying the samples, please compile a comprehensive report assessing how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"Based on the mRNA TPM expression data for this patient’s tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the following attributes—male, White, primary bladder tissue, BLCA diagnosis, and a tumor mutational burden of 35.0 mutations per megabase—can you assess whether the patient is likely to respond to Atezolizumab, including your supporting rationale?","Based on the mRNA TPM expression data for this patient’s tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the following attributes—male, White, primary bladder tissue, BLCA diagnosis, and a tumor mutational burden of 35.0 mutations per megabase—can you assess whether the patient is likely to respond to Atezolizumab, including your supporting rationale? Please log in to the secure COMPASS system and download the transcriptomic data for the tumor samples. For each patient, review the immune biomarker details and classify the samples into one of these two categories:

• Immunosuppressed: indicated by reduced natural killer cell activity, evidence of T‐cell exhaustion, and decreased B‐cell counts.
• Active Immune Response: indicated by increased macrophage activity, enhanced interferon‐gamma signaling, and specific genetic markers associated with immune activation.

After completing the classification, compile a detailed report analyzing how these immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"Based on mRNA TPM data from this patient’s tumor immune microenvironment and the following clinical details—female, White, bladder tissue involvement, diagnosed with Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 6.0 mutations per MB—can you provide an evidence-based interpretation regarding her predicted response to Atezolizumab? Please include the rationale supporting the classification as a responder or non-responder.","Based on mRNA TPM data from this patient’s tumor immune microenvironment and the following clinical details—female, White, bladder tissue involvement, diagnosed with Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 6.0 mutations per MB—can you provide an evidence-based interpretation regarding her predicted response to Atezolizumab? Please include the rationale supporting the classification as a responder or non-responder. Please access the secure COMPASS system and download the transcriptomic data for the tumor samples. For each patient, examine the details of immune biomarkers and assign the samples to one of the two following groups:

• Immunosuppressed: characterized by diminished natural killer cell activity, signs of T‐cell exhaustion, and lower B‐cell counts.
• Active Immune Response: characterized by heightened macrophage activity, increased interferon‐gamma signaling, and distinct genetic markers that suggest immune activation.

Once you have completed the classification, prepare a comprehensive report evaluating the potential impact of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"For a female patient of white race with bladder urothelial carcinoma (BLCA) characterized by a tumor mutational burden of 3.0 mutations per megabase and mRNA TPM data reflecting the tumor immune microenvironment, can you provide an assessment as to whether she is likely to respond to atezolizumab, along with the rationale for your conclusion?","For a female patient of white race with bladder urothelial carcinoma (BLCA) characterized by a tumor mutational burden of 3.0 mutations per megabase and mRNA TPM data reflecting the tumor immune microenvironment, can you provide an assessment as to whether she is likely to respond to atezolizumab, along with the rationale for your conclusion? Please log into the secure COMPASS system and download the transcriptomic data for the tumor samples. For each patient, review the immune biomarker details and assign their samples to one of the two following categories:

• Immunosuppressed: exhibiting reduced natural killer cell activity, evidence of T‐cell exhaustion, and lower B‐cell counts.
• Active Immune Response: exhibiting increased macrophage activity, elevated interferon‐gamma signaling, and specific genetic markers indicating immune activation.

After completing the classification, compile a detailed report that evaluates how these immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"I have processed mRNA TPM data that reflect the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and wish to evaluate their likely response to Atezolizumab. The patient's details are as follows: male, White, tumor originating from the bladder, with a tumor mutational burden of 5.0 mutations per megabase. Based on this information, could you provide an assessment regarding whether this patient is likely to be a responder or non-responder to Atezolizumab, including the key factors informing your conclusion?","I have processed mRNA TPM data that reflect the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and wish to evaluate their likely response to Atezolizumab. The patient's details are as follows: male, White, tumor originating from the bladder, with a tumor mutational burden of 5.0 mutations per megabase. Based on this information, could you provide an assessment regarding whether this patient is likely to be a responder or non-responder to Atezolizumab, including the key factors informing your conclusion? Please access the secure COMPASS system to download the transcriptomic data for tumor samples. For each patient, evaluate the immune biomarker information and categorize the samples into one of the following groups:

• Immunosuppressed: characterized by reduced natural killer cell activity, evidence of T‐cell exhaustion, and decreased B‐cell counts.
• Active Immune Response: characterized by increased macrophage activity, heightened interferon‐gamma signaling, and the presence of specific genetic markers that indicate immune activation.

After completing this classification, prepare a detailed report discussing how these immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"Based on the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you assess whether this male, White patient—with a tumor mutational burden of 5 mutations/MB and an unspecified tissue biopsy—is likely to respond to Atezolizumab? Please include the rationale behind your conclusion.","Based on the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you assess whether this male, White patient—with a tumor mutational burden of 5 mutations/MB and an unspecified tissue biopsy—is likely to respond to Atezolizumab? Please include the rationale behind your conclusion. Access the secure COMPASS system to retrieve the transcriptomic data for the tumor samples. For each patient, review the immune biomarker information and classify the samples into one of two groups:

1. Immunosuppressed – defined by low natural killer cell activity, signs of T‐cell exhaustion, and reduced B‐cell counts.
2. Active Immune Response – defined by increased macrophage activity, elevated interferon‐gamma signaling, and the presence of specific genetic markers indicative of immune activation.

Once the classification is complete, compile a detailed report analyzing how these immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"Given mRNA TPM data from a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you assess whether the patient is likely to respond to Atezolizumab treatment? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 5.0 FMOne mutations per MB. Please provide a classification as responder or non-responder along with your supporting rationale.","Given mRNA TPM data from a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you assess whether the patient is likely to respond to Atezolizumab treatment? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 5.0 FMOne mutations per MB. Please provide a classification as responder or non-responder along with your supporting rationale. Please log in to the secure COMPASS system and retrieve the transcriptomic data for the tumor samples. For each patient, review the immune biomarker profiles and use the following criteria to categorize the samples:

• Immunosuppressed: characterized by low natural killer cell activity, signs of T‐cell exhaustion, and decreased B‐cell counts.
• Active Immune Response: indicated by increased macrophage activity, elevated interferon‐gamma signaling, and the presence of specific genetic markers that suggest immune activation.

After classifying each sample, prepare a detailed report that analyzes how these immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"Based on mRNA TPM profiling of a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), and considering the following patient details: male, white, kidney tissue sampling, BLCA diagnosis with a tumor mutational burden of 5.0 mutations/MB, how would you assess the likelihood of responsiveness to Atezolizumab? Please indicate whether you classify the patient as a responder or non-responder and provide the supporting rationale for your conclusion.","Based on mRNA TPM profiling of a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), and considering the following patient details: male, white, kidney tissue sampling, BLCA diagnosis with a tumor mutational burden of 5.0 mutations/MB, how would you assess the likelihood of responsiveness to Atezolizumab? Please indicate whether you classify the patient as a responder or non-responder and provide the supporting rationale for your conclusion. Please access the secure COMPASS system and obtain the transcriptomic data for the tumor samples. For each patient, review their immune biomarker profiles and classify the samples using the following criteria:

• Immunosuppressed: Defined by low natural killer cell activity, evidence of T‐cell exhaustion, and reduced B‐cell counts.
• Active Immune Response: Indicated by increased macrophage activity, heightened interferon‐gamma signaling, and the detection of specific genetic markers associated with immune activation.

Once you have classified the samples, prepare a comprehensive report detailing how these immune profiles could potentially affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"Could you help evaluate whether a patient with Bladder Urothelial Carcinoma (BLCA) is likely to respond to Atezolizumab, based on their tumor immune microenvironment mRNA TPM data? The patient is a White male with bladder tissue involvement, a BLCA diagnosis, and an indeterminate tumor mutational burden (FMOne mutation burden per MB reported as nan). Please provide your conclusion on whether the patient is classified as a responder or non-responder, along with the supporting reasoning.","Could you help evaluate whether a patient with Bladder Urothelial Carcinoma (BLCA) is likely to respond to Atezolizumab, based on their tumor immune microenvironment mRNA TPM data? The patient is a White male with bladder tissue involvement, a BLCA diagnosis, and an indeterminate tumor mutational burden (FMOne mutation burden per MB reported as nan). Please provide your conclusion on whether the patient is classified as a responder or non-responder, along with the supporting reasoning. Log into the secure COMPASS system and retrieve the transcriptomic data for each tumor sample. For every patient, examine the immune biomarker profiles and categorize the samples based on the following criteria:

• Immunosuppressed: Characterized by diminished natural killer cell activity, signs of T‐cell exhaustion, and lower B‐cell counts.
• Active Immune Response: Marked by increased macrophage activity, elevated interferon‐gamma signaling, and the presence of specific genetic markers that indicate immune activation.

After completing the classification, compile a detailed report that explains how these immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The clinical details are as follows: Male, race coded as OTHER, tumor tissue from the bladder, and a tumor mutational burden of 3.0 mutations per megabase. Based on this profile, could you provide an evidence-based assessment of whether this patient is likely to respond to Atezolizumab, including the rationale for your conclusion?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The clinical details are as follows: Male, race coded as OTHER, tumor tissue from the bladder, and a tumor mutational burden of 3.0 mutations per megabase. Based on this profile, could you provide an evidence-based assessment of whether this patient is likely to respond to Atezolizumab, including the rationale for your conclusion? Please access the secure COMPASS system and download the transcriptomic datasets for each tumor specimen. For each patient, review the immune biomarker profiles and classify the samples as follows:

• Immunosuppressed: These samples demonstrate reduced natural killer cell activity, evidence of T-cell exhaustion, and decreased B-cell numbers.
• Active Immune Response: These samples show heightened macrophage activity, increased interferon-gamma signaling, and specific genetic markers indicative of immune activation.

Once you have completed the classification, prepare a comprehensive report detailing how these immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,Can you evaluate whether this male Caucasian patient with bladder urothelial carcinoma—whose tumor mRNA TPM data and immune microenvironment profile (with a reported tumor mutational burden of 10 mutations per Mb) and ureter tissue involvement—would likely respond to atezolizumab? Please provide your reasoning for categorizing him as a responder or non-responder.,"Can you evaluate whether this male Caucasian patient with bladder urothelial carcinoma—whose tumor mRNA TPM data and immune microenvironment profile (with a reported tumor mutational burden of 10 mutations per Mb) and ureter tissue involvement—would likely respond to atezolizumab? Please provide your reasoning for categorizing him as a responder or non-responder. Please log in to the secure COMPASS system and download the transcriptomic datasets corresponding to each tumor specimen. For every patient, systematically evaluate the immune biomarker profiles and assign each sample to one of the following categories:

• Immunosuppressed: Characterized by reduced activity of natural killer cells, signs of T-cell exhaustion, and lower numbers of B-cells.
• Active Immune Response: Characterized by increased macrophage activity, elevated interferon-gamma signaling, and genetic markers associated with immune system activation.

After completing the classification, compile a detailed report discussing how these immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"I have mRNA TPM data profiling the tumor immune microenvironment from a white male patient with bladder urothelial carcinoma (BLCA) and lymph node involvement, with a tumor mutational burden of 3.0 mutations/MB. Based on these findings, could you assess whether this patient is likely to respond to Atezolizumab, and please provide your supporting rationale?","I have mRNA TPM data profiling the tumor immune microenvironment from a white male patient with bladder urothelial carcinoma (BLCA) and lymph node involvement, with a tumor mutational burden of 3.0 mutations/MB. Based on these findings, could you assess whether this patient is likely to respond to Atezolizumab, and please provide your supporting rationale? Please access the secure COMPASS platform and download the transcriptomic datasets for each tumor specimen. For each patient sample, review the immune biomarker data and classify the sample as either:

• Immunosuppressed: This group shows decreased activity of natural killer cells, evidence of T-cell exhaustion, and a reduced number of B-cells.
• Active Immune Response: This group demonstrates increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers indicating immune system activation.

Once the classifications are complete, please prepare a comprehensive report that discusses the potential impact of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"Given a patient's processed mRNA TPM data representing the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you assess the predicted response to Atezolizumab based on the following clinical details: a  male, White patient with bladder tissue involvement, diagnosed with BLCA, and exhibiting a tumor mutational burden of 3.0 (FMOne mutation burden per MB)? Please provide a conclusion on whether this patient is likely to be a responder or non-responder, along with the supporting rationale.","Given a patient's processed mRNA TPM data representing the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you assess the predicted response to Atezolizumab based on the following clinical details: a  male, White patient with bladder tissue involvement, diagnosed with BLCA, and exhibiting a tumor mutational burden of 3.0 (FMOne mutation burden per MB)? Please provide a conclusion on whether this patient is likely to be a responder or non-responder, along with the supporting rationale. Please log into the secure COMPASS platform and retrieve the transcriptomic datasets corresponding to each tumor specimen. For every patient sample, evaluate the immune biomarker data and categorize the sample into one of two groups:

1. Immunosuppressed: characterized by reduced natural killer cell activity, signs of T-cell exhaustion, and a lower count of B-cells.
2. Active Immune Response: characterized by heightened macrophage activity, increased interferon-gamma signaling, and genetic markers indicative of immune activation.

After completing the classifications, compile a detailed report that examines how these distinct immune profiles could potentially affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"We have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a Black or African American female, with lung tissue sampled and a tumor mutational burden of 11.0 mutations per MB. Based on this information, how would you assess her likelihood of responding to Atezolizumab, and what is the rationale for your assessment?","We have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a Black or African American female, with lung tissue sampled and a tumor mutational burden of 11.0 mutations per MB. Based on this information, how would you assess her likelihood of responding to Atezolizumab, and what is the rationale for your assessment? Please sign in to the secure COMPASS platform to access the transcriptomic datasets for each tumor specimen. For every patient sample, review the immune biomarker data and assign the sample to one of the following categories:

1. Immunosuppressed: This group is characterized by diminished natural killer cell activity, evidence of T-cell exhaustion, and a lower count of B-cells.
2. Active Immune Response: This group is defined by increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers that suggest active immune stimulation.

After classifying the samples, compile a detailed report that explores how these distinct immune profiles may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"Using processed mRNA TPM data from a male, white patient with bladder urothelial carcinoma (tissue sample from a lymph node and an FMOne mutation burden reported as NaN), can you assess the likelihood of a positive response to Atezolizumab? Please provide your conclusion as to whether the patient is predicted to be a responder or non-responder, along with the supporting rationale.","Using processed mRNA TPM data from a male, white patient with bladder urothelial carcinoma (tissue sample from a lymph node and an FMOne mutation burden reported as NaN), can you assess the likelihood of a positive response to Atezolizumab? Please provide your conclusion as to whether the patient is predicted to be a responder or non-responder, along with the supporting rationale. Please log in to the secure COMPASS platform to retrieve the transcriptomic datasets corresponding to each tumor specimen. For each patient sample, carefully review the immune biomarker data and categorize the sample as follows:

1. Immunosuppressed: This category is identified by reduced natural killer cell activity, signs of T-cell exhaustion, and a decreased number of B-cells.
2. Active Immune Response: This category is marked by elevated macrophage activity, strengthened interferon-gamma signaling, and genetic indicators of an actively stimulated immune system.

After you have classified the samples, prepare a comprehensive report that analyzes the potential influence of these distinct immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"I have mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a white male, with liver tissue involvement, and the tumor mutational burden is not available (nan). Based on this information, could you please assess the likelihood of this patient responding to Atezolizumab and provide the supporting rationale?","I have mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a white male, with liver tissue involvement, and the tumor mutational burden is not available (nan). Based on this information, could you please assess the likelihood of this patient responding to Atezolizumab and provide the supporting rationale? Log in to the secure COMPASS platform to access the transcriptomic datasets for each tumor specimen. For every patient sample, review the immune biomarker data and classify the sample into one of the following categories:

1. Immunosuppressed: Characterized by reduced natural killer cell activity, evidence of T-cell exhaustion, and a lower B-cell count.
2. Active Immune Response: Indicated by increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers reflecting an actively engaged immune system.

After classifying the samples, compile a detailed report analyzing how these distinct immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"Based on the patient's mRNA TPM data describing the tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA), along with the following details: female, white, tissue from the ureter, and a tumor mutational burden of 26.0 mutations per MB, could you please evaluate and determine whether this patient is more likely to respond to Atezolizumab? Please include your rationale supporting the predicted therapeutic response classification.","Based on the patient's mRNA TPM data describing the tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA), along with the following details: female, white, tissue from the ureter, and a tumor mutational burden of 26.0 mutations per MB, could you please evaluate and determine whether this patient is more likely to respond to Atezolizumab? Please include your rationale supporting the predicted therapeutic response classification. Please access the secure COMPASS platform to retrieve the transcriptomic data for each tumor sample. For each patient specimen, carefully review the immune biomarker results and assign the sample to one of two categories as follows:

• Immunosuppressed – This group includes samples that exhibit reduced natural killer cell function, signs of T-cell exhaustion, and lower B-cell levels.

• Active Immune Response – This group includes samples that show increased macrophage activity, enhanced interferon-gamma signaling, and genetic indicators of an actively engaged immune system.

Once you have classified the samples, please prepare a comprehensive report that examines how these differing immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient details are as follows: male, White, bladder tissue origin, and a tumor mutational burden of 14 mutations per megabase. Based on these characteristics, could you evaluate the likelihood of this patient responding to Atezolizumab, and provide a classification of responder or non-responder along with the supporting rationale?","I have processed mRNA TPM data representing the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient details are as follows: male, White, bladder tissue origin, and a tumor mutational burden of 14 mutations per megabase. Based on these characteristics, could you evaluate the likelihood of this patient responding to Atezolizumab, and provide a classification of responder or non-responder along with the supporting rationale? Please log into the secure COMPASS platform to obtain the transcriptomic data for each tumor sample. For each patient specimen, review the immune biomarker results and classify the sample into one of the following two categories:

• Immunosuppressed – Samples in this category show diminished natural killer cell function, evidence of T-cell exhaustion, and reduced B-cell levels.

• Active Immune Response – Samples here demonstrate increased macrophage activity, elevated interferon-gamma signaling, and genetic markers indicative of an engaged immune response.

After classifying the samples, prepare a detailed report discussing how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"Based on processed mRNA TPM data of the tumor immune microenvironment for a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA), can you determine the predicted response to Atezolizumab? Please note that the tissue sample was derived from lung tissue and the FMOne mutation burden per MB is not available. Kindly provide a classification of responder versus non-responder along with your supporting rationale.","Based on processed mRNA TPM data of the tumor immune microenvironment for a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA), can you determine the predicted response to Atezolizumab? Please note that the tissue sample was derived from lung tissue and the FMOne mutation burden per MB is not available. Kindly provide a classification of responder versus non-responder along with your supporting rationale. Please access the secure COMPASS platform to download the transcriptomic data for each tumor sample. For each patient specimen, review the immune biomarker findings and assign the sample to one of the two categories described below:

• Immunosuppressed – These samples exhibit reduced natural killer cell function, signs of T-cell exhaustion, and decreased B-cell levels.

• Active Immune Response – These samples display heightened macrophage activity, increased interferon-gamma signaling, and genetic markers that indicate an engaged immune response.

After classifying the samples, please prepare a comprehensive report that discusses how these distinct immune profiles could potentially influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"Based on mRNA TPM analysis of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), could you assess the predicted response to Atezolizumab using the following patient details: female, White, tumor tissue originating from the ureter, and a tumor mutational burden of 4.0 mutations per megabase? Please classify the patient as a responder or non-responder and provide your rationale.","Based on mRNA TPM analysis of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), could you assess the predicted response to Atezolizumab using the following patient details: female, White, tumor tissue originating from the ureter, and a tumor mutational burden of 4.0 mutations per megabase? Please classify the patient as a responder or non-responder and provide your rationale. Please log in to the secure COMPASS platform to download the transcriptomic data for each tumor sample. For every patient specimen, review the immune biomarker results and classify the sample into one of the following two categories:

• Immunosuppressed: This category is characterized by diminished natural killer cell activity, evidence of T-cell exhaustion, and decreased B-cell levels.

• Active Immune Response: This category is defined by increased macrophage activity, elevated interferon-gamma signaling, and genetic markers that suggest a robust immune engagement.

After you have classified all samples, compile a detailed report analyzing how these different immune profiles could potentially impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"I have mRNA TPM data reflecting the tumor immune microenvironment of a male, White patient with bladder tissue affected by Bladder Urothelial Carcinoma (BLCA), and a Tumor Mutational Burden of 3.0 mutations per MB. Could you help determine whether this patient is more likely to respond to Atezolizumab, and explain your reasoning based on these details?","I have mRNA TPM data reflecting the tumor immune microenvironment of a male, White patient with bladder tissue affected by Bladder Urothelial Carcinoma (BLCA), and a Tumor Mutational Burden of 3.0 mutations per MB. Could you help determine whether this patient is more likely to respond to Atezolizumab, and explain your reasoning based on these details? Please access the secure COMPASS platform to download the transcriptomic data corresponding to each tumor sample. For every patient specimen, carefully review the immune biomarker data and classify the sample into one of the following two categories:

• Immunosuppressed – characterized by reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.

• Active Immune Response – indicated by increased macrophage activity, heightened interferon-gamma signaling, and genetic markers that reflect robust immune engagement.

Once all samples have been appropriately classified, generate a comprehensive report evaluating how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"Based on mRNA TPM data for a patient with bladder urothelial carcinoma (BLCA), could you assess the predicted responsiveness to Atezolizumab? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 22.0 (FMOne mutations per MB). Please classify the patient as a responder or non-responder and provide the rationale for your conclusion.","Based on mRNA TPM data for a patient with bladder urothelial carcinoma (BLCA), could you assess the predicted responsiveness to Atezolizumab? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 22.0 (FMOne mutations per MB). Please classify the patient as a responder or non-responder and provide the rationale for your conclusion. Please log into the secure COMPASS platform and download the transcriptomic data for each tumor sample. For every patient specimen, thoroughly examine the immune biomarker information and classify the sample using one of the following criteria:

1. Immunosuppressed: This category is characterized by diminished natural killer cell function, evidence of T-cell exhaustion, and lower counts of B-cells.
2. Active Immune Response: This category is identified by increased macrophage activity, elevated interferon-gamma signaling, and genetic markers indicative of a robust immune response.

Once you have classified all samples, compile a comprehensive report that evaluates how these distinct immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), and I seek an assessment of the patient’s predicted responsiveness to Atezolizumab. The patient’s profile is as follows: Male, White, bladder tissue origin, with BLCA diagnosis, and an indeterminate FMOne mutation burden (nan mutations per MB). Based on this information, could you provide a determination of whether the patient is more likely to be a responder or a non-responder to Atezolizumab, including the supporting rationale?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), and I seek an assessment of the patient’s predicted responsiveness to Atezolizumab. The patient’s profile is as follows: Male, White, bladder tissue origin, with BLCA diagnosis, and an indeterminate FMOne mutation burden (nan mutations per MB). Based on this information, could you provide a determination of whether the patient is more likely to be a responder or a non-responder to Atezolizumab, including the supporting rationale? Please access the secure COMPASS platform and download the transcriptomic data for each tumor sample. For every patient sample, carefully review the immune biomarker data and categorize the sample as follows:

1. Immunosuppressed: This classification is used when there is reduced natural killer cell activity, noticeable T-cell exhaustion, and lower numbers of B-cells.
2. Active Immune Response: This category applies when there is increased macrophage activity, heightened interferon-gamma signaling, and genetic markers that suggest a vigorous immune response.

After classifying all samples according to these criteria, please prepare a detailed report discussing how these immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"Given the processed mRNA TPM data of a BLCA patient's tumor immune microenvironment (attributes: female, white, tissue from a lymph node, TMB of 3.0 mutations/MB), can you determine if the patient is likely to be a responder or non-responder to Atezolizumab? Please provide your rationale for this classification.","Given the processed mRNA TPM data of a BLCA patient's tumor immune microenvironment (attributes: female, white, tissue from a lymph node, TMB of 3.0 mutations/MB), can you determine if the patient is likely to be a responder or non-responder to Atezolizumab? Please provide your rationale for this classification. Please log in to the secure COMPASS platform and download the transcriptomic data for each tumor sample. For every patient sample, review the data on immune biomarkers and classify each sample based on the following criteria:

1. Immunosuppressed: Classify as such if there is evidence of decreased natural killer cell activity, significant T-cell exhaustion, and a reduction in B-cell numbers.
2. Active Immune Response: Classify as such if there is increased activity of macrophages, enhanced interferon-gamma signaling, and the presence of genetic markers indicating a robust immune response.

Once all samples have been categorized, compile a comprehensive report outlining how these distinct immune profiles may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"I have analyzed mRNA TPM data from a patient with Bladder Urothelial Carcinoma and evaluated their tumor immune microenvironment to predict responsiveness to Atezolizumab. The patient is a white male with a kidney tissue sample, and their tumor mutational burden is high at 62.0 FMOne mutations per megabase. Based on these clinical and molecular features, can you provide your assessment on whether this patient is likely to respond to Atezolizumab, including the supporting rationale?","I have analyzed mRNA TPM data from a patient with Bladder Urothelial Carcinoma and evaluated their tumor immune microenvironment to predict responsiveness to Atezolizumab. The patient is a white male with a kidney tissue sample, and their tumor mutational burden is high at 62.0 FMOne mutations per megabase. Based on these clinical and molecular features, can you provide your assessment on whether this patient is likely to respond to Atezolizumab, including the supporting rationale? Access the secure COMPASS platform and download the transcriptomic data for each tumor sample. For every patient, carefully review the immune biomarkers and classify the samples into one of two groups:

• Immunosuppressed: Assign this classification if the sample shows reduced natural killer cell activity, marked T-cell exhaustion, and a decrease in B-cell counts.  
• Active Immune Response: Assign this classification if the sample demonstrates increased macrophage activity, heightened interferon-gamma signaling, and the presence of genetic markers associated with a strong immune response.

After categorizing all samples, prepare a detailed report that explains how these distinct immune profiles could influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"I have processed mRNA TPM data from a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the predicted response to Atezolizumab. The patient's characteristics are as follows: male, race categorized as 'other', tissue type 'other', and a tumor mutational burden of 14.0 mutations per megabase. Could you please determine whether this patient is likely to respond to Atezolizumab and explain the reasoning behind your conclusion?","I have processed mRNA TPM data from a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the predicted response to Atezolizumab. The patient's characteristics are as follows: male, race categorized as 'other', tissue type 'other', and a tumor mutational burden of 14.0 mutations per megabase. Could you please determine whether this patient is likely to respond to Atezolizumab and explain the reasoning behind your conclusion? Access the secure COMPASS platform and download the transcriptomic data for each tumor sample. For every patient, review the relevant immune biomarkers and classify the sample according to one of these criteria:

• Immunosuppressed: Use this classification if the data indicate reduced activity of natural killer cells, significant T-cell exhaustion, and decreased B-cell numbers.
• Active Immune Response: Use this classification if the data reveal increased macrophage activity, enhanced interferon-gamma signaling, and the presence of genetic markers that suggest a robust immune response.

Once all samples have been categorized, prepare a comprehensive report discussing how these distinct immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"Given the processed mRNA TPM data for a patient's tumor immune microenvironment in bladder urothelial carcinoma, with the following characteristics: male, white, lymph node tissue involvement, and a tumor mutational burden of 7.0 mutations per megabase, can you determine whether this patient is likely to respond to atezolizumab therapy and provide the rationale behind your conclusion?","Given the processed mRNA TPM data for a patient's tumor immune microenvironment in bladder urothelial carcinoma, with the following characteristics: male, white, lymph node tissue involvement, and a tumor mutational burden of 7.0 mutations per megabase, can you determine whether this patient is likely to respond to atezolizumab therapy and provide the rationale behind your conclusion? Log in to the secure COMPASS platform and download the transcriptomic datasets for each tumor sample. For each patient, review the immune biomarker data and assign one of the following classifications:

• Immunosuppressed: Apply this label if the data show reduced natural killer cell activity, marked T-cell exhaustion, and lower B-cell counts.
• Active Immune Response: Apply this label if the data demonstrate an increase in macrophage activity, enhanced interferon-gamma signaling, and genetic markers indicating a strong immune response.

After categorizing all samples, compile a detailed report that discusses how these different immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"Based on the mRNA TPM data for the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), can you determine if the patient is likely to respond to Atezolizumab treatment? The patient’s profile is as follows: Male; Race: Unknown; Tissue: bladder; Tumor Mutational Burden: 15 mutations per megabase. Please provide a conclusion on the predicted responder status along with your supporting rationale.","Based on the mRNA TPM data for the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), can you determine if the patient is likely to respond to Atezolizumab treatment? The patient’s profile is as follows: Male; Race: Unknown; Tissue: bladder; Tumor Mutational Burden: 15 mutations per megabase. Please provide a conclusion on the predicted responder status along with your supporting rationale. Please access the secure COMPASS platform and download the transcriptomic datasets for each tumor sample. For each patient, carefully examine the immune biomarker data and classify them as follows:

• Immunosuppressed: Use this classification when the data indicate reduced natural killer cell activity, pronounced T-cell exhaustion, and decreased B-cell counts.
• Active Immune Response: Use this classification when the data reveal increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers consistent with a robust immune response.

Once you have categorized all samples, prepare a comprehensive report discussing how these distinct immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"For a patient with bladder urothelial carcinoma whose processed mRNA TPM data reflects the tumor immune microenvironment—with clinical details including male sex, White race, kidney tissue involvement, and a tumor mutational burden of 5.0 mutations per MB—how would you assess the likelihood of a response to Atezolizumab? Please provide your conclusion along with supporting reasoning.","For a patient with bladder urothelial carcinoma whose processed mRNA TPM data reflects the tumor immune microenvironment—with clinical details including male sex, White race, kidney tissue involvement, and a tumor mutational burden of 5.0 mutations per MB—how would you assess the likelihood of a response to Atezolizumab? Please provide your conclusion along with supporting reasoning. Please log in to the secure COMPASS platform and download the transcriptomic datasets for all tumor samples. For each patient, review the immune biomarker data and assign one of the following classifications:

• Immunosuppressed: When the data show reduced natural killer cell activity, marked T-cell exhaustion, and decreased B-cell counts.
• Active Immune Response: When the data indicate increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers that suggest a robust immune response.

After categorizing all the samples, compile a detailed report discussing how these immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  male of White race with the tumor located in the bladder, and the tumor mutational burden is not available. Based on this information, can we predict whether the patient is likely to respond to Atezolizumab, and could you please provide the rationale behind this prediction?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  male of White race with the tumor located in the bladder, and the tumor mutational burden is not available. Based on this information, can we predict whether the patient is likely to respond to Atezolizumab, and could you please provide the rationale behind this prediction? Please access the secure COMPASS platform and download the transcriptomic datasets for all tumor samples. For each patient, carefully review the immune biomarker information and classify them into one of two groups:

• Immunosuppressed: This category is applicable when the data indicate reduced natural killer cell activity, significant T-cell exhaustion, and lowered B-cell counts.
• Active Immune Response: Use this category when the data show increased macrophage activity, elevated interferon-gamma signaling, and genetic markers consistent with an effective immune response.

Once you have categorized all the patients, prepare a comprehensive report that analyzes how these distinct immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"Based on the processed mRNA TPM data of the patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and considering her clinical characteristics—female, White, tissue source from the ureter, and an unspecified tumor mutational burden (nan)—could you determine whether she is more likely to respond to Atezolizumab? Please provide the rationale supporting your conclusion.","Based on the processed mRNA TPM data of the patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and considering her clinical characteristics—female, White, tissue source from the ureter, and an unspecified tumor mutational burden (nan)—could you determine whether she is more likely to respond to Atezolizumab? Please provide the rationale supporting your conclusion. Please log in to the secure COMPASS platform and download the transcriptomic datasets corresponding to all tumor samples. For each patient, review the immune biomarker data in detail and assign them to one of the following groups:

• Immunosuppressed: This group includes patients whose data reveal diminished natural killer cell function, marked T-cell exhaustion, and decreased B-cell counts.
• Active Immune Response: This group includes patients with evidence of heightened macrophage activity, increased interferon-gamma signaling, and genetic indicators of an effective immune response.

After categorizing all patients, compile a detailed report evaluating how these distinct immune profiles might influence their responses to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"I have analyzed mRNA TPM data from the tumor microenvironment of a patient with bladder urothelial carcinoma (BLCA), and the patient presents with the following characteristics: male, white, bladder tissue, and a tumor mutational burden of 24 mutations/MB. Based on this information, can we determine whether the patient is likely to respond to Atezolizumab? Please provide your conclusion with supporting rationale.","I have analyzed mRNA TPM data from the tumor microenvironment of a patient with bladder urothelial carcinoma (BLCA), and the patient presents with the following characteristics: male, white, bladder tissue, and a tumor mutational burden of 24 mutations/MB. Based on this information, can we determine whether the patient is likely to respond to Atezolizumab? Please provide your conclusion with supporting rationale. Please access the secure COMPASS platform and download the transcriptomic datasets for all tumor samples. For each patient, carefully review the provided immune biomarker data and assign them to one of the following groups:

• Immunosuppressed: Patients with reduced natural killer cell function, notable T-cell exhaustion, and lower B-cell counts.
• Active Immune Response: Patients displaying increased macrophage activity, elevated interferon-gamma signaling, and genetic signs of an effective immune response.

Once all patients have been categorized, prepare a comprehensive report analyzing how these different immune profiles may affect their treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"I have analyzed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) to characterize the tumor immune microenvironment and am interested in assessing the potential responsiveness to Atezolizumab. The patient is a white male with a bladder tumor, although the tumor mutational burden is not available (FMOne mutation burden per MB: nan). Based on these clinical parameters and available molecular data, could you provide an evaluation regarding whether this patient is likely to be a responder or non-responder to Atezolizumab, along with the underlying rationale?","I have analyzed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) to characterize the tumor immune microenvironment and am interested in assessing the potential responsiveness to Atezolizumab. The patient is a white male with a bladder tumor, although the tumor mutational burden is not available (FMOne mutation burden per MB: nan). Based on these clinical parameters and available molecular data, could you provide an evaluation regarding whether this patient is likely to be a responder or non-responder to Atezolizumab, along with the underlying rationale? Access the secure COMPASS platform and download the transcriptomic datasets for all tumor samples. For each patient, review the immune biomarker data provided and categorize them as follows:

• Immunosuppressed: Patients exhibiting reduced natural killer cell function, significant T-cell exhaustion, and lower B-cell counts.  
• Active Immune Response: Patients showing increased macrophage activity, elevated interferon-gamma signaling, and genetic indicators of an effective immune response.

After categorizing each patient, prepare a detailed report that analyzes how these immune profiles may influence their treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with ureter tissue involvement and a tumor mutational burden of 8.0 mutations per megabase. Based on these parameters, could you determine whether the patient is predicted to be a responder or non-responder to atezolizumab, and provide the rationale for your conclusion?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with ureter tissue involvement and a tumor mutational burden of 8.0 mutations per megabase. Based on these parameters, could you determine whether the patient is predicted to be a responder or non-responder to atezolizumab, and provide the rationale for your conclusion? Please log in to the secure COMPASS platform and download the transcriptomic datasets for all tumor samples. For each patient, examine the provided immune biomarker data and classify their immune profile into one of two categories:

• Immunosuppressed: Patients who show decreased natural killer cell function, marked T-cell exhaustion, and reduced B-cell counts.
• Active Immune Response: Patients who display increased macrophage activity, heightened interferon-gamma signaling, and genetic evidence of an effective immune response.

After classifying each patient, compile a comprehensive report that evaluates how these immune profiles could potentially impact their treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"I have processed mRNA TPM data characterizing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) as part of an analysis to predict responsiveness to Atezolizumab. The patient is a  (M, White) with tissue sample from the kidney and a tumor mutational burden of 4.0 FMOne mutations per MB. Based on this information, can you provide an evaluation on whether this patient is more likely to be a responder or non-responder to Atezolizumab, and detail the reasoning behind your conclusion?","I have processed mRNA TPM data characterizing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) as part of an analysis to predict responsiveness to Atezolizumab. The patient is a  (M, White) with tissue sample from the kidney and a tumor mutational burden of 4.0 FMOne mutations per MB. Based on this information, can you provide an evaluation on whether this patient is more likely to be a responder or non-responder to Atezolizumab, and detail the reasoning behind your conclusion? Access the secure COMPASS platform using your credentials and download the transcriptomic datasets for all tumor samples. For each patient, review their immune biomarker data and assign their immune profile to one of two categories as follows:

• Immunosuppressed: Patients whose data indicate decreased natural killer cell function, significant T-cell exhaustion, and reduced B-cell counts.
• Active Immune Response: Patients whose data show increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers consistent with a robust immune response.

Once you have classified the patients, please compile a detailed report discussing how these immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"I have evaluated mRNA TPM data for the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma, with the following characteristics: Male, White, bladder tissue origin, and a Tumor Mutational Burden of 14.0 mutations per MB. Could you please interpret these findings to determine whether this patient is likely to respond to Atezolizumab therapy, and provide the supporting rationale for this conclusion?","I have evaluated mRNA TPM data for the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma, with the following characteristics: Male, White, bladder tissue origin, and a Tumor Mutational Burden of 14.0 mutations per MB. Could you please interpret these findings to determine whether this patient is likely to respond to Atezolizumab therapy, and provide the supporting rationale for this conclusion? Please log into the secure COMPASS platform with your credentials and download the transcriptomic datasets for all tumor samples. For each patient, review the immune biomarker data and classify their immune profile based on the following criteria:

• Immunosuppressed: This category includes patients whose data show reduced natural killer cell activity, significant T-cell exhaustion, and lower B-cell counts.
• Active Immune Response: This category applies to patients with increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers indicating a robust immune response.

After classifying each patient, compile a detailed report that discusses how these immune profiles may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"Based on mRNA TPM data from the immune microenvironment of a bladder tumor, with the following patient details—Sex: Male, Race: White, Disease: Bladder Urothelial Carcinoma (BLCA), Tissue: bladder, and a Tumor Mutational Burden of 5.0 mutations per MB—how would you assess the predicted responsiveness to Atezolizumab, and what is the rationale behind your conclusion?","Based on mRNA TPM data from the immune microenvironment of a bladder tumor, with the following patient details—Sex: Male, Race: White, Disease: Bladder Urothelial Carcinoma (BLCA), Tissue: bladder, and a Tumor Mutational Burden of 5.0 mutations per MB—how would you assess the predicted responsiveness to Atezolizumab, and what is the rationale behind your conclusion? Please access the secure COMPASS platform using your login credentials and download the transcriptomic datasets for all tumor samples. For each patient, evaluate the immune biomarker data and classify their immune profile as follows:

• Immunosuppressed Profile: Patients showing reduced activity of natural killer cells, significant T-cell exhaustion, and low B-cell counts.  
• Active Immune Response Profile: Patients with evidence of increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers indicating a strong immune response.

After you have categorized each patient, compile a comprehensive report that discusses the potential implications of these immune profiles for treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"Based on mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA) and the following clinical details—male, Caucasian, bladder tissue origin, and a tumor mutational burden of 10 mutations per megabase—could you assess whether this patient is likely to respond to Atezolizumab, and explain the reasoning behind your prediction?","Based on mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA) and the following clinical details—male, Caucasian, bladder tissue origin, and a tumor mutational burden of 10 mutations per megabase—could you assess whether this patient is likely to respond to Atezolizumab, and explain the reasoning behind your prediction? Access the secure COMPASS platform with your credentials and download the transcriptomic datasets for all tumor samples. Then, for each patient, assess the immune biomarker data and classify their immune status using the following criteria:

• Immunosuppressed Profile: This category includes patients with decreased natural killer cell activity, marked T-cell exhaustion, and low B-cell counts.

• Active Immune Response Profile: This group comprises patients demonstrating increased macrophage activity, enhanced interferon-gamma signaling, and genetic indicators of a robust immune response.

Once the categorization is complete, please prepare a comprehensive report detailing how these immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"I have processed mRNA TPM data from a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the predicted response to Atezolizumab. The patient is a white male, the specimen was obtained from kidney tissue, and the tumor mutational burden is not available (reported as nan). Based on this data, can you determine whether the patient is likely to respond to Atezolizumab, and please provide your reasoning?","I have processed mRNA TPM data from a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the predicted response to Atezolizumab. The patient is a white male, the specimen was obtained from kidney tissue, and the tumor mutational burden is not available (reported as nan). Based on this data, can you determine whether the patient is likely to respond to Atezolizumab, and please provide your reasoning? Please log into the secure COMPASS platform using your credentials and download the transcriptomic datasets for all tumor samples. For each patient, evaluate the immune biomarker data and classify their immune status as follows:

• Immunosuppressed Profile: Patients exhibiting reduced natural killer cell activity, significant T-cell exhaustion, and low B-cell counts.

• Active Immune Response Profile: Patients showing increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers indicative of a strong immune response.

After classification, prepare a detailed report that discusses how these immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"Based on the mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you please assess whether this patient, a white male with lymph node tissue involvement and an undefined tumor mutational burden, is likely to respond to Atezolizumab? Please include your rationale and supporting evidence in the assessment.","Based on the mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you please assess whether this patient, a white male with lymph node tissue involvement and an undefined tumor mutational burden, is likely to respond to Atezolizumab? Please include your rationale and supporting evidence in the assessment. Please access the secure COMPASS platform using your credentials to download the transcriptomic datasets for all tumor samples. Then, for each patient, review the immune biomarker data and classify their immune status into one of two profiles as follows:

• Immunosuppressed Profile: Patients who demonstrate reduced natural killer cell activity, significant T-cell exhaustion, and decreased B-cell counts.

• Active Immune Response Profile: Patients who exhibit increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers that indicate a robust immune response.

After classifying the patients, prepare a detailed report analyzing how these immune profiles could potentially affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"Based on the processed mRNA TPM data for the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), please determine whether this patient—male, White, with bladder tissue involvement and a tumor mutational burden of 19.0 mutations per megabase—is predicted to respond to Atezolizumab. Please provide your conclusion along with the underlying rationale.","Based on the processed mRNA TPM data for the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), please determine whether this patient—male, White, with bladder tissue involvement and a tumor mutational burden of 19.0 mutations per megabase—is predicted to respond to Atezolizumab. Please provide your conclusion along with the underlying rationale. Please log in to the secure COMPASS portal with your credentials and download the transcriptomic datasets for all tumor samples. For each patient, examine the immune biomarker data and categorize their immune status into one of two groups:

• Immunosuppressed Profile: This group comprises patients showing reduced natural killer cell activity, marked T-cell exhaustion, and lower B-cell counts.

• Active Immune Response Profile: This group includes patients displaying increased macrophage activity, heightened interferon-gamma signaling, and genetic indicators of a strong immune response.

After completing the classifications, prepare a comprehensive report detailing how these distinct immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"I have analyzed the patient's mRNA TPM data reflecting the tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the predicted response to Atezolizumab. The patient is a female of non-Caucasian race, with a primary tissue of the ureter and a tumor mutational burden of 5 mutations per megabase. Based on this information, could you please provide an assessment of whether the patient is likely to respond to Atezolizumab, along with the supporting rationale for your conclusion?","I have analyzed the patient's mRNA TPM data reflecting the tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the predicted response to Atezolizumab. The patient is a female of non-Caucasian race, with a primary tissue of the ureter and a tumor mutational burden of 5 mutations per megabase. Based on this information, could you please provide an assessment of whether the patient is likely to respond to Atezolizumab, along with the supporting rationale for your conclusion? Please access the secure COMPASS portal using your credentials to download the transcriptomic datasets for all tumor samples. For each patient, review the immune biomarker data and assign them to one of the following categories:

• Immunosuppressed Profile: Patients with decreased natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.

• Active Immune Response Profile: Patients showing increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers indicative of a robust immune response.

Once you have classified the patients, compile a detailed report discussing how these immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"For a female patient with bladder urothelial carcinoma (BLCA) of white race, with a tumor mutational burden of 2.0 mutations per MB and processed mRNA TPM data from the tumor immune microenvironment, how would you determine her predicted responsiveness to Atezolizumab? Please provide your conclusion (responder vs. non-responder) along with the supporting rationale.","For a female patient with bladder urothelial carcinoma (BLCA) of white race, with a tumor mutational burden of 2.0 mutations per MB and processed mRNA TPM data from the tumor immune microenvironment, how would you determine her predicted responsiveness to Atezolizumab? Please provide your conclusion (responder vs. non-responder) along with the supporting rationale. Please log in to the secure COMPASS portal with your credentials and download the transcriptomic datasets for all tumor samples. Review the immune biomarker data for each patient, and classify them into one of the following categories:

• Immunosuppressed Profile: Patients with decreased natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts.

• Active Immune Response Profile: Patients exhibiting increased macrophage activity, heightened interferon-gamma signaling, and genetic markers that suggest a robust immune response.

After you have completed the patient classifications, compile a detailed report that discusses how these distinct immune profiles could influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"Based on processed mRNA TPM data reflecting the tumor microenvironment for bladder urothelial carcinoma (BLCA), could you evaluate whether this patient is likely to respond to Atezolizumab? The patient is a white male with a bladder origin tumor and a tumor mutational burden of 14.0 FMOne mutations per megabase. Please provide your conclusion along with the supporting clinical reasoning.","Based on processed mRNA TPM data reflecting the tumor microenvironment for bladder urothelial carcinoma (BLCA), could you evaluate whether this patient is likely to respond to Atezolizumab? The patient is a white male with a bladder origin tumor and a tumor mutational burden of 14.0 FMOne mutations per megabase. Please provide your conclusion along with the supporting clinical reasoning. Please access the secure COMPASS portal using your login credentials and download the transcriptomic datasets for all tumor samples. Next, examine the immune biomarker data for each patient and assign them to one of the following categories:

• Immunosuppressed Profile: Characterized by reduced natural killer cell function, evidence of T-cell exhaustion, and lower B-cell counts.

• Active Immune Response Profile: Marked by increased macrophage activity, enhanced interferon-gamma signaling, and genetic indicators of a vigorous immune response.

Once patient classification is complete, prepare a comprehensive report that evaluates how these immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"Based on processed mRNA TPM data characterizing the tumor immune microenvironment in a patient with bladder urothelial carcinoma, with a tumor mutational burden of 17 mutations per megabase, a female sex, and White race (tissue data unavailable), could you assess whether this patient is likely to be a responder or non-responder to atezolizumab treatment, and explain the rationale behind your determination?","Based on processed mRNA TPM data characterizing the tumor immune microenvironment in a patient with bladder urothelial carcinoma, with a tumor mutational burden of 17 mutations per megabase, a female sex, and White race (tissue data unavailable), could you assess whether this patient is likely to be a responder or non-responder to atezolizumab treatment, and explain the rationale behind your determination? Please log in to the secured COMPASS portal using your credentials and download the transcriptomic datasets for all tumor samples. After downloading, review the immune biomarker data for each patient and categorize them based on the following immune profiles:

• Immunosuppressed Profile: Defined by diminished natural killer cell function, signs of T-cell exhaustion, and reduced B-cell counts.

• Active Immune Response Profile: Characterized by elevated macrophage activity, robust interferon-gamma signaling, and genetic markers indicating a strong immune response.

After classifying the patients, compile a detailed report that analyzes how these immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"I have processed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is male, of Caucasian descent, and has a bladder tumor with a reported tumor mutational burden (FMO mutations per MB) of ""nan"". Based on these factors, could you assess the likelihood that this patient will respond to Atezolizumab, and provide your reasoning?","I have processed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is male, of Caucasian descent, and has a bladder tumor with a reported tumor mutational burden (FMO mutations per MB) of ""nan"". Based on these factors, could you assess the likelihood that this patient will respond to Atezolizumab, and provide your reasoning? Please access the secure COMPASS portal using your credentials and download the transcriptomic datasets for all tumor samples. Once downloaded, carefully review the immune biomarker data for each patient and assign them to one of the following immune profiles:

• Immunosuppressed Profile: This profile is characterized by reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response Profile: This profile features increased macrophage activity, strong interferon-gamma signaling, and genetic indicators of robust immune responses.

After categorizing the patients, prepare a comprehensive report analyzing how these distinct immune profiles may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"Given the tumor immune microenvironment mRNA TPM data and the following patient details—male, White, bladder tissue, diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tumor mutational burden of 6.0 mutations per MB—can you please determine whether this patient is likely to respond to Atezolizumab, and provide the reasoning behind your conclusion?","Given the tumor immune microenvironment mRNA TPM data and the following patient details—male, White, bladder tissue, diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tumor mutational burden of 6.0 mutations per MB—can you please determine whether this patient is likely to respond to Atezolizumab, and provide the reasoning behind your conclusion? Please log in to the secure COMPASS portal using your credentials. Once logged in, download the transcriptomic datasets for all tumor samples. Next, review the immune biomarker data for each patient in detail and assign them to one of the following immune profiles:

• Immunosuppressed Profile: Characterized by diminished natural killer cell activity, indications of T-cell exhaustion, and reduced B-cell counts.
• Active Immune Response Profile: Characterized by heightened macrophage activity, strong interferon-gamma signaling, and genetic markers that suggest a robust immune response.

After classifying the patients, compile a detailed report evaluating how these immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"I have evaluated the mRNA TPM data characterizing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white female with a tumor mutational burden of 9.0 mutations per MB on bladder tissue. Based on these details, could you provide your assessment on whether this patient is predicted to respond to Atezolizumab, and explain the reasoning behind your conclusion?","I have evaluated the mRNA TPM data characterizing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white female with a tumor mutational burden of 9.0 mutations per MB on bladder tissue. Based on these details, could you provide your assessment on whether this patient is predicted to respond to Atezolizumab, and explain the reasoning behind your conclusion? Please access the secure COMPASS portal using your login credentials. Once you have logged in, download the transcriptomic datasets for all tumor samples. Next, review the immune biomarker data for each patient carefully. Based on your review, classify each patient into one of two immune profiles:

• Immunosuppressed Profile – characterized by reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts.
• Active Immune Response Profile – characterized by increased macrophage activity, strong interferon-gamma signaling, and genetic markers indicative of a vigorous immune response.

After completing the classifications, compile a comprehensive report that examines how these immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"A patient with bladder urothelial carcinoma has been evaluated using mRNA TPM data to characterize the tumor immune microenvironment. The patient is a white female, with tumor tissue from the kidney, and a tumor mutational burden of 5 mutations per MB. Based on these clinical and molecular features, can you determine whether the patient is predicted to respond to Atezolizumab, and please explain the rationale for your conclusion.","A patient with bladder urothelial carcinoma has been evaluated using mRNA TPM data to characterize the tumor immune microenvironment. The patient is a white female, with tumor tissue from the kidney, and a tumor mutational burden of 5 mutations per MB. Based on these clinical and molecular features, can you determine whether the patient is predicted to respond to Atezolizumab, and please explain the rationale for your conclusion. Please log into the secure COMPASS portal using your credentials. Once you are in, download the transcriptomic datasets for all tumor samples. Then, review each patient's immune biomarker data thoroughly and assign them to one of two categories based on their profiles:

• Immunosuppressed Profile – marked by diminished natural killer cell function, signs of T‐cell exhaustion, and lower levels of B cells.
• Active Immune Response Profile – marked by heightened macrophage activity, robust interferon-gamma signaling, and genetic indicators of a strong immune response.

After classifying the patients, prepare a detailed report that discusses how these immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"Based on the mRNA TPM data of the tumor immune microenvironment and the following patient characteristics—male, White, liver tissue sample, diagnosed with Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 5.0 mutations/MB—can you determine whether this patient is predicted to respond to atezolizumab? Please provide your conclusion along with the supporting rationale.","Based on the mRNA TPM data of the tumor immune microenvironment and the following patient characteristics—male, White, liver tissue sample, diagnosed with Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 5.0 mutations/MB—can you determine whether this patient is predicted to respond to atezolizumab? Please provide your conclusion along with the supporting rationale. Please log into the secure COMPASS portal with your credentials. Once logged in, download the transcriptomic datasets for all tumor samples. For each patient, carefully review the immune biomarker data and classify their profile as follows:

• Immunosuppressed Profile – characterized by reduced natural killer cell function, evidence of T‐cell exhaustion, and lower levels of B cells.
• Active Immune Response Profile – indicated by increased macrophage activity, strong interferon-gamma signaling, and genetic markers reflecting a robust immune response.

After categorizing each patient, prepare a detailed report discussing how these immune profiles might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a white male with a bladder tumor, and the tumor mutational burden data is not available (nan). Based on these findings, could you please determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your assessment?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a white male with a bladder tumor, and the tumor mutational burden data is not available (nan). Based on these findings, could you please determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your assessment? Please sign in to the secure COMPASS portal using your credentials. After logging in, download the transcriptomic datasets for all tumor samples. Next, for each patient, review the immune biomarker data and classify their immune profile into one of the following groups:

• Immunosuppressed Profile – marked by reduced natural killer cell function, signs of T‐cell exhaustion, and lower B cell counts.
• Active Immune Response Profile – characterized by increased macrophage activity, pronounced interferon-gamma signaling, and genetic markers that indicate a strong immune response.

Once you have categorized the patients, compile a comprehensive report that discusses the potential implications of these immune profiles on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e71235-ar-e712352.pkl. "
BLCA,,,,NR,"Based on the processed mRNA TPM data assessing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), how would you evaluate this patient's likelihood of responding to Atezolizumab? The patient’s details are as follows: male, white, tissue origin is kidney, and the tumor mutational burden is not available. Please provide your conclusion on responder status with the supporting clinical rationale.","Based on the processed mRNA TPM data assessing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), how would you evaluate this patient's likelihood of responding to Atezolizumab? The patient’s details are as follows: male, white, tissue origin is kidney, and the tumor mutational burden is not available. Please provide your conclusion on responder status with the supporting clinical rationale. Please log into the secure COMPASS portal using your credentials. Once logged in, download the transcriptomic datasets for all tumor samples. For each patient, review the immune biomarker data and assign their immune profile to one of the following groups:

• Immunosuppressed Profile – characterized by reduced natural killer cell function, signs of T‐cell exhaustion, and lower B‐cell counts.
• Active Immune Response Profile – characterized by increased macrophage activity, pronounced interferon-gamma signaling, and genetic markers indicative of a robust immune response.

After categorizing the patients, prepare a detailed report discussing how these immune profiles might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"I have processed mRNA TPM data representing a patient's tumor immune microenvironment in the context of bladder urothelial carcinoma (BLCA). The patient is a 7.0 FMOne mutation per MB tumor mutational burden, male, White, with kidney tissue involvement. Based on these data, could you provide your clinical assessment regarding the patient's likely response to Atezolizumab, classifying them as a responder or non-responder, and explaining your rationale?","I have processed mRNA TPM data representing a patient's tumor immune microenvironment in the context of bladder urothelial carcinoma (BLCA). The patient is a 7.0 FMOne mutation per MB tumor mutational burden, male, White, with kidney tissue involvement. Based on these data, could you provide your clinical assessment regarding the patient's likely response to Atezolizumab, classifying them as a responder or non-responder, and explaining your rationale? Please access the secure COMPASS portal using your credentials. Once you're logged in, download the transcriptomic datasets for all tumor samples. For each patient, review the immune biomarker data and classify their immune profile into one of the following two categories:

• Immunosuppressed Profile – identified by reduced natural killer cell activity, indications of T‐cell exhaustion, and decreased B‐cell counts.
• Active Immune Response Profile – identified by heightened macrophage activity, pronounced interferon-gamma signaling, and genetic indicators suggesting a robust immune reaction.

After you have completed the classifications, compile a comprehensive report detailing how these immune profiles could affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"Based on the patient's processed mRNA TPM data of the tumor immune microenvironment in bladder urothelial carcinoma, along with the clinical attributes (male, White, bladder tissue, and a tumor mutational burden of 1.0 per MB), is the patient predicted to respond to Atezolizumab treatment? Please provide a conclusion with supporting rationale.","Based on the patient's processed mRNA TPM data of the tumor immune microenvironment in bladder urothelial carcinoma, along with the clinical attributes (male, White, bladder tissue, and a tumor mutational burden of 1.0 per MB), is the patient predicted to respond to Atezolizumab treatment? Please provide a conclusion with supporting rationale. Please log in to the secure COMPASS portal using your credentials. Once logged in, download the transcriptomic datasets for all tumor samples. For each patient, review their immune biomarker data and determine whether they exhibit an immunosuppressed profile (characterized by decreased natural killer cell activity, signs of T‑cell exhaustion, and lower B‑cell counts) or an active immune response profile (characterized by increased macrophage activity, elevated interferon-gamma signaling, and genetic markers indicating a strong immune reaction). After completing these classifications, prepare a detailed report describing how each immune profile might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"For a patient with bladder urothelial carcinoma (male, white, tumor tissue: bladder) and available mRNA TPM data reflecting the tumor immune microenvironment, how would you predict responsiveness to Atezolizumab despite an unavailable tumor mutational burden assessment (noted as ""nan"")? Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with the supporting clinical rationale.","For a patient with bladder urothelial carcinoma (male, white, tumor tissue: bladder) and available mRNA TPM data reflecting the tumor immune microenvironment, how would you predict responsiveness to Atezolizumab despite an unavailable tumor mutational burden assessment (noted as ""nan"")? Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with the supporting clinical rationale. Please access the secure COMPASS portal with your credentials. After logging in, download the transcriptomic data for all tumor samples. For each patient, evaluate the immune biomarker data to classify their profile as either immunosuppressed—indicated by reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts—or as having an active immune response—characterized by heightened macrophage activity, increased interferon-gamma signaling, and genetic markers of a robust immune reaction. Following this analysis, compile a detailed report outlining how each immune profile could potentially impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"Given the processed mRNA TPM data for a patient's tumor immune microenvironment in a case of bladder urothelial carcinoma (BLCA), can you assess the predicted responsiveness to Atezolizumab? The patient is a white male with bladder tissue involvement, a diagnosis of BLCA, and a tumor mutational burden of 6.0 mutations per megabase. Please provide your conclusion on whether this patient is likely to respond to Atezolizumab, along with the supporting rationale.","Given the processed mRNA TPM data for a patient's tumor immune microenvironment in a case of bladder urothelial carcinoma (BLCA), can you assess the predicted responsiveness to Atezolizumab? The patient is a white male with bladder tissue involvement, a diagnosis of BLCA, and a tumor mutational burden of 6.0 mutations per megabase. Please provide your conclusion on whether this patient is likely to respond to Atezolizumab, along with the supporting rationale. Please log in to the secure COMPASS portal using your credentials. Once logged in, download the transcriptomic data for all tumor samples. For each patient, evaluate the immune biomarker data to categorize their profile as either immunosuppressed—demonstrated by reduced natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts—or as exhibiting an active immune response—indicated by increased macrophage activity, elevated interferon-gamma signaling, and genetic markers consistent with robust immunity. Finally, compile a detailed report that outlines how each immune profile might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"Given that we have mRNA TPM data representing the tumor immune microenvironment for a female, white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 3.0 mutations per MB, can you please provide an assessment of whether this patient is more likely to respond or not respond to Atezolizumab, along with the supporting rationale?","Given that we have mRNA TPM data representing the tumor immune microenvironment for a female, white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 3.0 mutations per MB, can you please provide an assessment of whether this patient is more likely to respond or not respond to Atezolizumab, along with the supporting rationale? Please access the secure COMPASS portal using your established credentials. Once logged in, download the transcriptomic data for all tumor samples. For each patient, assess their immune biomarker profile and classify it as either immunosuppressed (characterized by lower natural killer cell activity, signs of T-cell exhaustion, and reduced B-cell counts) or as indicative of an active immune response (evidenced by increased macrophage activity, heightened interferon-gamma signaling, and genetic markers of strong immunity). Finally, prepare a comprehensive report summarizing how each immune profile may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"Based on mRNA TPM data reflecting the tumor immune microenvironment in a male White patient with bladder urothelial carcinoma (TMB: 7.0 mutations/MB), what is the predicted response to Atezolizumab? Please provide a determination of responder versus non-responder status along with the supporting rationale for your assessment.","Based on mRNA TPM data reflecting the tumor immune microenvironment in a male White patient with bladder urothelial carcinoma (TMB: 7.0 mutations/MB), what is the predicted response to Atezolizumab? Please provide a determination of responder versus non-responder status along with the supporting rationale for your assessment. Please log into the secure COMPASS portal using your existing credentials. Once you have accessed the system, download the transcriptomic data for every tumor sample. For each patient’s sample, evaluate their immune biomarker profile. Specifically, classify the profile as immunosuppressed if there are indicators such as reduced natural killer cell activity, evidence of T-cell exhaustion, and lower B-cell counts, or as showing an active immune response if there is increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers that suggest strong immunity. Finally, compile a detailed report summarizing the potential impact of each immune profile on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient’s characteristics are as follows: male, White, bladder tissue sample, and a tumor mutational burden of 14.0 mutations per megabase. Based on these parameters, could you evaluate whether the patient is likely to respond to Atezolizumab and provide the rationale for your conclusion?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient’s characteristics are as follows: male, White, bladder tissue sample, and a tumor mutational burden of 14.0 mutations per megabase. Based on these parameters, could you evaluate whether the patient is likely to respond to Atezolizumab and provide the rationale for your conclusion? Please access the secure COMPASS portal using your current login credentials. Once logged in, download the transcriptomic data for all tumor samples. For each patient's sample, review and analyze the immune biomarker profile. Specifically, designate the profile as immunosuppressed if there is evidence of diminished natural killer cell activity, T-cell exhaustion, and reduced B-cell levels. Conversely, classify the profile as indicative of an active immune response if there is increased macrophage activity, heightened interferon-gamma signaling, and genetic markers consistent with robust immunity. Finally, prepare a comprehensive report outlining how each immune profile might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"Given the following patient details—male, White, kidney tissue, diagnosed with bladder urothelial carcinoma, and a tumor mutational burden of 2.0 mutations per megabase—can you provide an evaluation of the predicted response to Atezolizumab, specifying whether this patient is likely to be a responder or non-responder, along with the underlying rationale?","Given the following patient details—male, White, kidney tissue, diagnosed with bladder urothelial carcinoma, and a tumor mutational burden of 2.0 mutations per megabase—can you provide an evaluation of the predicted response to Atezolizumab, specifying whether this patient is likely to be a responder or non-responder, along with the underlying rationale? Please log into the secure COMPASS portal using your current credentials and download the transcriptomic data for all tumor samples. Then, review the immune biomarker profiles for each patient's sample. If you find evidence of reduced natural killer cell activity, T-cell exhaustion, and lower B-cell levels, classify the profile as immunosuppressed. On the other hand, if there is increased macrophage activity, elevated interferon-gamma signaling, and genetic indicators of strong immunity, label the profile as reflective of an active immune response. Finally, prepare a detailed report discussing how each immune profile could potentially influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,I have processed mRNA TPM data that reflects the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a white male with bladder tissue involvement and an undefined tumor mutational burden. Could you please evaluate whether this patient is likely to respond to atezolizumab treatment and explain the reasoning behind your assessment?,"I have processed mRNA TPM data that reflects the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a white male with bladder tissue involvement and an undefined tumor mutational burden. Could you please evaluate whether this patient is likely to respond to atezolizumab treatment and explain the reasoning behind your assessment? Please access the secure COMPASS portal using your current credentials and download the transcriptomic data for all tumor samples. For each patient, carefully review the immune biomarker profiles. If you observe decreased natural killer cell activity, signs of T-cell exhaustion, and lower B-cell counts, categorize the profile as immunosuppressed. Conversely, if you detect increased macrophage activity, higher interferon-gamma signaling, and genetic markers indicative of robust immunity, classify the profile as an active immune response. Finally, compile a comprehensive report that discusses how each type of immune profile might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"We have processed mRNA TPM data from a patient’s tumor immune microenvironment in the context of bladder urothelial carcinoma. The patient is a  male of Caucasian descent, with tissue obtained from a lymph node, and the tumor mutational burden (FMOne mutation burden per MB) data is unavailable. Could you please provide a clinical evaluation of whether this patient is likely to respond to Atezolizumab, along with your supporting rationale?","We have processed mRNA TPM data from a patient’s tumor immune microenvironment in the context of bladder urothelial carcinoma. The patient is a  male of Caucasian descent, with tissue obtained from a lymph node, and the tumor mutational burden (FMOne mutation burden per MB) data is unavailable. Could you please provide a clinical evaluation of whether this patient is likely to respond to Atezolizumab, along with your supporting rationale? Access the secure COMPASS portal using your current credentials and download the transcriptomic data for all tumor samples. For each patient, examine their immune biomarker profiles in detail. If you find decreased natural killer cell activity, indicators of T-cell exhaustion, or reduced B-cell counts, classify the profile as immunosuppressed. Alternatively, if you observe increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers associated with a strong immune response, label the profile as representing an active immune response. Finally, prepare a detailed report that analyzes how each immune profile could influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"Based on the patient's characteristics—male, White, lung tissue sample, diagnosed with Bladder Urothelial Carcinoma (BLCA), and an FMOne tumor mutational burden of 1.0 mutation per MB—could you please provide a determination on whether this patient is likely to be responsive to Atezolizumab? Additionally, please include the rationale supporting this classification based on the processed mRNA TPM data of the tumor immune microenvironment.","Based on the patient's characteristics—male, White, lung tissue sample, diagnosed with Bladder Urothelial Carcinoma (BLCA), and an FMOne tumor mutational burden of 1.0 mutation per MB—could you please provide a determination on whether this patient is likely to be responsive to Atezolizumab? Additionally, please include the rationale supporting this classification based on the processed mRNA TPM data of the tumor immune microenvironment. Please log in to the secure COMPASS portal using your current credentials and download the transcriptomic data for all available tumor samples. For each patient, conduct a thorough review of their immune biomarker profiles. Patients presenting with reduced natural killer cell activity, signs of T-cell exhaustion, or lower B-cell counts should be classified as having an immunosuppressed profile. In contrast, those exhibiting increased macrophage activity, elevated interferon-gamma signaling, and genetic markers indicative of a robust immune response should be designated as having an active immune response. Finally, prepare a detailed report analyzing the potential impact of each immune profile on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"Given mRNA TPM data from a patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA), along with the following details: male, white, primary tissue from the ureter, and a tumor mutational burden of 14 mutations per MB, how would you assess the likelihood of a positive response to atezolizumab? Please provide your conclusion as to whether the patient is expected to be a responder or non-responder, including your supporting clinical rationale.","Given mRNA TPM data from a patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA), along with the following details: male, white, primary tissue from the ureter, and a tumor mutational burden of 14 mutations per MB, how would you assess the likelihood of a positive response to atezolizumab? Please provide your conclusion as to whether the patient is expected to be a responder or non-responder, including your supporting clinical rationale. Please access the secure COMPASS portal with your current credentials and download the transcriptomic datasets for all available tumor samples. For each patient, carefully assess their immune biomarker profiles. Patients with decreased natural killer cell activity, evidence of T-cell exhaustion, or reduced B-cell counts should be classified as having an immunosuppressed profile. Conversely, patients showing increased macrophage activity, heightened interferon-gamma signaling, and genetic indicators of a strong immune response should be classified as having an active immune profile. Finally, compile a detailed report analyzing the potential implications of each immune profile on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"For a patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM data reflecting the tumor microenvironment has been analyzed, and who has the following attributes: male, White, tissue sample from kidney, and a tumor mutational burden of 14 mutations per megabase, can you provide an evaluation of whether this patient is likely to respond to Atezolizumab? Please include your reasoning based on these characteristics.","For a patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM data reflecting the tumor microenvironment has been analyzed, and who has the following attributes: male, White, tissue sample from kidney, and a tumor mutational burden of 14 mutations per megabase, can you provide an evaluation of whether this patient is likely to respond to Atezolizumab? Please include your reasoning based on these characteristics. Please log in to the secure COMPASS portal using your current credentials and download the transcriptomic datasets for all tumor samples. For every patient, review the immune biomarker profiles thoroughly. If you observe reduced natural killer cell activity, signs of T-cell exhaustion, or lower B-cell counts, classify that patient as having an immunosuppressed profile. In contrast, if the data indicate increased macrophage activity, elevated interferon-gamma signaling, and genetic markers consistent with a strong immune response, classify the patient as having an active immune profile. Once these classifications are complete, prepare a detailed report discussing the potential impact of each immune profile on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"Given mRNA TPM data from a patient's bladder tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA), and considering the patient's characteristics (male, Black or African American) with a tumor mutational burden of 9.0 mutations per MB, could you assess whether this patient is likely to be classified as a responder or a non-responder to Atezolizumab? Please include the supporting rationale in your determination.","Given mRNA TPM data from a patient's bladder tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA), and considering the patient's characteristics (male, Black or African American) with a tumor mutational burden of 9.0 mutations per MB, could you assess whether this patient is likely to be classified as a responder or a non-responder to Atezolizumab? Please include the supporting rationale in your determination. Please access the secure COMPASS portal using your current login credentials and download the transcriptomic datasets for all tumor samples. For each patient, carefully review the immune biomarker profiles. If you find evidence of reduced natural killer cell activity, T-cell exhaustion, or decreased B-cell counts, label the patient as having an immunosuppressed profile. Conversely, if the data show increased macrophage activity, heightened interferon-gamma signaling, and genetic markers that indicate a robust immune response, label the patient as having an active immune profile. After categorizing the patients accordingly, compile a detailed report that explains how each immune profile might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a primary bladder tumor and a tumor mutational burden of 8.0 mutations per megabase. Could you assess the likelihood of a favorable response to Atezolizumab therapy for this patient and provide the scientific rationale for your conclusion?,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a primary bladder tumor and a tumor mutational burden of 8.0 mutations per megabase. Could you assess the likelihood of a favorable response to Atezolizumab therapy for this patient and provide the scientific rationale for your conclusion? Access the secure COMPASS portal using your current login credentials and download the transcriptomic datasets for all tumor samples. For each patient, review the immune biomarker profiles in detail. If you observe indications of reduced natural killer cell activity, T-cell exhaustion, or diminished B-cell counts, classify the patient as having an immunosuppressed profile. Conversely, if the data indicate increased macrophage activity, elevated interferon-gamma signaling, and genetic markers consistent with a robust immune response, classify the patient as having an active immune profile. Once all patients have been categorized, prepare a comprehensive report discussing how each immune profile may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"I have processed the mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a  'white female' with a bladder tumor and a tumor mutational burden of 7.0 mutations per MB. Based on this molecular and clinical profile, could you provide an assessment of her likelihood to respond to Atezolizumab, including the rationale behind the classification as either a responder or non-responder?","I have processed the mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a  'white female' with a bladder tumor and a tumor mutational burden of 7.0 mutations per MB. Based on this molecular and clinical profile, could you provide an assessment of her likelihood to respond to Atezolizumab, including the rationale behind the classification as either a responder or non-responder? Please log into the secure COMPASS portal using your existing credentials and download the transcriptomic datasets for all tumor samples. For each patient, carefully review their immune biomarker profiles. If you identify signs such as decreased natural killer cell activity, T-cell exhaustion, or reduced B-cell counts, classify that patient as having an immunosuppressed profile. Conversely, if the data show increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers indicating a strong immune response, classify the patient as having an active immune profile. After categorizing all patients, compile a detailed report outlining how each immune profile may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"Based on the mRNA TPM data representing the tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) and the patient’s attributes (female, Asian, kidney tissue, BLCA diagnosis, and a tumor mutational burden of 4.0 mutations per MB), can you determine whether this patient is likely to respond to Atezolizumab? Please include your rationale for classifying the patient as a responder or non-responder.","Based on the mRNA TPM data representing the tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) and the patient’s attributes (female, Asian, kidney tissue, BLCA diagnosis, and a tumor mutational burden of 4.0 mutations per MB), can you determine whether this patient is likely to respond to Atezolizumab? Please include your rationale for classifying the patient as a responder or non-responder. Please log into the secure COMPASS portal with your current credentials and download the transcriptomic datasets for all tumor samples. For each patient, review the immune biomarker data: if you observe decreased natural killer cell activity, evidence of T-cell exhaustion, or lower B-cell counts, classify that patient as having an immunosuppressed profile. Conversely, if you detect increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers indicative of a robust immune response, classify that patient as having an active immune profile. Once you have categorized all patients accordingly, prepare a detailed report discussing how each immune profile may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"I have processed mRNA TPM data that characterizes the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a white male, and the tissue sample is from the kidney. The tumor mutational burden is measured at 7.0 mutations per MB. Given this information, could you please evaluate whether the patient is likely to be a responder to Atezolizumab, and explain your reasoning?","I have processed mRNA TPM data that characterizes the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a white male, and the tissue sample is from the kidney. The tumor mutational burden is measured at 7.0 mutations per MB. Given this information, could you please evaluate whether the patient is likely to be a responder to Atezolizumab, and explain your reasoning? Log into the secure COMPASS portal using your current credentials and download the transcriptomic datasets for all tumor samples. For each patient, carefully review the immune biomarker data. If you note decreased natural killer cell activity, signs of T-cell exhaustion, or reduced B-cell counts, label the patient as exhibiting an immunosuppressed profile. In contrast, if you find evidence of increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers that indicate a robust immune response, label the patient as having an active immune profile. Once you have categorized all patients, prepare a detailed report evaluating how each immune profile might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"I have processed mRNA TPM data from a male patient with Bladder Urothelial Carcinoma (BLCA) and evaluated the tumor immune microenvironment. The patient is White, the tissue of origin is the bladder, and the tumor mutational burden is not available. Based on this profile, can you determine whether this patient is likely to respond to Atezolizumab, and please provide the reasoning behind your conclusion?","I have processed mRNA TPM data from a male patient with Bladder Urothelial Carcinoma (BLCA) and evaluated the tumor immune microenvironment. The patient is White, the tissue of origin is the bladder, and the tumor mutational burden is not available. Based on this profile, can you determine whether this patient is likely to respond to Atezolizumab, and please provide the reasoning behind your conclusion? Please access the secure COMPASS portal with your current credentials and download the transcriptomic datasets for all tumor samples. For each patient, review the immune biomarker data in detail. Identify patients as immunosuppressed if their data shows reduced natural killer cell activity, evidence of T-cell exhaustion, or lower B-cell counts. Conversely, patients should be classified as having an active immune profile if there is increased macrophage activity, enhanced interferon-gamma signaling, and genetic markers indicating a strong immune response. Finally, compile a comprehensive report discussing how these immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"I have processed mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) to evaluate his tumor immune microenvironment and predict responsiveness to Atezolizumab. The patient is a 5.0 TMB (FMOne mutation burden per MB) male of White race, and the tumor tissue is from the bladder. Based on these characteristics, could you provide a conclusion regarding his likelihood of responding to Atezolizumab, along with the underlying reasoning?","I have processed mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) to evaluate his tumor immune microenvironment and predict responsiveness to Atezolizumab. The patient is a 5.0 TMB (FMOne mutation burden per MB) male of White race, and the tumor tissue is from the bladder. Based on these characteristics, could you provide a conclusion regarding his likelihood of responding to Atezolizumab, along with the underlying reasoning? Please log into the secure COMPASS portal using your existing credentials and download the transcriptomic datasets for all tumor samples. For each patient, review the immune biomarker data thoroughly. Patients should be flagged as immunosuppressed if their data indicate reduced natural killer cell activity, signs of T-cell exhaustion, or decreased B-cell counts. In contrast, classify patients as having an active immune profile when there is evidence of increased macrophage activity, enhanced interferon-gamma signaling, along with genetic markers that support a robust immune response. Finally, prepare a detailed report analyzing how these immune profiles might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"Based on processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), where the patient is a white female with a bladder tumor and a tumor mutational burden of 7.0 mutations/Mb, can you provide an assessment of her likely responsiveness to Atezolizumab, including the supporting rationale?","Based on processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), where the patient is a white female with a bladder tumor and a tumor mutational burden of 7.0 mutations/Mb, can you provide an assessment of her likely responsiveness to Atezolizumab, including the supporting rationale? Please access the secure COMPASS portal using your current login details and download the transcriptomic datasets for all tumor samples. For each patient, carefully review the immune biomarker data. Classify patients as immunosuppressed if they present with reduced natural killer cell activity, evidence of T-cell exhaustion, or decreased B-cell counts. Conversely, label them as having an active immune profile when increased macrophage activity, enhanced interferon-gamma signaling, and supportive genetic markers are observed. Finally, compile a detailed report assessing how these immune profiles may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"Based on the patient's processed mRNA TPM data and clinical characteristics (male, white, tissue type ""other"", diagnosis of Bladder Urothelial Carcinoma, and a tumor mutational burden of 10 mutations per megabase), how would you assess his likelihood of responding to Atezolizumab? Please include your reasoning for classifying him as a responder or non-responder.","Based on the patient's processed mRNA TPM data and clinical characteristics (male, white, tissue type ""other"", diagnosis of Bladder Urothelial Carcinoma, and a tumor mutational burden of 10 mutations per megabase), how would you assess his likelihood of responding to Atezolizumab? Please include your reasoning for classifying him as a responder or non-responder. Please log into the secure COMPASS portal using your current credentials to download the transcriptomic datasets for all tumor samples. For each patient, review the immune biomarker data meticulously. Classify patients as immunosuppressed if they show reduced natural killer cell activity, signs of T-cell exhaustion, or decreased B-cell counts. Alternatively, label patients as having an active immune profile if there is evidence of increased macrophage activity, enhanced interferon-gamma signaling, and favorable genetic markers. Finally, prepare a comprehensive report evaluating how these immune profiles could impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ffa5c7-ar-ffa5c7c.pkl. "
